<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Immunotherapy for IgM anti‐myelin‐associated glycoprotein paraprotein‐associated peripheral neuropathies - Lunn, MPT - 2016 | Cochrane Library</title> <meta content="Immunotherapy for IgM anti‐myelin‐associated glycoprotein paraprotein‐associated peripheral neuropathies - Lunn, MPT - 2016 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002827.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Immunotherapy for IgM anti‐myelin‐associated glycoprotein paraprotein‐associated peripheral neuropathies - Lunn, MPT - 2016 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002827.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD002827.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Immunotherapy for IgM anti‐myelin‐associated glycoprotein paraprotein‐associated peripheral neuropathies" name="citation_title"/> <meta content="Michael PT Lunn" name="citation_author"/> <meta content="National Hospital for Neurology and Neurosurgery" name="citation_author_institution"/> <meta content="michael.lunn@uclh.nhs.uk" name="citation_author_email"/> <meta content="Eduardo Nobile‐Orazio" name="citation_author"/> <meta content="Milan University" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="10" name="citation_issue"/> <meta content="10.1002/14651858.CD002827.pub4" name="citation_doi"/> <meta content="2016" name="citation_date"/> <meta content="2016/10/04" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002827.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002827.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002827.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Demyelinating Diseases [immunology, *therapy]; Immunoglobulin M [blood, *immunology]; Immunoglobulins, Intravenous [therapeutic use]; Immunosuppressive Agents [therapeutic use]; Immunotherapy [*methods]; Myelin-Associated Glycoprotein [*immunology]; Paraproteinemias [immunology, *therapy]; Paraproteins [immunology]; Peripheral Nervous System Diseases [immunology, *therapy]; Plasma Exchange [methods]; Randomized Controlled Trials as Topic; Rituximab [therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002827.pub4&amp;doi=10.1002/14651858.CD002827.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002827.pub4&amp;doi=10.1002/14651858.CD002827.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002827.pub4&amp;doi=10.1002/14651858.CD002827.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002827.pub4&amp;doi=10.1002/14651858.CD002827.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002827.pub4&amp;doi=10.1002/14651858.CD002827.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002827.pub4&amp;doi=10.1002/14651858.CD002827.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002827.pub4&amp;doi=10.1002/14651858.CD002827.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002827.pub4&amp;doi=10.1002/14651858.CD002827.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002827.pub4&amp;doi=10.1002/14651858.CD002827.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002827.pub4&amp;doi=10.1002/14651858.CD002827.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002827.pub4&amp;doi=10.1002/14651858.CD002827.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002827.pub4&amp;doi=10.1002/14651858.CD002827.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002827.pub4&amp;doi=10.1002/14651858.CD002827.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002827.pub4&amp;doi=10.1002/14651858.CD002827.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002827.pub4&amp;doi=10.1002/14651858.CD002827.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002827.pub4&amp;doi=10.1002/14651858.CD002827.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002827.pub4&amp;doi=10.1002/14651858.CD002827.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002827.pub4&amp;doi=10.1002/14651858.CD002827.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002827.pub4&amp;doi=10.1002/14651858.CD002827.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002827.pub4&amp;doi=10.1002/14651858.CD002827.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002827.pub4&amp;doi=10.1002/14651858.CD002827.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002827.pub4&amp;doi=10.1002/14651858.CD002827.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002827.pub4&amp;doi=10.1002/14651858.CD002827.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="tIsQXAzh";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD002827\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD002827\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002827\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002827\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","ms","hr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD002827.pub4",title:"Immunotherapy for IgM anti\\u2010myelin\\u2010associated glycoprotein paraprotein\\u2010associated peripheral neuropathies",firstPublishedDate:"Oct 4, 2016 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Neuromuscular Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=tIsQXAzh&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002827.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD002827.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD002827.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD002827.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002827.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD002827.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD002827.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD002827.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD002827.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD002827.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2881 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD002827.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002827.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002827.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002827.pub4/full#CD002827-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002827.pub4/full#CD002827-sec-0076"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002827.pub4/full#CD002827-sec-0015"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002827.pub4/full#CD002827-sec-0016"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002827.pub4/full#CD002827-sec-0020"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002827.pub4/full#CD002827-sec-0021"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002827.pub4/full#CD002827-sec-0036"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002827.pub4/full#CD002827-sec-0065"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002827.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002827.pub4/appendices#CD002827-sec-0081"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002827.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002827.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/table_n/CD002827StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/table_n/CD002827StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002827.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002827.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002827.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD002827.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD002827.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD002827.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2016 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Immunotherapy for IgM anti‐myelin‐associated glycoprotein paraprotein‐associated peripheral neuropathies </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002827.pub4/information#CD002827-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Michael PT Lunn</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002827.pub4/information#CD002827-cr-0003">Eduardo Nobile‐Orazio</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/information/en#CD002827-sec-0090">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 04 October 2016 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD002827.pub4">https://doi.org/10.1002/14651858.CD002827.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD002827-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD002827-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD002827-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD002827-abs-0008">فارسی</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD002827-abs-0001" lang="en"> <section id="CD002827-sec-0001"> <h3 class="title" id="CD002827-sec-0001">Background</h3> <p>Serum monoclonal anti‐myelin‐associated glycoprotein (anti‐MAG) antibodies may be pathogenic in some people with immunoglobulin M (IgM) paraprotein and demyelinating neuropathy. Immunotherapies aimed at reducing the level of these antibodies might be expected to be beneficial. This is an update of a review first published in 2003 and previously updated in 2006 and 2012. </p> </section> <section id="CD002827-sec-0002"> <h3 class="title" id="CD002827-sec-0002">Objectives</h3> <p>To assess the effects of immunotherapy for IgM anti‐MAG paraprotein‐associated demyelinating peripheral neuropathy. </p> </section> <section id="CD002827-sec-0003"> <h3 class="title" id="CD002827-sec-0003">Search methods</h3> <p>On 1 February 2016 we searched the Cochrane Neuromuscular Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, and Embase for randomised controlled trials (RCTs). We also checked trials registers and bibliographies, and contacted authors and experts in the field. </p> </section> <section id="CD002827-sec-0004"> <h3 class="title" id="CD002827-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) or quasi‐RCTs involving participants of any age treated with any type of immunotherapy for anti‐MAG antibody‐associated demyelinating peripheral neuropathy with monoclonal gammopathy of undetermined significance and of any severity. </p> <p>Our primary outcome measures were numbers of participants improved in disability assessed with either or both of the Neuropathy Impairment Scale (NIS) or the modified Rankin Scale (mRS) at six months after randomisation. Secondary outcome measures were: mean improvement in disability, assessed with either the NIS or the mRS, 12 months after randomisation; change in impairment as measured by improvement in the 10‐metre walk time, change in a validated linear disability measure such as the Rasch‐built Overall Disability Scale (R‐ODS) at six and 12 months after randomisation, change in subjective clinical scores and electrophysiological parameters at six and 12 months after randomisation; change in serum IgM paraprotein concentration or anti‐MAG antibody titre at six months after randomisation; and adverse effects of treatments. </p> </section> <section id="CD002827-sec-0005"> <h3 class="title" id="CD002827-sec-0005">Data collection and analysis</h3> <p>We followed standard methodological procedures expected by Cochrane.</p> </section> <section id="CD002827-sec-0006"> <h3 class="title" id="CD002827-sec-0006">Main results</h3> <p>We identified eight eligible trials (236 participants), which tested intravenous immunoglobulin (IVIg), interferon alfa‐2a, plasma exchange, cyclophosphamide and steroids, and rituximab. Two trials of IVIg (22 and 11 participants, including 20 with antibodies against MAG), had comparable interventions and outcomes, but both were short‐term trials. We also included two trials of rituximab with comparable interventions and outcomes. </p> <p>There were very few clinical or statistically significant benefits of the treatments used on the outcomes predefined for this review, but not all the predefined outcomes were used in every included trial and more responsive outcomes are being developed. A well‐performed trial of IVIg, which was at low risk of bias, showed a statistical benefit in terms of improvement in mRS at two weeks and 10‐metre walk time at four weeks, but these short‐term outcomes are of questionable clinical significance. Cyclophosphamide failed to show any benefit in the single trial's primary outcome, and showed a barely significant benefit in the primary outcome specified here, but some toxic adverse events were identified. </p> <p>Two trials of rituximab (80 participants) have been published, one of which (26 participants) was at high risk of bias. In the meta‐analysis, although the data are of low quality, rituximab is beneficial in improving disability scales (Inflammatory Neuropathy Cause and Treatment (INCAT) improved at eight to 12 months (risk ratio (RR) 3.51, 95% confidence interval (CI) 1.30 to 9.45; 73 participants)) and significantly more participants improve in the global impression of change score (RR 1.86, 95% CI 1.27 to 2.71; 70 participants). Other measures did not improve significantly, but wide CIs do not preclude some effect. Reported adverse effects of rituximab were few, and mostly minor. </p> <p>There were few serious adverse events in the other trials.</p> </section> <section id="CD002827-sec-0007"> <h3 class="title" id="CD002827-sec-0007">Authors' conclusions</h3> <p>There is inadequate reliable evidence from trials of immunotherapies in anti‐MAG paraproteinaemic neuropathy to form an evidence base supporting any particular immunotherapy treatment. IVIg has a statistically but probably not clinically significant benefit in the short term. The meta‐analysis of two trials of rituximab provides, however, low‐quality evidence of a benefit from this agent. The conclusions of this meta‐analysis await confirmation, as one of the two included studies is of very low quality. We require large well‐designed randomised trials of at least 12 months' duration to assess existing or novel therapies, preferably employing unified, consistent, well‐designed, responsive, and valid outcome measures. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD002827-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD002827-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD002827-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD002827-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD002827-abs-0006">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD002827-abs-0005">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD002827-abs-0004">Русский</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD002827-abs-0003" lang="en"> <h3>Immune treatments for peripheral neuropathy caused by an IgM paraprotein antibody, which may bind to MAG, a protein on the myelin sheath of nerves </h3> <p><b>Review question</b> </p> <p>What are the benefits and harms of immune treatments for peripheral neuropathy caused by an IgM paraprotein antibody that may bind to myelin‐associated glycoprotein (MAG)? </p> <p><b>Background</b> </p> <p>There are several types of antibodies in the human body. They are more or less specifically adapted to recognise a target, usually a 'foreign' protein such as a bit of a bacterium, virus or tumour. In some people too much of one type of antibody is made, called a paraprotein. Some of these paraproteins are of the IgM class (IgM antibodies are usually an 'early attack force' type of antibody). Some of these antibodies may react against myelin‐associated glycoprotein, also known as MAG. MAG is a molecule on the insulating myelin sheath of nerves. The antibody probably results in damage to the nerve myelin to which it is bound and thus causes a specific type of damage to the nerves, known as a peripheral neuropathy. Anti‐MAG paraprotein‐associated peripheral neuropathy is a condition affecting more men than women, most commonly over the age of 60 years. It causes progressive sensory symptoms, unsteadiness and tremor, and sometimes some weakness of the feet and lower legs. </p> <p>Treatments that act on the immune system such as plasma exchange (which removes circulating antibodies and replaces blood plasma with a clean plasma substitute), intravenous immunoglobulin (IVIg; antibodies that have been purified from donated blood), rituximab (which kills some of the cells that produce the antibody), corticosteroids, or anticancer drugs might be expected to reduce levels of these neuropathy‐causing IgM antibodies and slow or prevent progression of the disease. </p> <p><b>Study characteristics</b> </p> <p>Many of these therapies have been tried in non‐randomised studies, but we found only eight small randomised controlled trials (RCTs), involving 236 participants, that met our criteria for inclusion. </p> <p><b>Results and quality of the evidence</b> </p> <p>Two trials with 22 and 11 participants (20 with antibodies against MAG) suggest that IVIg may sometimes produce short‐term measurable benefit and is relatively safe, but the benefit is of doubtful clinical significance. No severe adverse effects related to IVIg were reported in these trials. A trial of cyclophosphamide and corticosteroids showed some mild benefit. Two trials of rituximab demonstrated a positive benefit of rituximab, but this evidence was of low quality because of small numbers of participants and concerns about the design of one of the two studies. Reported adverse effects of rituximab were few, and mostly minor. Other trials did not allow us to draw conclusions about the efficacy of other agents and reported few serious adverse events. We need large, well‐designed RCTs to assess the efficacy of the existing and new therapies, and better ways for doctors and researchers to detect changes that people report in response to treatments. </p> <p>The evidence is up to date to February 2016.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD002827-sec-0076" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD002827-sec-0076"></div> <h3 class="title" id="CD002827-sec-0077">Implications for practice</h3> <section id="CD002827-sec-0077"> <p>The evidence from trials of immunotherapies in anti‐myelin‐associated glycoprotein (anti‐MAG) paraprotein‐associated peripheral neuropathies is inadequate to identify whether any particular immunotherapy treatment is significantly beneficial. The eight published randomised controlled trials (RCTs) of immunotherapy in anti‐MAG IgM paraproteinaemic neuropathy were all individually either too small, too short or too flawed for us to draw confident conclusions about the efficacy of individual treatments or comparisons between them. </p> <p>In meta‐analysis there is low‐quality evidence (two small studies, one significantly biased including inconsistency, indirectness), that rituximab is of benefit in stabilising or improving anti‐MAG neuropathy. </p> </section> <h3 class="title" id="CD002827-sec-0078">Implications for research</h3> <section id="CD002827-sec-0078"> <p>The statistically significant short‐term benefit from IVIg may not be clinically significant. The evidence is of low quality and needs further confirmation. More large, carefully‐constructed, collaborative studies are required to identify whether anti‐CD20 therapies or other treatments are effective. </p> <p>The IgM paraproteinaemic neuropathies are chronic and slowly progressive. We chose to measure our outcomes at six and 12 months as these are more likely to reflect a time course over which measurable progression or recovery might occur. Endpoints of four weeks or even three to four months may not be long enough to detect clinical stabilisation or improvement. <a href="./references#CD002827-bbs2-0003" title="DalakasMC , RakocevicG , SalajeghehM , DambrosiaJM , HahnAF , RajuR , et al. Placebo‐controlled trial of rituximab in IgM anti–myelin‐associated glycoprotein antibody demyelinating neuropathy. Annals of Neurology2009;65(3):286–93. [PUBMED: 19334068] ">Dalakas 2009</a>, <a href="./references#CD002827-bbs2-0004" title="LégerJM , VialaK , NicolasG , CréangeA , VallatJM , PougetJ , et al. Placebo controlled trial of rituximab in IgM anti‐myelin‐associated glycoprotein neuropathy. Neurology2013;80(24):2217‐25. [PUBMED: 23667063] ">Léger 2013</a> and <a href="./references#CD002827-bbs2-0007" title="NiermeijerJMF ,  EurelingsM ,  Van der LindenMW ,   Lokhorst HM ,   Franssen H ,   Fischer K , et al. Intermittent cyclophosphamide with prednisone versus placebo for polyneuropathy with IgM monoclonal gammopathy. Neurology2007;69(1):50‐9. [PUBMED: 17606880] ">Niermeijer 2007</a> used sensible longer‐term outcomes and future studies should replicate this. We would encourage the authors of future trials to collect consistent, comparable and clinically‐meaningful endpoint data. We predefined our primary outcome measures as improvement in the Neuropathy Impairment Scale and modified Rankin Scale (disability) at six months. The inclusion of a disability measure in future trials would be appropriate, being relevant both to patients and to healthcare providers. We have included Rasch‐built disability scores in the secondary outcome measures for future studies, as these show promise in reflecting change and more effectively representing a greater range of disability. These remain in development and have not so far appeared in any trial. Predictive scoring systems which allow the clinician to estimate the trajectory and likely outcome of patients at an early stage will allow people who warrant treatment to be identified earlier in the disease; work needs to be undertaken to study the natural history of the disease progression. </p> <p>The Perinoms study is completed and a further study (Perinoms 2) is underway at the time of publication, which will define appropriate outcome measures for clinical and research outcome measurement in this condition. </p> <p>Studies of other novel agents such as cladribine or fludarabine may be indicated.</p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD002827-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD002827-sec-0015"></div> <div class="table" id="CD002827-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Rituximab versus placebo for treating IgM anti‐myelin‐associated glycoprotein paraprotein‐associated peripheral neuropathy</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Should rituximab versus placebo be used for IgM anti‐myelin‐associated glycoprotein paraprotein‐associated peripheral neuropathies?</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with IgM anti‐myelin‐associated glycoprotein paraprotein‐associated peripheral neuropathies<br/> <b>Setting:</b> hospital and outpatient treatment centres<br/> <b>Intervention:</b> rituximab<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with rituximab</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants improved in disability</b> <br/> Assessed with: INCAT score or INCAT Leg Disability Score<br/> Follow‐up: range 8 to 12 months<sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 3.51<br/> (1.30 to 9.45) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>73<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Statistically significant effect in meta‐analysis</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>74 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>260 per 1000<br/> (96 to 700) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean improvement in disability</b> </p> <p>Assessed with: INCAT score or INCAT leg disability score<br/> Scale from: 0 to 12 in INCAT and 0 to 7 in INCAT leg disability.<br/> Follow‐up: range 8 to 12 months<sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean improvement in INCAT score (see text) at 8 to 12 months was ‐0.18</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean improvement in INCAT score (see text) at 8 to 12 months in the intervention group was 0.45 lower (0.85 lower to 0.05 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Statistically significant improvement versus placebo but probably less than MCID</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Improvement in 10‐metre walk time</b> at 8 to 12 months<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean improvement in 10‐metre walk time at 8 to 12 months was 0.14 seconds</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean improvement in 10‐metre walk time at 8 to 12 months in the intervention group was 0.35 seconds more (1.89 more to 1.19 less) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68<br/> (2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MCID for 10‐metre walk approximately 0.4 seconds. Borders on clinically significant improvement, but wide CIs </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Participant subjective impression of change stable or improved at 8 to 12 months</b> <br/> Assessed with: VAS </p> <p>from: 0 to 10<br/> Follow‐up: mean 8 months<sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.86<br/> (1.27 to 2.71) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>70<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Patient global impression of change improved similarly in both studies in a time‐dependent manner (see data tables) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>447 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>832 per 1000<br/> (568 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in serum IgM paraprotein concentration 8 months after treatment</b><sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in IgM level 8 months after treatment was 32.3 mg/L</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in IgM level 8 months after treatment in the intervention group was 287.7 mg/L lower (328.98 lower to 244.42 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An unsurprising reduction in IgM in the rituximab‐treated group</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Any adverse event</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.18<br/> (0.84 to 1.66) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>80<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No statistically significant difference in adverse effects. Serious adverse effects too few to make comment. Consistency of adverse event collection always suspect </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>561 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>662 per 1000<br/> (471 to 931) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>IgM:</b> immunoglobulin M; <b>INCAT score:</b> Inflammatory Neuropathy Cause and Treatment score;<b>MCID:</b> minimum clinically important difference; <b>RR:</b> risk ratio; <b>VAS:</b> visual analogue scale </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>The outcomes in the rituximab study were recorded at between 8 and 12 months, which is rational for the treatment of a disease with rituximab. Thus we have reported this interval for this intervention (see text).<br/> <sup>2</sup>Downgraded twice for imprecision (small underpowered studies) and unresponsive outcome measures.<br/> <sup>3</sup>Downgraded twice for imprecision (small underpowered studies) and indirectness (patient impression of change).<br/> <sup>4</sup>Downgraded once for imprecision (small underpowered studies).<br/> <sup>5</sup>Downgraded three times for imprecision (small studies and small even numbers), trial design and inconsistent adverse event recording. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD002827-sec-0016" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD002827-sec-0016"></div> <p>Up to 10% of people with a peripheral neuropathy which is not secondary to another primary illness have a paraprotein in the serum (<a href="./references#CD002827-bbs2-0061" title="KellyJJ , KyleRA , O'BrienPC , DyckPJ . Prevalence of monoclonal protein in peripheral neuropathy. Neurology1981;31(11):1480‐3. ">Kelly 1981</a>). A paraprotein is an abnormal protein produced by bone marrow cells and may belong to one of the three classes of immunoglobulin (Ig), IgG, IgA or IgM. The majority of paraproteins in people with peripheral neuropathy are IgM, produced by an initially benign condition of blood cells called monoclonal gammopathy of undetermined significance (MGUS). Of this group of paraproteins, 50% react with the CD57/HNK‐1 carbohydrate epitope found on myelin‐associated glycoprotein (MAG). This epitope is also found on other peripheral nerve myelin molecules (myelin protein zero, peripheral myelin protein 22, sulphated glucuronyl paragloboside (SGPG), sulphated glucuronyl lactosaminyl paragloboside (SGLPG) and others) but the antibodies are commonly referred to as anti‐MAG. </p> <section id="CD002827-sec-0017"> <h3 class="title" id="CD002827-sec-0017">Description of the condition</h3> <p>The clinical neuropathy associated with anti‐MAG antibodies is usually relatively phenotypically homogeneous, and consists of a slowly progressive distal sensorimotor neuropathy with a variable degree of ataxia and prominent tremor (<a href="./references#CD002827-bbs2-0034" title="ChassandeB , LegerJM , Younes‐ChennoufiAB , BengoufaD , MaisonobeT , BoucheP , et al. Peripheral neuropathy associated with IgM monoclonal gammopathy: correlations between M‐protein antibody activity and clinical/electrophysiological features in 40 cases. Muscle &amp; Nerve1998;21(6):55‐62. ">Chassande 1998</a>; <a href="./references#CD002827-bbs2-0088" title="SmithIS , KahnSN , LaceyBW , KingRHM , EamesRA , WhybrewDJ , et al. Chronic demyelinating neuropathy associated with benign IgM paraproteinaemia. Brain1983;106(Pt 1):169‐95. ">Smith 1983</a>; <a href="./references#CD002827-bbs2-0089" title="SmithT , ShermanW , OlarteMR , LovelaceRE . Peripheral neuropathy associated with plasma cell dyscrasia: a clinical and electrophysiological follow‐up study. Acta Neurologica Scandanavica1987;75(4):244‐8. ">Smith 1987</a>; <a href="./references#CD002827-bbs2-0099" title="YeungKB , ThomasPK , KingRH , WaddyH , WillRG , HughesRAC , et al. The clinical spectrum of peripheral neuropathies associated with benign monoclonal IgM, IgG and IgA paraproteinaemia. Comparative clinical, immunological and nerve biopsy findings. Journal of Neurology1991;238(7):383‐91. ">Yeung 1991</a>). The neurophysiological features are demyelination, characteristically with more slowing of conduction in the distal than the proximal nerve segments (<a href="./references#CD002827-bbs2-0060" title="KakuDA , EnglandJD , SumnerAJ . Distal accentuation of conduction slowing in polyneuropathy associated with antibodies to myelin‐associated glycoprotein and sulphated glucuronyl paragloboside. Brain1994;117(Pt 5):941‐7. ">Kaku 1994</a>). The term anti‐MAG IgM paraproteinaemic demyelinating peripheral neuropathy (PDPN) is therefore sometimes used to refer to this condition. </p> <p>Other antibody reactivities exist in people with neuropathy and an IgM paraprotein and they have tentatively been classified into small homogeneous groupings. Examples include motor neuropathies with anti‐GM1 antibodies (<a href="./references#CD002827-bbs2-0090" title="SteckAJ , KuntzerT . Anti‐glycoconjugate antibodies and dysglobulinemic or dysimmune peripheral neuropathies. Revue Neurologique1996;152:400‐4. ">Steck 1996</a>), chronic sensory ataxic neuropathy associated with antibodies to GQ1b and other gangliosides with at least two sialic acid groups called CANOMAD (<a href="./references#CD002827-bbs2-0097" title="WillisonHJ , O'LearyCP , VeitchJ , BlumhardtLD , BusbyM , DonaghyM , et al. The clinical and laboratory features of chronic sensory ataxic neuropathy with anti‐disialosyl IgM antibodies. Brain2001;124(10):1968‐77. ">Willison 2001</a>), and sensory demyelinating neuropathies with anti‐sulfatide antibodies (<a href="./references#CD002827-bbs2-0045" title="FerrariS , MorbinM , Nobile‐OrazioE , MussoA , TomelleriG , BertolasiL , et al. Antisulfatide polyneuropathy: antibody‐mediated complement attack on peripheral myelin. Acta Neuropathologica1998;96(6):569‐74. ">Ferrari 1998</a>). However, the most clearly described, relatively homogeneous group remains the neuropathy associated with IgM anti‐MAG antibodies, the subject of this review.<br/> <br/> Considerable evidence exists that anti‐MAG antibodies are pathogenic. Deposits of the IgM paraprotein have been demonstrated in sural nerves of affected people (<a href="./references#CD002827-bbs2-0093" title="TakatsuM , HaysAP , LatovN , AbramsGM , NemniR , ShermanWH , et al. Immunofluorescence study of patients with neuropathy and IgM M proteins. Annals of Neurology1985;18(2):173‐81. ">Takatsu 1985</a>). The paraprotein is bound to myelin in a similar distribution to MAG. In some cases the binding has been associated with the deposition of activated complement components (<a href="./references#CD002827-bbs2-0055" title="HaysAP , LeeSS , LatovN . Immune reactive C3d on the surface of myelin sheaths in neuropathy. Journal of Neuroimmunology1988;18(3):231‐44. ">Hays 1988</a>; <a href="./references#CD002827-bbs2-0072" title="MonacoS , BonettiB , FerrariS , MorettoG , NardelliE , TedescoF , et al. Complement‐mediated demyelination in patients with IgM monoclonal gammopathy and polyneuropathy. New England Journal of Medicine1990;322(10):649‐52. [MEDLINE: 90158704] ">Monaco 1990</a>). Demyelination has also been induced in some animal models by the passive transfer of anti‐MAG antibodies (<a href="./references#CD002827-bbs2-0094" title="TatumAH . Experimental paraprotein neuropathy, demyelination by passive transfer of human IgM anti‐myelin‐associated glycoprotein. Annals of Neurology1993;33(5):502‐6. ">Tatum 1993</a>; <a href="./references#CD002827-bbs2-0096" title="WillisonHJ , TrappBD , BacherJD , DalakasMC , GriffinJW , QuarlesRH . Demyelination induced by intraneural injection of human antimyelin‐associated glycoprotein antibodies. Muscle &amp; Nerve1988;11(11):1169‐76. ">Willison 1988</a>), and more recently by immunisation with SGPG (<a href="./references#CD002827-bbs2-0059" title="IlyasAA , GuY , DalakasMC , QuarlesRH , BhattS . Induction of experimental ataxic sensory neuronopathy in cats by immunization with purified SGPG. Journal of the Peripheral Nervous System2008;193(1‐2):87‐93. ">Ilyas 2008</a>). People have been reported to respond to immunotherapies, the improvement sometimes correlating with a reduction in levels of IgM (<a href="./references#CD002827-bbs2-0098" title="WilsonHC , LunnMPT , ScheyS , HughesRAC . Successful treatment of IgM paraproteinaemic neuropathy with fludarabine. Journal of Neurology, Neurosurgery and Psychiatry1999;66(5):575‐80. ">Wilson 1999</a>). </p> </section> <section id="CD002827-sec-0018"> <h3 class="title" id="CD002827-sec-0018">Description of the intervention</h3> <p>There are a number of possible therapies which have been described as effective in the treatment of anti‐MAG paraproteinaemic neuropathy, including plasma exchange, corticosteroids, intravenous immunoglobulin (IVIg), cyclophosphamide, fludarabine and cytarabine, chlorambucil, alpha‐interferon, rituximab or combinations of these agents. These are described below in the <a href="./full#CD002827-sec-0036">Results</a> and <a href="#CD002827-sec-0065">Discussion</a> sections. </p> <p>Currently, treatment is largely decided on the informed choice of the individual. Many people are too old or too mildly affected to make the risks of treatment worthwhile. There are only eight randomised controlled trials (RCTs) testing the efficacy of the various immunosuppressive regimens in IgM paraproteinaemic neuropathies (<a href="./references#CD002827-bbs2-0001" title="ComiG , RoveriL , SwanA , WillisonH , BojarM , IllaI , et al. Inflammatory Neuropathy Cause And Treatment (INCAT) Group. A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy. Journal of Neurology2002;249(10):1370‐7. [PUBMED: 12382151] ">Comi 2002</a>; <a href="./references#CD002827-bbs2-0002" title="DalakasMC , QuarlesRH , FarrerRG , DambrosiaJ , SoueidanS , SteinDP , et al. A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy. Annals of Neurology1996;40(5):792‐5. [PUBMED: 8957021] ">Dalakas 1996</a>; <a href="./references#CD002827-bbs2-0003" title="DalakasMC , RakocevicG , SalajeghehM , DambrosiaJM , HahnAF , RajuR , et al. Placebo‐controlled trial of rituximab in IgM anti–myelin‐associated glycoprotein antibody demyelinating neuropathy. Annals of Neurology2009;65(3):286–93. [PUBMED: 19334068] ">Dalakas 2009</a>; <a href="./references#CD002827-bbs2-0014" title="DyckPJ , LowPA , WindebankAJ , JaradehSS , GosselinS , BourqueP , et al. Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance. New England Journal of Medicine1991;325(21):1482‐6. [MEDLINE: 92049565] ">Dyck 1991</a>; <a href="./references#CD002827-bbs2-0004" title="LégerJM , VialaK , NicolasG , CréangeA , VallatJM , PougetJ , et al. Placebo controlled trial of rituximab in IgM anti‐myelin‐associated glycoprotein neuropathy. Neurology2013;80(24):2217‐25. [PUBMED: 23667063] ">Léger 2013</a>; <a href="./references#CD002827-bbs2-0005" title="MarietteX , ChastangC , ClavelouP , LouboutinJ‐P , LegerJM , BrouetJC . A randomised clinical trial comparing interferon‐alpha and intravenous immunoglobulin in polyneuropathy associated with monoclonal IgM. The IgM‐associated Polyneuropathy Study Group. Journal of Neurology, Neurosurgery and Psychiatry1997;63(1):28‐34. [PUBMED: 9221964] ">Mariette 1997</a>; <a href="./references#CD002827-bbs2-0006" title="MarietteX , BrouetJC , ChevretS , LegerJM , ClavelouP , PougetJ , et al. A randomized double blind trial versus placebo does not confirm the benefit of alpha‐interferon in polyneuropathy associated with monoclonal IgM. Journal of Neurology, Neurosurgery and Psychiatry2000;69(2):279‐80. [PUBMED: 10960293] ">Mariette 2000</a>; <a href="./references#CD002827-bbs2-0007" title="NiermeijerJMF ,  EurelingsM ,  Van der LindenMW ,   Lokhorst HM ,   Franssen H ,   Fischer K , et al. Intermittent cyclophosphamide with prednisone versus placebo for polyneuropathy with IgM monoclonal gammopathy. Neurology2007;69(1):50‐9. [PUBMED: 17606880] ">Niermeijer 2007</a>; <a href="./references#CD002827-bbs2-0008" title="OksenhendlerE , ChevretS , LegerJM , LouboutinJP , BusselA , BrouetJC . Plasma exchange and chlorambucil in polyneuropathy associated with monoclonal IgM gammopathy. IgM‐associated Polyneuropathy Study Group. Journal of Neurology, Neurosurgery and Psychiatry1995;59(3):243‐7. [PUBMED: 7673949] ">Oksenhendler 1995</a>). Most case series have been small, included diverse groups of participants and have not presented results of efficacy clearly. </p> </section> <section id="CD002827-sec-0019"> <h3 class="title" id="CD002827-sec-0019">How the intervention might work</h3> <p>Treatment strategies have either aimed to reduce the IgM paraprotein concentration, by removing the antibody or targeting the presumed monoclonal B‐cell clone and reducing its production, or to interfere with the presumed effector mechanisms such as complement activation or macrophage recruitment. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD002827-sec-0020" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD002827-sec-0020"></div> <p>To assess the effects of immunotherapy for IgM anti‐MAG paraprotein‐associated demyelinating peripheral neuropathy. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD002827-sec-0021" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD002827-sec-0021"></div> <section id="CD002827-sec-0022"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD002827-sec-0023"> <h4 class="title">Types of studies</h4> <p>We included RCTs and quasi‐RCTs using any immunotherapy in anti‐MAG paraproteinaemic demyelinating peripheral neuropathy (PDPN). </p> </section> <section id="CD002827-sec-0024"> <h4 class="title">Types of participants</h4> <p>We included participants of any age with a diagnosis of MGUS, demyelinating neuropathy and anti‐MAG antibodies. Other causes of peripheral neuropathy should have been ruled out. </p> <p>Paraproteins were to be of the IgM class and shown to be reactive with MAG or SGPG by a validated method which could be: </p> <p> <ul id="CD002827-list-0001"> <li> <p>western blotting against human sciatic nerve homogenate;</p> </li> <li> <p>enzyme‐linked immunosorbent assay (ELISA) for MAG or SGPG or SGLPG;</p> </li> <li> <p>complement fixation test against human sciatic nerve homogenate (confirmed by a second method); </p> </li> <li> <p>thin layer chromatographic immuno‐overlay against SGPG or SGLPG.</p> </li> </ul> </p> <p>As anti‐MAG methods varied, we accepted positive anti‐MAG results as reported by the trial authors and we did not define a threshold titre for positivity. </p> <p>The neuropathy was to be typical distal symmetrical sensory or sensorimotor and should fit published criteria for slowing of motor nerve conduction in chronic inflammatory demyelinating polyradiculoneuropathy (<a href="./references#CD002827-bbs2-0028" title="Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force. Research criteria for the diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Neurology1991;41(5):617‐8. ">Ad Hoc 1991</a> or <a href="./references#CD002827-bbs2-0073" title="NicolasG , MaisonobeT , LeForestierN , LégerJM , BoucheP . Proposed revised electrophysiological criteria for chronic inflammatory demyelinating polyradiculoneuropathy. Muscle &amp; Nerve2002;25(1):26‐30. ">Nicolas 2002</a>), with or without prominent slowing in distal nerve segments. The occurrence of conduction block in this neuropathy is debated and was not an exclusion criterion. </p> <p>We included studies that did not exactly fulfil these criteria, if necessary after consultation with the original study authors, provided the review authors agreed that IgM anti‐MAG‐associated demyelinating neuropathy was the preferred diagnosis. We noted any departure from the diagnostic criteria. </p> </section> <section id="CD002827-sec-0025"> <h4 class="title">Types of interventions</h4> <p>We included any type of immunotherapy used for the treatment of IgM paraprotein‐associated demyelinating peripheral neuropathy with anti‐MAG antibodies. We considered the following therapies for inclusion: plasmapheresis or plasma exchange or selective apheresis, intravenous immunoglobulin (IVIg), corticosteroids (prednisolone, prednisone, methylprednisolone, dexamethasone), chlorambucil, cyclophosphamide, azathioprine, fludarabine,cladribine, interferon alfa‐2a, adriamycin, melphalan, and monoclonal antibody‐based therapies (for example, rituximab). We considered comparisons versus placebo, another treatment, or an alternative dosage or treatment protocol. Therapies could be administered using any protocol (for example, single agent, combined therapy or sequential administration). If the control arm received a co‐intervention then the experimental arm had to also receive that same treatment. </p> </section> <section id="CD002827-sec-0026"> <h4 class="title">Types of outcome measures</h4> <section id="CD002827-sec-0027"> <h5 class="title">Primary outcomes</h5> <p>Predefined primary outcome measures were numbers of participants improved in disability at six months after randomisation assessed with either or both of:<br/> (a) the Neuropathy Impairment Scale (NIS) (<a href="./references#CD002827-bbs2-0040" title="DyckPJ , ShermanWR , HallcherLM , ServiceFJ , O'BrienPC , GrinaLA , et al. Human diabetic endoneurial sorbitol, fructose, and myo‐inositol related to sural nerve morphometry. Annals of Neurology1980;8(6):590‐6. ">Dyck 1980</a>; <a href="./references#CD002827-bbs2-0041" title="DyckPJ , HughesRAC , O'BrienPC . Quantitating overall neuropathic symptoms, impairments and outcomes. In: DyckPJ , ThomasPK editor(s). Peripheral Neuropathy. 4th Edition. Philadelphia: Elsevier Saunders, 2005:1031‐53. ">Dyck 2005</a>) by at least 10% (maximum score 244);<br/> (b) the modified Rankin Scale (mRS) (<a href="./references#CD002827-bbs2-0030" title="BamfordJM , SandercockPA , WarlowCP , SlatteryJ . Interobserver agreement for the assessment of handicap in stroke patients. Stroke1989;20(6):828. ">Bamford 1989</a>) (scale 0 to 6). </p> <p>We selected the NIS and mRS as primary outcome measures, as we considered them to be broad, commonly‐used scores that were potentially easy to retrospectively derive from collected data. We predefined six months as the favoured time point for re‐evaluation on the basis that IgM anti‐MAG paraprotein‐associated neuropathy is a chronic and slowly progressive disorder. A reduction in either score indicates improvement and as there is no published minimum clinically important difference for the NIS, we defined a 10% change as improvement. </p> </section> <section id="CD002827-sec-0028"> <h5 class="title">Secondary outcomes</h5> <p>Secondary outcome measures were:</p> <p> <ol id="CD002827-list-0002"> <li> <p>mean improvement in disability assessed with either the NIS or the mRS, or both, 12 months after randomisation; </p> </li> <li> <p>change in impairment as measured by improvement in 10‐metre walk time six and 12 months after randomisation (improvement is reduction in walk time); </p> </li> <li> <p>change in a validated linear disability measure such as the Rasch‐built Overall Disability Scale (R‐ODS) at six and 12 months after randomisation; </p> </li> <li> <p>change in subjective clinical scores at six and 12 months after randomisation;</p> </li> <li> <p>change in electrophysiological measures:</p> <ol id="CD002827-list-0003"> <li> <p>reappearance of sural sensory nerve action potentials (SNAPs) or compound muscle action potentials (CMAPs) in previously inexcitable nerves, or </p> </li> <li> <p>electrophysiological change in at least two nerves (where improvement was defined as more than a 20% increase in motor or sensory nerve conduction velocities or more than a 20% decrease in motor distal latencies) compared to baseline at six and 12 months after randomisation; </p> </li> </ol> </li> <li> <p>change in serum IgM paraprotein concentration or anti‐MAG titre (significant improvement defined as at least a 20% reduction in IgM or a 50% reduction of anti‐MAG titre compared to baseline at six months after randomisation); </p> </li> <li> <p>adverse effects from treatment during the trial period, graded as:</p> <ul id="CD002827-list-0004"> <li> <p>minor ‐ not requiring action;</p> </li> <li> <p>moderate ‐ requiring alteration in dosage, drug regimen or other intervention; or</p> </li> <li> <p>severe ‐ requiring withdrawal from study or resulting in hospitalisation or death.</p> </li> </ul> </li> </ol> </p> </section> </section> </section> <section id="CD002827-sec-0029"> <h3 class="title">Search methods for identification of studies</h3> <p>We searched the Cochrane Neuromuscular Specialised Register (1 February 2016), the Cochrane Central Register of Controlled Trials (CENTRAL) (2016, Issue 1 in the Cochrane Library), MEDLINE (January 1966 to January 2016) and Embase (January 1980 to January 2016) for randomised controlled trials. We reviewed bibliographies to identify other controlled trials. We contacted trial authors and experts in the field to identify additional published or unpublished data. </p> <p>We also searched ClinicalTrials.gov (ClinicalTrials.gov) and the World Health Organization International Clinical trials Registry Platform (ICTRP) (www.who.int/ictrp/en/), on 23 October 2014. </p> <p>The detailed search strategies are in the appendices: MEDLINE (<a href="./appendices#CD002827-sec-0082">Appendix 1</a>), Embase (<a href="./appendices#CD002827-sec-0083">Appendix 2</a>), CENTRAL (<a href="./appendices#CD002827-sec-0084">Appendix 3</a>) and Cochrane Neuromuscular Specialised Register (<a href="./appendices#CD002827-sec-0085">Appendix 4</a>). We searched clinical trials registries from within their search engines with the terms "myelin associated glycoprotein", "anti‐MAG neuropathy" and "paraproteinaemic neuropathy" (<a href="./appendices#CD002827-sec-0086">Appendix 5</a>). </p> </section> <section id="CD002827-sec-0030"> <h3 class="title" id="CD002827-sec-0030">Data collection and analysis</h3> <section id="CD002827-sec-0031"> <h4 class="title">Selection of studies</h4> <p>Two review authors independently checked titles and abstracts identified from database searches and bibliographies. Both review authors obtained and assessed the full text of all potentially relevant studies. Both review authors decided which trials fitted the inclusion criteria, resolving disagreements about inclusion by discussion. </p> </section> <section id="CD002827-sec-0032"> <h4 class="title">Data extraction and management</h4> <p>Both review authors independently performed data extraction onto a custom‐designed data extraction sheet, cross‐checked the data and resolved differences by discussion. We requested and obtained missing data from the trial authors whenever possible. </p> </section> <section id="CD002827-sec-0033"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>The review authors assessed the risk of bias in included studies using the methods described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD002827-bbs2-0056" title="HigginsJPT , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). They considered: sequence generation; allocation concealment; blinding of participants, personnel and outcome assessors; incomplete outcome data; selective outcome reporting; and other potential sources of bias. </p> <p>We graded these items as at low risk of bias, high risk of bias or unclear. Each review author graded the risk of bias independently; we then compared the results and reached agreement about differences by consensus. </p> </section> <section id="CD002827-sec-0034"> <h4 class="title">Data synthesis</h4> <p>We pooled trial outcomes for interventions when possible. We calculated a weighted treatment effect across trials (using a fixed‐effect model) with the Cochrane statistical package Review Manager 5 (<a href="./references#CD002827-bbs2-0081" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). We expressed results as risk ratios (RRs) with 95% confidence intervals (CIs) for dichotomous outcomes, and mean differences (MDs) with 95% CIs for continuous outcomes. We tried to analyse all the primary and secondary outcomes under consideration. Because very little meta‐analysis was possible, we did not perform sensitivity analysis. We did not plan any subgroup analyses. </p> <section id="CD002827-sec-0035"> <h5 class="title">`Summary of findings' tables</h5> <p>We included 'Summary of findings' tables where it was possible to populate these with meaningful data. Where possible, we reported all outcomes at six months after randomisation: </p> <p> <ol id="CD002827-list-0005"> <li> <p>number of participants improved in disability assessed with either or both of the NIS and the mRS; </p> </li> <li> <p>mean improvement in disability assessed with either the NIS or the mRS;</p> </li> <li> <p>change in impairment as measured by improvement in 10‐metre walk time;</p> </li> <li> <p>change in subjective clinical scores (participant subjective impression of change stable or improved); </p> </li> <li> <p>change in serum IgM paraprotein concentration; and</p> </li> <li> <p>any adverse event.</p> </li> </ol> </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD002827-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD002827-sec-0036"></div> <section id="CD002827-sec-0037"> <h3 class="title">Description of studies</h3> <section id="CD002827-sec-0038"> <h4 class="title">Results of the search</h4> <p>Up to 2006, a search of the Cochrane Neuromuscular Specialised Register revealed 12 possible trials. Searching MEDLINE and Embase with the same strategy and handsearching bibliographies failed to reveal further trials. A further search to July 2009 for the update identified trials and papers as follows: CENTRAL: 4, MEDLINE: 679 (13 papers reviewed), and Embase: 212 (seven reviewed). Review of the full texts identified two new eligible studies (<a href="./references#CD002827-bbs2-0003" title="DalakasMC , RakocevicG , SalajeghehM , DambrosiaJM , HahnAF , RajuR , et al. Placebo‐controlled trial of rituximab in IgM anti–myelin‐associated glycoprotein antibody demyelinating neuropathy. Annals of Neurology2009;65(3):286–93. [PUBMED: 19334068] ">Dalakas 2009</a>; <a href="./references#CD002827-bbs2-0007" title="NiermeijerJMF ,  EurelingsM ,  Van der LindenMW ,   Lokhorst HM ,   Franssen H ,   Fischer K , et al. Intermittent cyclophosphamide with prednisone versus placebo for polyneuropathy with IgM monoclonal gammopathy. Neurology2007;69(1):50‐9. [PUBMED: 17606880] ">Niermeijer 2007</a>). A further search for the 2012 update identified the following numbers of papers: Cochrane Neuromuscular Specialised Register: 3, CENTRAL: 52, MEDLINE: 116, and Embase: 317, with no new trials identified. In 2015, searches identified the following numbers of papers: Cochrane Neuromuscular Specialised Register: 27 papers, CENTRAL: 76 papers, MEDLINE: 65 new papers (1035 total), Embase: 112 new papers (1645 total). A search of the Database of Abstracts of Reviews of Effectiveness (DARE) identified four papers and searches of <a href="http://ClinicalTrials.gov" target="_blank">ClinicalTrials.gov</a> and ICTRP (<a href="http://www.who.int/ictrp/en/" target="_blank">www.who.int/ictrp/en/</a>) identified three each (identified from the resources above). </p> <p><a href="#CD002827-fig-0001">Figure 1</a> presents a flow chart of the study selection process for this update. </p> <div class="figure" id="CD002827-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="PRISMA chart for searched to included studies of IgM paraproteinaemic neuropathy" data-id="CD002827-fig-0001" src="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/image_n/nCD002827-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>PRISMA chart for searched to included studies of IgM paraproteinaemic neuropathy</p> </div> </div> </div> </section> <section id="CD002827-sec-0039"> <h4 class="title">Included studies</h4> <p>The eight included studies enrolled 236 participants (see <a href="./references#CD002827-sec-0096" title="">Characteristics of included studies</a>; <a href="#CD002827-fig-0001">Figure 1</a>), of whom 104 were treated at some stage with the study intervention. In only three trials were all the predeclared inclusion criteria met (<a href="./references#CD002827-bbs2-0001" title="ComiG , RoveriL , SwanA , WillisonH , BojarM , IllaI , et al. Inflammatory Neuropathy Cause And Treatment (INCAT) Group. A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy. Journal of Neurology2002;249(10):1370‐7. [PUBMED: 12382151] ">Comi 2002</a>; <a href="./references#CD002827-bbs2-0003" title="DalakasMC , RakocevicG , SalajeghehM , DambrosiaJM , HahnAF , RajuR , et al. Placebo‐controlled trial of rituximab in IgM anti–myelin‐associated glycoprotein antibody demyelinating neuropathy. Annals of Neurology2009;65(3):286–93. [PUBMED: 19334068] ">Dalakas 2009</a>; <a href="./references#CD002827-bbs2-0007" title="NiermeijerJMF ,  EurelingsM ,  Van der LindenMW ,   Lokhorst HM ,   Franssen H ,   Fischer K , et al. Intermittent cyclophosphamide with prednisone versus placebo for polyneuropathy with IgM monoclonal gammopathy. Neurology2007;69(1):50‐9. [PUBMED: 17606880] ">Niermeijer 2007</a>). Three studies stated that the participants had benign monoclonal gammopathy or monoclonal gammopathy of undetermined significance (<a href="./references#CD002827-bbs2-0001" title="ComiG , RoveriL , SwanA , WillisonH , BojarM , IllaI , et al. Inflammatory Neuropathy Cause And Treatment (INCAT) Group. A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy. Journal of Neurology2002;249(10):1370‐7. [PUBMED: 12382151] ">Comi 2002</a>; <a href="./references#CD002827-bbs2-0003" title="DalakasMC , RakocevicG , SalajeghehM , DambrosiaJM , HahnAF , RajuR , et al. Placebo‐controlled trial of rituximab in IgM anti–myelin‐associated glycoprotein antibody demyelinating neuropathy. Annals of Neurology2009;65(3):286–93. [PUBMED: 19334068] ">Dalakas 2009</a>; <a href="./references#CD002827-bbs2-0007" title="NiermeijerJMF ,  EurelingsM ,  Van der LindenMW ,   Lokhorst HM ,   Franssen H ,   Fischer K , et al. Intermittent cyclophosphamide with prednisone versus placebo for polyneuropathy with IgM monoclonal gammopathy. Neurology2007;69(1):50‐9. [PUBMED: 17606880] ">Niermeijer 2007</a>). Other studies may have included participants with Waldenstrom's macroglobulinaemia (<a href="./references#CD002827-bbs2-0005" title="MarietteX , ChastangC , ClavelouP , LouboutinJ‐P , LegerJM , BrouetJC . A randomised clinical trial comparing interferon‐alpha and intravenous immunoglobulin in polyneuropathy associated with monoclonal IgM. The IgM‐associated Polyneuropathy Study Group. Journal of Neurology, Neurosurgery and Psychiatry1997;63(1):28‐34. [PUBMED: 9221964] ">Mariette 1997</a>; <a href="./references#CD002827-bbs2-0006" title="MarietteX , BrouetJC , ChevretS , LegerJM , ClavelouP , PougetJ , et al. A randomized double blind trial versus placebo does not confirm the benefit of alpha‐interferon in polyneuropathy associated with monoclonal IgM. Journal of Neurology, Neurosurgery and Psychiatry2000;69(2):279‐80. [PUBMED: 10960293] ">Mariette 2000</a>; <a href="./references#CD002827-bbs2-0008" title="OksenhendlerE , ChevretS , LegerJM , LouboutinJP , BusselA , BrouetJC . Plasma exchange and chlorambucil in polyneuropathy associated with monoclonal IgM gammopathy. IgM‐associated Polyneuropathy Study Group. Journal of Neurology, Neurosurgery and Psychiatry1995;59(3):243‐7. [PUBMED: 7673949] ">Oksenhendler 1995</a>), or participants with other causes of neuropathy (<a href="./references#CD002827-bbs2-0002" title="DalakasMC , QuarlesRH , FarrerRG , DambrosiaJ , SoueidanS , SteinDP , et al. A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy. Annals of Neurology1996;40(5):792‐5. [PUBMED: 8957021] ">Dalakas 1996</a>). Three studies stated that all participants had a demyelinating neuropathy (<a href="./references#CD002827-bbs2-0001" title="ComiG , RoveriL , SwanA , WillisonH , BojarM , IllaI , et al. Inflammatory Neuropathy Cause And Treatment (INCAT) Group. A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy. Journal of Neurology2002;249(10):1370‐7. [PUBMED: 12382151] ">Comi 2002</a>; <a href="./references#CD002827-bbs2-0002" title="DalakasMC , QuarlesRH , FarrerRG , DambrosiaJ , SoueidanS , SteinDP , et al. A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy. Annals of Neurology1996;40(5):792‐5. [PUBMED: 8957021] ">Dalakas 1996</a>; <a href="./references#CD002827-bbs2-0003" title="DalakasMC , RakocevicG , SalajeghehM , DambrosiaJM , HahnAF , RajuR , et al. Placebo‐controlled trial of rituximab in IgM anti–myelin‐associated glycoprotein antibody demyelinating neuropathy. Annals of Neurology2009;65(3):286–93. [PUBMED: 19334068] ">Dalakas 2009</a>), but only one of these stipulated the electrophysiological criteria for demyelination used (<a href="./references#CD002827-bbs2-0001" title="ComiG , RoveriL , SwanA , WillisonH , BojarM , IllaI , et al. Inflammatory Neuropathy Cause And Treatment (INCAT) Group. A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy. Journal of Neurology2002;249(10):1370‐7. [PUBMED: 12382151] ">Comi 2002</a>). All of the included participants had serum IgM anti‐MAG activity tested but this was established by various methods of western blotting, immunofluorescence or anti‐SGPG ELISA testing. In total, 194 of 236 participants had anti‐MAG activity, and in four of eight studies all the participants in the study had anti‐MAG activity (<a href="./references#CD002827-bbs2-0003" title="DalakasMC , RakocevicG , SalajeghehM , DambrosiaJM , HahnAF , RajuR , et al. Placebo‐controlled trial of rituximab in IgM anti–myelin‐associated glycoprotein antibody demyelinating neuropathy. Annals of Neurology2009;65(3):286–93. [PUBMED: 19334068] ">Dalakas 2009</a>; <a href="./references#CD002827-bbs2-0004" title="LégerJM , VialaK , NicolasG , CréangeA , VallatJM , PougetJ , et al. Placebo controlled trial of rituximab in IgM anti‐myelin‐associated glycoprotein neuropathy. Neurology2013;80(24):2217‐25. [PUBMED: 23667063] ">Léger 2013</a>; <a href="./references#CD002827-bbs2-0005" title="MarietteX , ChastangC , ClavelouP , LouboutinJ‐P , LegerJM , BrouetJC . A randomised clinical trial comparing interferon‐alpha and intravenous immunoglobulin in polyneuropathy associated with monoclonal IgM. The IgM‐associated Polyneuropathy Study Group. Journal of Neurology, Neurosurgery and Psychiatry1997;63(1):28‐34. [PUBMED: 9221964] ">Mariette 1997</a>; <a href="./references#CD002827-bbs2-0006" title="MarietteX , BrouetJC , ChevretS , LegerJM , ClavelouP , PougetJ , et al. A randomized double blind trial versus placebo does not confirm the benefit of alpha‐interferon in polyneuropathy associated with monoclonal IgM. Journal of Neurology, Neurosurgery and Psychiatry2000;69(2):279‐80. [PUBMED: 10960293] ">Mariette 2000</a>). <a href="./references#CD002827-bbs2-0007" title="NiermeijerJMF ,  EurelingsM ,  Van der LindenMW ,   Lokhorst HM ,   Franssen H ,   Fischer K , et al. Intermittent cyclophosphamide with prednisone versus placebo for polyneuropathy with IgM monoclonal gammopathy. Neurology2007;69(1):50‐9. [PUBMED: 17606880] ">Niermeijer 2007</a> stated that numbers of participants were too small to establish an effect of anti‐MAG antibodies and no original data were available to analyse the subgroup of anti‐MAG participants in the other three studies. </p> <p>The interventions and trial designs of the eight included studies were widely different. Two studies compared IVIg with placebo in a placebo‐controlled cross‐over design (<a href="./references#CD002827-bbs2-0001" title="ComiG , RoveriL , SwanA , WillisonH , BojarM , IllaI , et al. Inflammatory Neuropathy Cause And Treatment (INCAT) Group. A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy. Journal of Neurology2002;249(10):1370‐7. [PUBMED: 12382151] ">Comi 2002</a>; <a href="./references#CD002827-bbs2-0002" title="DalakasMC , QuarlesRH , FarrerRG , DambrosiaJ , SoueidanS , SteinDP , et al. A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy. Annals of Neurology1996;40(5):792‐5. [PUBMED: 8957021] ">Dalakas 1996</a>). Both of these studies included a one‐month minimum washout period between the cross‐over arms, considered rather short given the half‐life of IgG, even though <a href="./references#CD002827-bbs2-0001" title="ComiG , RoveriL , SwanA , WillisonH , BojarM , IllaI , et al. Inflammatory Neuropathy Cause And Treatment (INCAT) Group. A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy. Journal of Neurology2002;249(10):1370‐7. [PUBMED: 12382151] ">Comi 2002</a> gave a single dose of IVIg compared to the three monthly doses in <a href="./references#CD002827-bbs2-0002" title="DalakasMC , QuarlesRH , FarrerRG , DambrosiaJ , SoueidanS , SteinDP , et al. A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy. Annals of Neurology1996;40(5):792‐5. [PUBMED: 8957021] ">Dalakas 1996</a>. One study compared interferon alfa‐2a with IVIg in an open‐label design (<a href="./references#CD002827-bbs2-0005" title="MarietteX , ChastangC , ClavelouP , LouboutinJ‐P , LegerJM , BrouetJC . A randomised clinical trial comparing interferon‐alpha and intravenous immunoglobulin in polyneuropathy associated with monoclonal IgM. The IgM‐associated Polyneuropathy Study Group. Journal of Neurology, Neurosurgery and Psychiatry1997;63(1):28‐34. [PUBMED: 9221964] ">Mariette 1997</a>) and another with placebo in a double‐blind design (<a href="./references#CD002827-bbs2-0006" title="MarietteX , BrouetJC , ChevretS , LegerJM , ClavelouP , PougetJ , et al. A randomized double blind trial versus placebo does not confirm the benefit of alpha‐interferon in polyneuropathy associated with monoclonal IgM. Journal of Neurology, Neurosurgery and Psychiatry2000;69(2):279‐80. [PUBMED: 10960293] ">Mariette 2000</a>). One study compared chlorambucil alone with a combination of chlorambucil and plasma exchange (<a href="./references#CD002827-bbs2-0008" title="OksenhendlerE , ChevretS , LegerJM , LouboutinJP , BusselA , BrouetJC . Plasma exchange and chlorambucil in polyneuropathy associated with monoclonal IgM gammopathy. IgM‐associated Polyneuropathy Study Group. Journal of Neurology, Neurosurgery and Psychiatry1995;59(3):243‐7. [PUBMED: 7673949] ">Oksenhendler 1995</a>). The most recent trials studied the effect of cyclophosphamide and prednisolone (<a href="./references#CD002827-bbs2-0007" title="NiermeijerJMF ,  EurelingsM ,  Van der LindenMW ,   Lokhorst HM ,   Franssen H ,   Fischer K , et al. Intermittent cyclophosphamide with prednisone versus placebo for polyneuropathy with IgM monoclonal gammopathy. Neurology2007;69(1):50‐9. [PUBMED: 17606880] ">Niermeijer 2007</a>), or rituximab (<a href="./references#CD002827-bbs2-0003" title="DalakasMC , RakocevicG , SalajeghehM , DambrosiaJM , HahnAF , RajuR , et al. Placebo‐controlled trial of rituximab in IgM anti–myelin‐associated glycoprotein antibody demyelinating neuropathy. Annals of Neurology2009;65(3):286–93. [PUBMED: 19334068] ">Dalakas 2009</a>; <a href="./references#CD002827-bbs2-0004" title="LégerJM , VialaK , NicolasG , CréangeA , VallatJM , PougetJ , et al. Placebo controlled trial of rituximab in IgM anti‐myelin‐associated glycoprotein neuropathy. Neurology2013;80(24):2217‐25. [PUBMED: 23667063] ">Léger 2013</a>). We included all eight studies, despite the lack of fulfilment of all inclusion criteria by five of them. </p> </section> <section id="CD002827-sec-0040"> <h4 class="title">Excluded studies</h4> <p>We excluded 19 studies that had been considered at the title selection stage (see <a href="#CD002827-sec-0040">Excluded studies</a>). Of these, we excluded one trial as serum IgM anti‐MAG activity was not tested in the 21 participants with IgM‐associated neuropathy and specific criteria for demyelinating neuropathies were not an entry criterion (<a href="./references#CD002827-bbs2-0014" title="DyckPJ , LowPA , WindebankAJ , JaradehSS , GosselinS , BourqueP , et al. Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance. New England Journal of Medicine1991;325(21):1482‐6. [MEDLINE: 92049565] ">Dyck 1991</a>). We excluded two rituximab trials: as one (with seven participants) was open (<a href="./references#CD002827-bbs2-0024" title="RenaudS , GregorM , FuhrP , LorenzD , DeuschlG , GratwohlA , et al. Rituximab in the treatment of polyneuropathy associated with anti‐MAG antibodies. Muscle &amp; Nerve2003;27(5):611‐5. ">Renaud 2003</a>), the other (including nine participants) had a non‐randomised control group and unblinded assessments (<a href="./references#CD002827-bbs2-0023" title="PestronkA , FlorenceJ , MillerT , ChoksiR , Al‐LoziMT , LevineTD . Treatment of IgM antibody associated polyneuropathies using rituximab. Journal of Neurology, Neurosurgery and Psychiatry2003;74(4):485‐9. ">Pestronk 2003</a>). Other reasons for excluding studies are shown in <a href="./references#CD002827-sec-0097" title="">Characteristics of excluded studies</a>. </p> </section> </section> <section id="CD002827-sec-0041"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="#CD002827-fig-0002">Figure 2</a> for a summary of the review authors' 'Risk of bias' assessments for the included studies. </p> <div class="figure" id="CD002827-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD002827-fig-0002" src="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/image_n/nCD002827-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <p>All the included trials had a randomised design and participants were randomly assigned to receive the intervention or control for the whole trial, or the first arm in cross‐over studies (see <a href="./references#CD002827-sec-0096" title="">Characteristics of included studies</a>). All but one of the studies stipulated explicit diagnostic criteria (<a href="./references#CD002827-bbs2-0002" title="DalakasMC , QuarlesRH , FarrerRG , DambrosiaJ , SoueidanS , SteinDP , et al. A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy. Annals of Neurology1996;40(5):792‐5. [PUBMED: 8957021] ">Dalakas 1996</a>). Baseline characteristics were not significantly different in six of the studies, but in <a href="./references#CD002827-bbs2-0003" title="DalakasMC , RakocevicG , SalajeghehM , DambrosiaJM , HahnAF , RajuR , et al. Placebo‐controlled trial of rituximab in IgM anti–myelin‐associated glycoprotein antibody demyelinating neuropathy. Annals of Neurology2009;65(3):286–93. [PUBMED: 19334068] ">Dalakas 2009</a> the groups were very unbalanced with very few men in the rituximab‐treated group at randomisation. Differences in baseline characteristics were also present in <a href="./references#CD002827-bbs2-0002" title="DalakasMC , QuarlesRH , FarrerRG , DambrosiaJ , SoueidanS , SteinDP , et al. A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy. Annals of Neurology1996;40(5):792‐5. [PUBMED: 8957021] ">Dalakas 1996</a>. </p> <p>The trials of IVIg both had low risk of bias (<a href="./references#CD002827-bbs2-0001" title="ComiG , RoveriL , SwanA , WillisonH , BojarM , IllaI , et al. Inflammatory Neuropathy Cause And Treatment (INCAT) Group. A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy. Journal of Neurology2002;249(10):1370‐7. [PUBMED: 12382151] ">Comi 2002</a>; <a href="./references#CD002827-bbs2-0002" title="DalakasMC , QuarlesRH , FarrerRG , DambrosiaJ , SoueidanS , SteinDP , et al. A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy. Annals of Neurology1996;40(5):792‐5. [PUBMED: 8957021] ">Dalakas 1996</a>). In <a href="./references#CD002827-bbs2-0002" title="DalakasMC , QuarlesRH , FarrerRG , DambrosiaJ , SoueidanS , SteinDP , et al. A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy. Annals of Neurology1996;40(5):792‐5. [PUBMED: 8957021] ">Dalakas 1996</a>, the risk of bias was a little greater, as allocation concealment was unclear and the participants randomised to placebo were much older than in the IVIg arm, although this did not reach significance with the nine anti‐MAG participants included. However, the sensory scores were significantly higher in the placebo group than the IVIg‐treated group. Furthermore, this study did not state explicit diagnostic criteria. Both trials suffer from a short washout period and a potential carry‐over effect, although this would be expected to reduce the significance of any therapeutic effect of IVIg. </p> <p>Mariette et al studied interferon alfa‐2a in two studies (<a href="./references#CD002827-bbs2-0005" title="MarietteX , ChastangC , ClavelouP , LouboutinJ‐P , LegerJM , BrouetJC . A randomised clinical trial comparing interferon‐alpha and intravenous immunoglobulin in polyneuropathy associated with monoclonal IgM. The IgM‐associated Polyneuropathy Study Group. Journal of Neurology, Neurosurgery and Psychiatry1997;63(1):28‐34. [PUBMED: 9221964] ">Mariette 1997</a>; <a href="./references#CD002827-bbs2-0006" title="MarietteX , BrouetJC , ChevretS , LegerJM , ClavelouP , PougetJ , et al. A randomized double blind trial versus placebo does not confirm the benefit of alpha‐interferon in polyneuropathy associated with monoclonal IgM. Journal of Neurology, Neurosurgery and Psychiatry2000;69(2):279‐80. [PUBMED: 10960293] ">Mariette 2000</a>). The second study was blinded and controlled and at a much lower risk of bias than the preliminary randomised open trial. Four of 10 participants in the IVIg group in <a href="./references#CD002827-bbs2-0005" title="MarietteX , ChastangC , ClavelouP , LouboutinJ‐P , LegerJM , BrouetJC . A randomised clinical trial comparing interferon‐alpha and intravenous immunoglobulin in polyneuropathy associated with monoclonal IgM. The IgM‐associated Polyneuropathy Study Group. Journal of Neurology, Neurosurgery and Psychiatry1997;63(1):28‐34. [PUBMED: 9221964] ">Mariette 1997</a> and three of 12 in the interferon group in <a href="./references#CD002827-bbs2-0006" title="MarietteX , BrouetJC , ChevretS , LegerJM , ClavelouP , PougetJ , et al. A randomized double blind trial versus placebo does not confirm the benefit of alpha‐interferon in polyneuropathy associated with monoclonal IgM. Journal of Neurology, Neurosurgery and Psychiatry2000;69(2):279‐80. [PUBMED: 10960293] ">Mariette 2000</a> dropped out early in the trial, which may confound results in these small groups. </p> <p><a href="./references#CD002827-bbs2-0008" title="OksenhendlerE , ChevretS , LegerJM , LouboutinJP , BusselA , BrouetJC . Plasma exchange and chlorambucil in polyneuropathy associated with monoclonal IgM gammopathy. IgM‐associated Polyneuropathy Study Group. Journal of Neurology, Neurosurgery and Psychiatry1995;59(3):243‐7. [PUBMED: 7673949] ">Oksenhendler 1995</a> studied plasma exchange plus chlorambucil versus chlorambucil alone. As a result of the plasma exchange procedure, the blinding and allocation concealment were inadequate. Furthermore, although dropouts were balanced in the two groups (four of 22 in one group and four of 23 in the other), and the investigators performed an intention‐to‐treat analysis, the dropout numbers were deemed significant given the small number of included participants. Overall, we judged the risk of bias in this small study to be high. </p> <p>The first published RCT of rituximab for paraproteinaemic demyelinating peripheral neuropathy (PDPN) was at high overall risk of bias (<a href="./references#CD002827-bbs2-0003" title="DalakasMC , RakocevicG , SalajeghehM , DambrosiaJM , HahnAF , RajuR , et al. Placebo‐controlled trial of rituximab in IgM anti–myelin‐associated glycoprotein antibody demyelinating neuropathy. Annals of Neurology2009;65(3):286–93. [PUBMED: 19334068] ">Dalakas 2009</a>). The treatment groups at entry were unbalanced with respect to sex distribution (PDPN affects more men than women, but only two of 13 participants randomised to treatment were men). The randomisation method was not clear, and although the National Institutes of Health (NIH) pharmacy provided drug and placebo, it is not clear that the trial maintained allocation concealment. Most importantly, one participant was randomised and then removed from the trial having received rituximab and suffered an adverse event; this participant's data were not analysed. A further participant was removed at the analysis stage when it became clear the person did not fulfil the inclusion criteria; statistical analyses were done including and excluding this participant. We judged a second trial of rituximab to be at low risk of bias. The trial was entered in <a href="http://ClinicalTrials.gov" target="_blank">ClinicalTrials.gov</a>, but the published protocol does not contain all outcomes presented in the trial report, which appear to have been added post protocol publication. To clarify the meta‐analysis, we requested trial data from the authors of these two studies. Data were provided for <a href="./references#CD002827-bbs2-0004" title="LégerJM , VialaK , NicolasG , CréangeA , VallatJM , PougetJ , et al. Placebo controlled trial of rituximab in IgM anti‐myelin‐associated glycoprotein neuropathy. Neurology2013;80(24):2217‐25. [PUBMED: 23667063] ">Léger 2013</a>. The authors of <a href="./references#CD002827-bbs2-0003" title="DalakasMC , RakocevicG , SalajeghehM , DambrosiaJM , HahnAF , RajuR , et al. Placebo‐controlled trial of rituximab in IgM anti–myelin‐associated glycoprotein antibody demyelinating neuropathy. Annals of Neurology2009;65(3):286–93. [PUBMED: 19334068] ">Dalakas 2009</a> were unable to provide any outcome data for their trial, which were lost with a retiring colleague. </p> <p>We considered the study of cyclophosphamide and steroid to be at low risk of bias in all domains (<a href="./references#CD002827-bbs2-0007" title="NiermeijerJMF ,  EurelingsM ,  Van der LindenMW ,   Lokhorst HM ,   Franssen H ,   Fischer K , et al. Intermittent cyclophosphamide with prednisone versus placebo for polyneuropathy with IgM monoclonal gammopathy. Neurology2007;69(1):50‐9. [PUBMED: 17606880] ">Niermeijer 2007</a>). We analysed the first six months of the trial, as after this point participants who experienced a clinical decline were rerandomised to treatment with a different corticosteroid or cyclophosphamide. </p> </section> <section id="CD002827-sec-0042"> <h3 class="title" id="CD002827-sec-0042">Effects of interventions</h3> <p>See: <a href="./full#CD002827-tbl-0001"><b>Summary of findings for the main comparison</b> Rituximab versus placebo for treating IgM anti‐myelin‐associated glycoprotein paraprotein‐associated peripheral neuropathy</a> </p> <section id="CD002827-sec-0043"> <h4 class="title">General comment</h4> <p>Two trials compared IVIg with placebo (<a href="./references#CD002827-bbs2-0001" title="ComiG , RoveriL , SwanA , WillisonH , BojarM , IllaI , et al. Inflammatory Neuropathy Cause And Treatment (INCAT) Group. A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy. Journal of Neurology2002;249(10):1370‐7. [PUBMED: 12382151] ">Comi 2002</a>; <a href="./references#CD002827-bbs2-0002" title="DalakasMC , QuarlesRH , FarrerRG , DambrosiaJ , SoueidanS , SteinDP , et al. A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy. Annals of Neurology1996;40(5):792‐5. [PUBMED: 8957021] ">Dalakas 1996</a>). Their designs differed in IVIg dose and outcome measures and neither provided six‐ or 12‐month assessments. </p> <p>Two trials tested rituximab in a very similar group of participants, using fairly similar outcomes. In <a href="./references#CD002827-bbs2-0003" title="DalakasMC , RakocevicG , SalajeghehM , DambrosiaJM , HahnAF , RajuR , et al. Placebo‐controlled trial of rituximab in IgM anti–myelin‐associated glycoprotein antibody demyelinating neuropathy. Annals of Neurology2009;65(3):286–93. [PUBMED: 19334068] ">Dalakas 2009</a>, 26 participants were randomised to rituximab or a placebo infusion. There were concerns about the validity of the statistical manipulations used in this trial (see above and below) and corroborative data were not available. <a href="./references#CD002827-bbs2-0004" title="LégerJM , VialaK , NicolasG , CréangeA , VallatJM , PougetJ , et al. Placebo controlled trial of rituximab in IgM anti‐myelin‐associated glycoprotein neuropathy. Neurology2013;80(24):2217‐25. [PUBMED: 23667063] ">Léger 2013</a> also studied rituximab and randomised 54 participants to rituximab or placebo. The study produced similar results to <a href="./references#CD002827-bbs2-0003" title="DalakasMC , RakocevicG , SalajeghehM , DambrosiaJM , HahnAF , RajuR , et al. Placebo‐controlled trial of rituximab in IgM anti–myelin‐associated glycoprotein antibody demyelinating neuropathy. Annals of Neurology2009;65(3):286–93. [PUBMED: 19334068] ">Dalakas 2009</a> (see analysis below). The trial data were analysed at slightly different time points, but the review authors considered eight‐ and 12‐ month outcomes similar enough in this slowly changing disease. </p> <p>The other four trials tested different interventions or combinations of treatment. <a href="./references#CD002827-bbs2-0008" title="OksenhendlerE , ChevretS , LegerJM , LouboutinJP , BusselA , BrouetJC . Plasma exchange and chlorambucil in polyneuropathy associated with monoclonal IgM gammopathy. IgM‐associated Polyneuropathy Study Group. Journal of Neurology, Neurosurgery and Psychiatry1995;59(3):243‐7. [PUBMED: 7673949] ">Oksenhendler 1995</a> compared plasma exchange with no plasma exchange in participants receiving chlorambucil. Mariette et al compared IVIg with interferon alfa‐2a (<a href="./references#CD002827-bbs2-0005" title="MarietteX , ChastangC , ClavelouP , LouboutinJ‐P , LegerJM , BrouetJC . A randomised clinical trial comparing interferon‐alpha and intravenous immunoglobulin in polyneuropathy associated with monoclonal IgM. The IgM‐associated Polyneuropathy Study Group. Journal of Neurology, Neurosurgery and Psychiatry1997;63(1):28‐34. [PUBMED: 9221964] ">Mariette 1997</a>), and, in a follow‐up study, interferon alfa‐2a with placebo (<a href="./references#CD002827-bbs2-0006" title="MarietteX , BrouetJC , ChevretS , LegerJM , ClavelouP , PougetJ , et al. A randomized double blind trial versus placebo does not confirm the benefit of alpha‐interferon in polyneuropathy associated with monoclonal IgM. Journal of Neurology, Neurosurgery and Psychiatry2000;69(2):279‐80. [PUBMED: 10960293] ">Mariette 2000</a>). <a href="./references#CD002827-bbs2-0007" title="NiermeijerJMF ,  EurelingsM ,  Van der LindenMW ,   Lokhorst HM ,   Franssen H ,   Fischer K , et al. Intermittent cyclophosphamide with prednisone versus placebo for polyneuropathy with IgM monoclonal gammopathy. Neurology2007;69(1):50‐9. [PUBMED: 17606880] ">Niermeijer 2007</a> randomised participants to cyclophosphamide and prednisolone pulses or placebo in a six‐month‐long phase one of a 24‐month trial. To satisfy ethical concerns, any participant who deteriorated in phase one was reassigned to cyclophosphamide and prednisolone (if they had received placebo in phase one) or dexamethasone (if they had received cyclophosphamide and prednisolone) (termed phase 2 of the study), making the 24‐month outcomes difficult to assess. In phase two the placebo group was not truly randomised, as phase two contained only participants who had not improved on placebo, nine of 19 participants having switched to active treatment in phase two. After discussion of the trial data released by the trial authors, we did not include six‐month to 24‐month outcomes in the analysis. </p> <p>The primary and secondary outcome measures used in all these trials varied widely and those predefined for this review were rarely provided. </p> </section> <section id="CD002827-sec-0044"> <h4 class="title">Intravenous immunoglobulin versus placebo</h4> <p>Investigated in <a href="./references#CD002827-bbs2-0001" title="ComiG , RoveriL , SwanA , WillisonH , BojarM , IllaI , et al. Inflammatory Neuropathy Cause And Treatment (INCAT) Group. A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy. Journal of Neurology2002;249(10):1370‐7. [PUBMED: 12382151] ">Comi 2002</a> and <a href="./references#CD002827-bbs2-0002" title="DalakasMC , QuarlesRH , FarrerRG , DambrosiaJ , SoueidanS , SteinDP , et al. A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy. Annals of Neurology1996;40(5):792‐5. [PUBMED: 8957021] ">Dalakas 1996</a>. See 'Summary of findings' (Additional <a href="#CD002827-tbl-0002">Table 1</a>). </p> <div class="table" id="CD002827-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">'Summary of findings' table: Intravenous immunoglobulin (IVIg) versus placebo</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>IVIg versus placebo for IgM anti‐myelin‐associated glycoprotein paraprotein‐associated peripheral neuropathies</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with IgM anti‐myelin‐associated glycoprotein paraprotein‐associated peripheral neuropathies<br/> <b>Settings:</b> hospital and outpatient treatment centres<br/> <b>Intervention:</b> IVIg versus placebo </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Outcomes</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Relative effect <br/> (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Number of participants <br/> (studies)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Quality of the evidence <br/> (GRADE)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Comments</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Risk with placebo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Risk with IVIg </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants improved in disability score at 6 months</b> ‐ not reported </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term outcomes only, not reported at 6 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean improvement in disability score at 6 months</b> ‐ not reported </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term outcomes only, not reported at 6 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Improvement in 10‐metre walk time at 6 months</b> ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Short‐term outcomes only, not reported at 6 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant subjective impression of change at 6 months ‐ number of participants reporting improvement</b> ‐ not reported </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term outcomes only, not reported at 6 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in serum IgM paraprotein concentration 8 months after treatment</b> ‐ not reported </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term outcomes only, not reported at 6 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Any adverse event</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Data for the anti‐MAG subgroup were not available. In one study, one participant had an aseptic meningitis and a rash after IVIg treatment, with 2 moderate adverse events in the placebo group. In the other trial, there were no serious adverse events with IVIg, but mild and transient effects were "more common in the IVIg than the placebo group". </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No further analysis was possible.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup>Incomplete reporting of adverse events in one study. </p> </div> </div> <section id="CD002827-sec-0045"> <h5 class="title">Primary outcome measures</h5> <p>One trial with 22 participants (<a href="./references#CD002827-bbs2-0001" title="ComiG , RoveriL , SwanA , WillisonH , BojarM , IllaI , et al. Inflammatory Neuropathy Cause And Treatment (INCAT) Group. A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy. Journal of Neurology2002;249(10):1370‐7. [PUBMED: 12382151] ">Comi 2002</a>), of IVIg versus placebo in IgM paraprotein‐associated neuropathy used the modified Rankin Scale (mRS). However, this was a short trial and the investigators only measured the primary outcome at two and four weeks, not at six months. Eleven of 22 participants had anti‐MAG antibodies but the data concerning the anti‐MAG participant subgroup were not available. At two weeks, the mRS score showed a significant improvement with IVIg (‐0.38, standard deviation (SD) 0.58) over placebo (+0.19, SD 0.51) at two weeks (P = 0.008), a difference that may not be clinically significant. No significant difference between the groups was present at four weeks. </p> <p>The primary outcome of <a href="./references#CD002827-bbs2-0001" title="ComiG , RoveriL , SwanA , WillisonH , BojarM , IllaI , et al. Inflammatory Neuropathy Cause And Treatment (INCAT) Group. A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy. Journal of Neurology2002;249(10):1370‐7. [PUBMED: 12382151] ">Comi 2002</a> was the Inflammatory Neuropathy Cause and Treatment (INCAT) disability score at four weeks. This was not one of our prespecified outcome measures (see <a href="#CD002827-sec-0065">Discussion</a>). After two weeks, the INCAT disability score did not change significantly; there was no difference between the groups and no evidence of a carry‐over effect. After four weeks, the INCAT disability score decreased by a mean of 0.55 (SD 0.67) grades in the IVIg period (P = 0.001), with no significant change (mean 0.05 (SD 0.90)) in the placebo period. Only the mean difference (MD) between the treatment effects in the two four‐week periods was significant (0.5 of a grade, 95% confidence interval (CI) 0.00 to 1.00). </p> </section> <section id="CD002827-sec-0046"> <h5 class="title">Secondary outcome measures</h5> <p>The secondary outcomes at time points selected for this review were not available because the trials were both so short. </p> <p>Related secondary outcomes were measured at different time points (two and four weeks) and the results were presented as MD between treatments. </p> <p>a. One trial assessed the 10‐metre walk (<a href="./references#CD002827-bbs2-0001" title="ComiG , RoveriL , SwanA , WillisonH , BojarM , IllaI , et al. Inflammatory Neuropathy Cause And Treatment (INCAT) Group. A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy. Journal of Neurology2002;249(10):1370‐7. [PUBMED: 12382151] ">Comi 2002</a>), but only at four weeks in the first arm of the study, as there was significant evidence of a carry‐over effect into the second arm. There was a significant reduction in 10‐metre walk time with IVIg compared with placebo in the whole IgM treatment group (MD 2.77 seconds, 95% CI 0.01 to 5.54). No data were available on the anti‐MAG participants alone, but the trial authors state that MAG antibodies "did not influence the response to IVIg treatment". </p> <p>b. Serum data: not enough information was available on anti‐MAG titres or serum IgM concentrations in <a href="./references#CD002827-bbs2-0002" title="DalakasMC , QuarlesRH , FarrerRG , DambrosiaJ , SoueidanS , SteinDP , et al. A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy. Annals of Neurology1996;40(5):792‐5. [PUBMED: 8957021] ">Dalakas 1996</a> to make a meaningful comment. </p> <p>No 12‐month outcomes were available.</p> </section> <section id="CD002827-sec-0047"> <h5 class="title">Adverse events</h5> <p>Two studies compared IVIg and placebo (<a href="./references#CD002827-bbs2-0001" title="ComiG , RoveriL , SwanA , WillisonH , BojarM , IllaI , et al. Inflammatory Neuropathy Cause And Treatment (INCAT) Group. A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy. Journal of Neurology2002;249(10):1370‐7. [PUBMED: 12382151] ">Comi 2002</a>; <a href="./references#CD002827-bbs2-0002" title="DalakasMC , QuarlesRH , FarrerRG , DambrosiaJ , SoueidanS , SteinDP , et al. A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy. Annals of Neurology1996;40(5):792‐5. [PUBMED: 8957021] ">Dalakas 1996</a>), but data for the anti‐MAG subgroup were not available. In <a href="./references#CD002827-bbs2-0001" title="ComiG , RoveriL , SwanA , WillisonH , BojarM , IllaI , et al. Inflammatory Neuropathy Cause And Treatment (INCAT) Group. A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy. Journal of Neurology2002;249(10):1370‐7. [PUBMED: 12382151] ">Comi 2002</a>, one participant had an aseptic meningitis and a rash after IVIg treatment. It is not clear whether she completed the three‐month trial period. Two moderate adverse events occurred in the placebo treatment arm in <a href="./references#CD002827-bbs2-0001" title="ComiG , RoveriL , SwanA , WillisonH , BojarM , IllaI , et al. Inflammatory Neuropathy Cause And Treatment (INCAT) Group. A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy. Journal of Neurology2002;249(10):1370‐7. [PUBMED: 12382151] ">Comi 2002</a>, one retinal vein thrombosis and one episode of transient diplopia. In <a href="./references#CD002827-bbs2-0002" title="DalakasMC , QuarlesRH , FarrerRG , DambrosiaJ , SoueidanS , SteinDP , et al. A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy. Annals of Neurology1996;40(5):792‐5. [PUBMED: 8957021] ">Dalakas 1996</a>, no serious adverse events occurred as a result of IVIg infusion, but mild and transient effects were "more common in the IVIg than the placebo group". No further analysis was possible. </p> <p>For adverse events of IVIg in the interferon alfa‐2a versus IVIg trial (<a href="./references#CD002827-bbs2-0005" title="MarietteX , ChastangC , ClavelouP , LouboutinJ‐P , LegerJM , BrouetJC . A randomised clinical trial comparing interferon‐alpha and intravenous immunoglobulin in polyneuropathy associated with monoclonal IgM. The IgM‐associated Polyneuropathy Study Group. Journal of Neurology, Neurosurgery and Psychiatry1997;63(1):28‐34. [PUBMED: 9221964] ">Mariette 1997</a>), see below. </p> </section> </section> <section id="CD002827-sec-0048"> <h4 class="title">Interferon alfa‐2a versus placebo or IVIg</h4> <p>Investigated in <a href="./references#CD002827-bbs2-0005" title="MarietteX , ChastangC , ClavelouP , LouboutinJ‐P , LegerJM , BrouetJC . A randomised clinical trial comparing interferon‐alpha and intravenous immunoglobulin in polyneuropathy associated with monoclonal IgM. The IgM‐associated Polyneuropathy Study Group. Journal of Neurology, Neurosurgery and Psychiatry1997;63(1):28‐34. [PUBMED: 9221964] ">Mariette 1997</a> and <a href="./references#CD002827-bbs2-0006" title="MarietteX , BrouetJC , ChevretS , LegerJM , ClavelouP , PougetJ , et al. A randomized double blind trial versus placebo does not confirm the benefit of alpha‐interferon in polyneuropathy associated with monoclonal IgM. Journal of Neurology, Neurosurgery and Psychiatry2000;69(2):279‐80. [PUBMED: 10960293] ">Mariette 2000</a>. </p> <section id="CD002827-sec-0049"> <h5 class="title">Primary outcome measures</h5> <p>The mRS was not assessed. The Neuropathy Impairment Scale (NIS) was the primary outcome in both studies involving interferon alfa‐2a (referred to as the Clinical Neuropathy Disability Score (CNDS), a scale derived with minor modifications from the NIS, maximum score 93 (higher scores indicate greater disability)). In the initial randomised but open parallel‐group study of interferon alfa‐2a versus IVIg (<a href="./references#CD002827-bbs2-0005" title="MarietteX , ChastangC , ClavelouP , LouboutinJ‐P , LegerJM , BrouetJC . A randomised clinical trial comparing interferon‐alpha and intravenous immunoglobulin in polyneuropathy associated with monoclonal IgM. The IgM‐associated Polyneuropathy Study Group. Journal of Neurology, Neurosurgery and Psychiatry1997;63(1):28‐34. [PUBMED: 9221964] ">Mariette 1997</a>), participants in the IVIg group worsened by a mean of 2.3 (SD 7.6) points on the NIS at six months, and those in the interferon alfa‐2a group improved by 7.5 (11.1) points, a MD of 9.80 (95% CI 1.46 to 18.14, n = 20) in favour of interferon alfa‐2a (<a href="./references#CD002827-fig-0004" title="">Analysis 1.1</a>). However, <a href="./references#CD002827-bbs2-0006" title="MarietteX , BrouetJC , ChevretS , LegerJM , ClavelouP , PougetJ , et al. A randomized double blind trial versus placebo does not confirm the benefit of alpha‐interferon in polyneuropathy associated with monoclonal IgM. Journal of Neurology, Neurosurgery and Psychiatry2000;69(2):279‐80. [PUBMED: 10960293] ">Mariette 2000</a> (n = 24), a randomised and blinded trial of interferon alfa‐2a versus placebo at low risk of bias, failed to confirm the beneficial effect of interferon alfa‐2a in the primary outcome at six months (<a href="./references#CD002827-fig-0007" title="">Analysis 2.1</a>). </p> </section> <section id="CD002827-sec-0050"> <h5 class="title">Secondary outcome measures</h5> <p>Neither trial assessed the 10‐metre walk at any time point.</p> <p>The two trials derived a subjective clinical score (<a href="./references#CD002827-bbs2-0005" title="MarietteX , ChastangC , ClavelouP , LouboutinJ‐P , LegerJM , BrouetJC . A randomised clinical trial comparing interferon‐alpha and intravenous immunoglobulin in polyneuropathy associated with monoclonal IgM. The IgM‐associated Polyneuropathy Study Group. Journal of Neurology, Neurosurgery and Psychiatry1997;63(1):28‐34. [PUBMED: 9221964] ">Mariette 1997</a>; <a href="./references#CD002827-bbs2-0006" title="MarietteX , BrouetJC , ChevretS , LegerJM , ClavelouP , PougetJ , et al. A randomized double blind trial versus placebo does not confirm the benefit of alpha‐interferon in polyneuropathy associated with monoclonal IgM. Journal of Neurology, Neurosurgery and Psychiatry2000;69(2):279‐80. [PUBMED: 10960293] ">Mariette 2000</a>). In the unblinded 1997 study, the subjective scores improved significantly in favour of interferon alfa‐2a over IVIg (MD 3.10, 95% CI 1.02 to 5.18, n = 20; <a href="./references#CD002827-fig-0005" title="">Analysis 1.2</a>). In the later blinded and reported 'negative' placebo‐controlled study of interferon alfa‐2a, the subjective scores were not presented in the published data. </p> <p>The presence of sural sensory nerve action potentials (SNAPs) was examined at six months in both studies. The number of participants with detectable sural nerve SNAPs did not improve with either interferon alfa‐2a or IVIg in the first study and exhibited "no significant improvement" in the second (data not presented). More participants had recordable median SNAPs after six months treatment with interferon alfa‐2a (2/7 improved to 5/7) compared to IVIg (4/8 declined to 1/8) in the first study (<a href="./references#CD002827-bbs2-0005" title="MarietteX , ChastangC , ClavelouP , LouboutinJ‐P , LegerJM , BrouetJC . A randomised clinical trial comparing interferon‐alpha and intravenous immunoglobulin in polyneuropathy associated with monoclonal IgM. The IgM‐associated Polyneuropathy Study Group. Journal of Neurology, Neurosurgery and Psychiatry1997;63(1):28‐34. [PUBMED: 9221964] ">Mariette 1997</a>). </p> <p>In <a href="./references#CD002827-bbs2-0005" title="MarietteX , ChastangC , ClavelouP , LouboutinJ‐P , LegerJM , BrouetJC . A randomised clinical trial comparing interferon‐alpha and intravenous immunoglobulin in polyneuropathy associated with monoclonal IgM. The IgM‐associated Polyneuropathy Study Group. Journal of Neurology, Neurosurgery and Psychiatry1997;63(1):28‐34. [PUBMED: 9221964] ">Mariette 1997</a>, IgM paraprotein bands and anti‐MAG activity were still detectable at six months in all participants but only decreased significantly in two participants receiving interferon alfa‐2a (50% reduction each). No 12‐month outcome data for serum data were published. </p> </section> <section id="CD002827-sec-0051"> <h5 class="title">Adverse events</h5> <p>In both interferon alfa‐2a trials all included participants had anti‐MAG serum activity (<a href="./references#CD002827-bbs2-0005" title="MarietteX , ChastangC , ClavelouP , LouboutinJ‐P , LegerJM , BrouetJC . A randomised clinical trial comparing interferon‐alpha and intravenous immunoglobulin in polyneuropathy associated with monoclonal IgM. The IgM‐associated Polyneuropathy Study Group. Journal of Neurology, Neurosurgery and Psychiatry1997;63(1):28‐34. [PUBMED: 9221964] ">Mariette 1997</a>; <a href="./references#CD002827-bbs2-0006" title="MarietteX , BrouetJC , ChevretS , LegerJM , ClavelouP , PougetJ , et al. A randomized double blind trial versus placebo does not confirm the benefit of alpha‐interferon in polyneuropathy associated with monoclonal IgM. Journal of Neurology, Neurosurgery and Psychiatry2000;69(2):279‐80. [PUBMED: 10960293] ">Mariette 2000</a>). Interferon alfa‐2a caused flu‐like symptoms in all 10 participants in the open study (<a href="./references#CD002827-bbs2-0005" title="MarietteX , ChastangC , ClavelouP , LouboutinJ‐P , LegerJM , BrouetJC . A randomised clinical trial comparing interferon‐alpha and intravenous immunoglobulin in polyneuropathy associated with monoclonal IgM. The IgM‐associated Polyneuropathy Study Group. Journal of Neurology, Neurosurgery and Psychiatry1997;63(1):28‐34. [PUBMED: 9221964] ">Mariette 1997</a>), which were persistent and required tapering of the dose in three (moderate side effects). A further three participants required dose‐tapering for systemic adverse effects (also moderate). One of 10 participants in the IVIg treatment group withdrew because of self‐limiting erythroderma (<a href="./references#CD002827-bbs2-0005" title="MarietteX , ChastangC , ClavelouP , LouboutinJ‐P , LegerJM , BrouetJC . A randomised clinical trial comparing interferon‐alpha and intravenous immunoglobulin in polyneuropathy associated with monoclonal IgM. The IgM‐associated Polyneuropathy Study Group. Journal of Neurology, Neurosurgery and Psychiatry1997;63(1):28‐34. [PUBMED: 9221964] ">Mariette 1997</a>). No other mild or moderate side effects were reported with IVIg. </p> <p>In the placebo‐controlled, blinded study, two of 12 participants withdrew from the study because of side effects (severe), one with diarrhoea and one with flu‐like symptoms (<a href="./references#CD002827-bbs2-0006" title="MarietteX , BrouetJC , ChevretS , LegerJM , ClavelouP , PougetJ , et al. A randomized double blind trial versus placebo does not confirm the benefit of alpha‐interferon in polyneuropathy associated with monoclonal IgM. Journal of Neurology, Neurosurgery and Psychiatry2000;69(2):279‐80. [PUBMED: 10960293] ">Mariette 2000</a>). One participant withdrew with worsening of neuropathy. There were no other severe side effects reported for interferon alfa‐2a. </p> </section> </section> <section id="CD002827-sec-0052"> <h4 class="title">Chlorambucil and plasma exchange versus chlorambucil alone</h4> <p>Investigated in <a href="./references#CD002827-bbs2-0008" title="OksenhendlerE , ChevretS , LegerJM , LouboutinJP , BusselA , BrouetJC . Plasma exchange and chlorambucil in polyneuropathy associated with monoclonal IgM gammopathy. IgM‐associated Polyneuropathy Study Group. Journal of Neurology, Neurosurgery and Psychiatry1995;59(3):243‐7. [PUBMED: 7673949] ">Oksenhendler 1995</a>. </p> <section id="CD002827-sec-0053"> <h5 class="title">Primary outcome measures</h5> <p>In a comparison of chlorambucil and plasma exchange versus chlorambucil alone in IgM paraprotein‐associated neuropathy, the NIS at four months showed no statistically significant difference in outcome (<a href="./references#CD002827-bbs2-0008" title="OksenhendlerE , ChevretS , LegerJM , LouboutinJP , BusselA , BrouetJC . Plasma exchange and chlorambucil in polyneuropathy associated with monoclonal IgM gammopathy. IgM‐associated Polyneuropathy Study Group. Journal of Neurology, Neurosurgery and Psychiatry1995;59(3):243‐7. [PUBMED: 7673949] ">Oksenhendler 1995</a>). The trialists assessed neither the NIS nor the mRS at the six‐month time point specified for this review. Data were not available for the anti‐MAG subgroup alone, as participants with anti‐MAG activity were not differentiated from those without. </p> </section> <section id="CD002827-sec-0054"> <h5 class="title">Secondary outcome measures</h5> <p>The change in NIS at 12 months was no different between the plasma exchange plus chlorambucil and the chlorambucil‐alone groups. </p> <p>The 10‐metre walk time was not recorded at six months.</p> <p>A subjective clinical score was not recorded at six months. There was "no difference" in the subjective clinical score at 12 months between the groups. </p> <p>SNAPs were not recorded at six months.</p> <p>IgM paraprotein concentrations and anti‐MAG (anti‐myelin IgM) titres were determined prior to entry but no results were given for later time points other than a comment in the paper that the response was not associated with a significant decrease in the serum IgM concentration. </p> </section> <section id="CD002827-sec-0055"> <h5 class="title">Adverse events</h5> <p>In <a href="./references#CD002827-bbs2-0008" title="OksenhendlerE , ChevretS , LegerJM , LouboutinJP , BusselA , BrouetJC . Plasma exchange and chlorambucil in polyneuropathy associated with monoclonal IgM gammopathy. IgM‐associated Polyneuropathy Study Group. Journal of Neurology, Neurosurgery and Psychiatry1995;59(3):243‐7. [PUBMED: 7673949] ">Oksenhendler 1995</a>, there were no serious adverse events from plasma exchange, but side effects of chlorambucil were common. Ten of the 44 participants required temporary suspension or tapering of the chlorambucil dosage because of haematotoxicity, but none had to cease treatment. </p> </section> </section> <section id="CD002827-sec-0056"> <h4 class="title">Rituximab versus placebo</h4> <p>In 2012 only one study had been published using rituximab as an intervention for paraproteinaemic neuropathy that fulfilled our inclusion criteria (<a href="./references#CD002827-bbs2-0003" title="DalakasMC , RakocevicG , SalajeghehM , DambrosiaJM , HahnAF , RajuR , et al. Placebo‐controlled trial of rituximab in IgM anti–myelin‐associated glycoprotein antibody demyelinating neuropathy. Annals of Neurology2009;65(3):286–93. [PUBMED: 19334068] ">Dalakas 2009</a>). A second study called RiMAG has now been published and we include it here (<a href="./references#CD002827-bbs2-0004" title="LégerJM , VialaK , NicolasG , CréangeA , VallatJM , PougetJ , et al. Placebo controlled trial of rituximab in IgM anti‐myelin‐associated glycoprotein neuropathy. Neurology2013;80(24):2217‐25. [PUBMED: 23667063] ">Léger 2013</a>). See <a href="./full#CD002827-tbl-0001">summary of findings Table for the main comparison</a>. </p> <p><a href="./references#CD002827-bbs2-0003" title="DalakasMC , RakocevicG , SalajeghehM , DambrosiaJM , HahnAF , RajuR , et al. Placebo‐controlled trial of rituximab in IgM anti–myelin‐associated glycoprotein antibody demyelinating neuropathy. Annals of Neurology2009;65(3):286–93. [PUBMED: 19334068] ">Dalakas 2009</a> randomised 26 participants to receive either rituximab or placebo at a standard dose of four infusions of 375 mg/m<sup>2</sup> every week for four weeks. Outcomes were measured at eight months (which for the purposes of this review we have used as six‐month outcomes). One randomised participant had a severe anaphylactic adverse event with the first infusion of the drug. The participant was replaced and not included in any further analysis. One further participant randomised to rituximab and treated in accord with the protocol was found to have had an INCAT leg score at entry of zero (inadvertently assigned as 1 at entry). He could not therefore have improved. We have performed the analysis here with the participant included as in the protocol for this review. </p> <p>Some discrepancies exist in the results in the published paper (see below) (<a href="./references#CD002827-bbs2-0003" title="DalakasMC , RakocevicG , SalajeghehM , DambrosiaJM , HahnAF , RajuR , et al. Placebo‐controlled trial of rituximab in IgM anti–myelin‐associated glycoprotein antibody demyelinating neuropathy. Annals of Neurology2009;65(3):286–93. [PUBMED: 19334068] ">Dalakas 2009</a>). These were resolved through enquiry with the trial author. Original trial data were not made available in 2012 and further requests in 2014 and 2015 were not fruitful. Trial data were "entered directly by the statistician who retired more than 10 years ago" and he was untraceable. </p> <p><a href="./references#CD002827-bbs2-0004" title="LégerJM , VialaK , NicolasG , CréangeA , VallatJM , PougetJ , et al. Placebo controlled trial of rituximab in IgM anti‐myelin‐associated glycoprotein neuropathy. Neurology2013;80(24):2217‐25. [PUBMED: 23667063] ">Léger 2013</a> randomised 54 participants to receive either rituximab in a standard 375 mg/m<sup>2</sup> dose or placebo. Outcomes were measured at 0 and 12 months, but upon request, the trial authors also made nine‐month data available for the INCAT scale, change in INCAT scale and IgM levels, to correspond to outcomes of <a href="./references#CD002827-bbs2-0003" title="DalakasMC , RakocevicG , SalajeghehM , DambrosiaJM , HahnAF , RajuR , et al. Placebo‐controlled trial of rituximab in IgM anti–myelin‐associated glycoprotein antibody demyelinating neuropathy. Annals of Neurology2009;65(3):286–93. [PUBMED: 19334068] ">Dalakas 2009</a>. We requested data for the leg subscale of the INCAT score but these were not available. The outcomes in the published and amended <a href="http://ClinicalTrials.gov" target="_blank">ClinicalTrials.gov</a> protocol are limited and do not fully correspond to the outcomes in the methods section of the published paper (which are those with results). There is no suggestion of suppression of negative outcome data or selective reporting, but these outcomes could have been decided post hoc. </p> <section id="CD002827-sec-0057"> <h5 class="title">Primary outcome measures</h5> <p>These two studies included neither the NIS nor the mRS as outcomes. The INCAT leg score reported in <a href="./references#CD002827-bbs2-0003" title="DalakasMC , RakocevicG , SalajeghehM , DambrosiaJM , HahnAF , RajuR , et al. Placebo‐controlled trial of rituximab in IgM anti–myelin‐associated glycoprotein antibody demyelinating neuropathy. Annals of Neurology2009;65(3):286–93. [PUBMED: 19334068] ">Dalakas 2009</a> corresponds broadly to the mRS and thus we used this in our analysis both as a continuous and a dichotomous outcome. For the dichotomous improvement we have compared the leg score at eight months from <a href="./references#CD002827-bbs2-0003" title="DalakasMC , RakocevicG , SalajeghehM , DambrosiaJM , HahnAF , RajuR , et al. Placebo‐controlled trial of rituximab in IgM anti–myelin‐associated glycoprotein antibody demyelinating neuropathy. Annals of Neurology2009;65(3):286–93. [PUBMED: 19334068] ">Dalakas 2009</a> with the dichotomous complete INCAT score at 12 months from <a href="./references#CD002827-bbs2-0004" title="LégerJM , VialaK , NicolasG , CréangeA , VallatJM , PougetJ , et al. Placebo controlled trial of rituximab in IgM anti‐myelin‐associated glycoprotein neuropathy. Neurology2013;80(24):2217‐25. [PUBMED: 23667063] ">Léger 2013</a> (<a href="./references#CD002827-fig-0009" title="">Analysis 3.1</a>; <a href="#CD002827-fig-0003">Figure 3</a>). The RR for improvement was 3.51, 95% CI 1.30 to 9.45 (I<sup>2</sup> = 0%, 73 participants). We will perform a six‐month meta‐analysis if other studies become available. Using the published eight‐month data from <a href="./references#CD002827-bbs2-0003" title="DalakasMC , RakocevicG , SalajeghehM , DambrosiaJM , HahnAF , RajuR , et al. Placebo‐controlled trial of rituximab in IgM anti–myelin‐associated glycoprotein antibody demyelinating neuropathy. Annals of Neurology2009;65(3):286–93. [PUBMED: 19334068] ">Dalakas 2009</a> and 12‐month data from <a href="./references#CD002827-bbs2-0004" title="LégerJM , VialaK , NicolasG , CréangeA , VallatJM , PougetJ , et al. Placebo controlled trial of rituximab in IgM anti‐myelin‐associated glycoprotein neuropathy. Neurology2013;80(24):2217‐25. [PUBMED: 23667063] ">Léger 2013</a>, the mean improvement in the INCAT leg disability score (MD ‐0.45, 95% CI ‐0.85 to ‐0.05; I<sup>2</sup> = 0%) was statistically significant, whether the INCAT 0‐score participant from <a href="./references#CD002827-bbs2-0003" title="DalakasMC , RakocevicG , SalajeghehM , DambrosiaJM , HahnAF , RajuR , et al. Placebo‐controlled trial of rituximab in IgM anti–myelin‐associated glycoprotein antibody demyelinating neuropathy. Annals of Neurology2009;65(3):286–93. [PUBMED: 19334068] ">Dalakas 2009</a> was included in the analysis or not (<a href="./full#CD002827-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./references#CD002827-fig-0010" title="">Analysis 3.2</a>). Participant‐level data obtained for nine‐month improvement from <a href="./references#CD002827-bbs2-0004" title="LégerJM , VialaK , NicolasG , CréangeA , VallatJM , PougetJ , et al. Placebo controlled trial of rituximab in IgM anti‐myelin‐associated glycoprotein neuropathy. Neurology2013;80(24):2217‐25. [PUBMED: 23667063] ">Léger 2013</a> (not published), which are at a more comparable time point to <a href="./references#CD002827-bbs2-0003" title="DalakasMC , RakocevicG , SalajeghehM , DambrosiaJM , HahnAF , RajuR , et al. Placebo‐controlled trial of rituximab in IgM anti–myelin‐associated glycoprotein antibody demyelinating neuropathy. Annals of Neurology2009;65(3):286–93. [PUBMED: 19334068] ">Dalakas 2009</a>, give a MD of ‐0.33, 95% CI ‐0.73 to 0.07 (I<sup>2</sup> = 0%, 70 participants) in the same direction as the longer time point but including the possibility of no effect (<a href="./references#CD002827-fig-0011" title="">Analysis 3.3</a>). </p> <div class="figure" id="CD002827-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 3 Rituximab versus placebo, outcome: 3.1 Number of participants improved on INCAT score (see text) at 8‐12 months." data-id="CD002827-fig-0003" src="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/image_n/nCD002827-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 3 Rituximab versus placebo, outcome: 3.1 Number of participants improved on INCAT score (see text) at 8‐12 months. </p> </div> </div> </div> <p>(Note: in the published paper of <a href="./references#CD002827-bbs2-0003" title="DalakasMC , RakocevicG , SalajeghehM , DambrosiaJM , HahnAF , RajuR , et al. Placebo‐controlled trial of rituximab in IgM anti–myelin‐associated glycoprotein antibody demyelinating neuropathy. Annals of Neurology2009;65(3):286–93. [PUBMED: 19334068] ">Dalakas 2009</a> there is a discrepancy between the data for the INCAT leg score in the text and in the published table. We checked the data with the trial authors who gave verbal clarification and we included the correct figures. No recorded trial data were made available.) </p> </section> <section id="CD002827-sec-0058"> <h5 class="title">Secondary outcome measures</h5> <p>Secondary outcomes that we could include in our analyses were the 10‐metre walk time, the change in IgM levels, and anti‐MAG titre, but these were all measured at eight months in <a href="./references#CD002827-bbs2-0003" title="DalakasMC , RakocevicG , SalajeghehM , DambrosiaJM , HahnAF , RajuR , et al. Placebo‐controlled trial of rituximab in IgM anti–myelin‐associated glycoprotein antibody demyelinating neuropathy. Annals of Neurology2009;65(3):286–93. [PUBMED: 19334068] ">Dalakas 2009</a> and at 12 months in <a href="./references#CD002827-bbs2-0004" title="LégerJM , VialaK , NicolasG , CréangeA , VallatJM , PougetJ , et al. Placebo controlled trial of rituximab in IgM anti‐myelin‐associated glycoprotein neuropathy. Neurology2013;80(24):2217‐25. [PUBMED: 23667063] ">Léger 2013</a>. Nine‐month data were not available for <a href="./references#CD002827-bbs2-0004" title="LégerJM , VialaK , NicolasG , CréangeA , VallatJM , PougetJ , et al. Placebo controlled trial of rituximab in IgM anti‐myelin‐associated glycoprotein neuropathy. Neurology2013;80(24):2217‐25. [PUBMED: 23667063] ">Léger 2013</a> except for the IgM levels. </p> <p>The 10‐metre walk times did not improve significantly, either in terms of time to walk (MD ‐0.35 seconds, 95% CI ‐1.89 to 1.19; I<sup>2</sup> = 0%, 68 participants) or numbers of participants improved (RR 1.80, 95% CI 0.83 to 3.92; 26 participants; <a href="./references#CD002827-bbs2-0003" title="DalakasMC , RakocevicG , SalajeghehM , DambrosiaJM , HahnAF , RajuR , et al. Placebo‐controlled trial of rituximab in IgM anti–myelin‐associated glycoprotein antibody demyelinating neuropathy. Annals of Neurology2009;65(3):286–93. [PUBMED: 19334068] ">Dalakas 2009</a> only ‐ data from Léger requested; <a href="./references#CD002827-fig-0013" title="">Analysis 3.5</a>; <a href="./references#CD002827-fig-0014" title="">Analysis 3.6</a>). As might be expected, there was a measurable and significant decrease in the level of serum IgM eight months after rituximab (reduction of 286 mg/dL, 95% CI 329 to 244; 26 participants; <a href="./references#CD002827-fig-0015" title="">Analysis 3.7</a>). Less expected (from reports of other studies of treatment of anti‐MAG neuropathy) but not surprising was a decrease in the titre of anti‐MAG activity of ‐17.79 units/mL (95% CI ‐33.33 to ‐2.25; <a href="./references#CD002827-fig-0016" title="">Analysis 3.8</a>; I<sup>2</sup> = 0%, 71 participants). </p> </section> <section id="CD002827-sec-0059"> <h5 class="title">Outcome measures not prespecified in this protocol</h5> <p>Both studies included participant "clinical assessments and questionnaires" (not further described). The RR for "stable or improved" at eight to 12 months was 1.86 (95% CI 1.27 to 2.71; I<sup>2</sup> = 0%, 70 participants) in favour of rituximab (<a href="./references#CD002827-fig-0017" title="">Analysis 3.9</a>). For participants "improved" only at eight to 12 months, the RR was 9.67 with a wide CI (95% CI 1.84 to 50.85; I<sup>2</sup> = 0%, 70 participants) albeit statistically significant (<a href="./references#CD002827-fig-0018" title="">Analysis 3.10</a>). <a href="./references#CD002827-bbs2-0004" title="LégerJM , VialaK , NicolasG , CréangeA , VallatJM , PougetJ , et al. Placebo controlled trial of rituximab in IgM anti‐myelin‐associated glycoprotein neuropathy. Neurology2013;80(24):2217‐25. [PUBMED: 23667063] ">Léger 2013</a> presented results for the Short Form 36 Health Survey (SF36) with a MD improvement of 15.50 (95% CI 5.24 to 25.76; 37 participants) in the physical subscores (<a href="./references#CD002827-fig-0019" title="">Analysis 3.11</a>) but no statistically significant change in the mental subscores (MD 6.60, 95% CI ‐0.35 to 13.55; 41 participants; <a href="./references#CD002827-fig-0020" title="">Analysis 3.12</a>). These assessments were not prespecified as primary or secondary outcomes. </p> </section> <section id="CD002827-sec-0060"> <h5 class="title">Adverse events</h5> <p>There were not significantly more adverse events in the rituximab group (RR 1.18, 95% CI 0.84 to 1.66; I<sup>2</sup> = 0%, 80 participants; <a href="./references#CD002827-fig-0021" title="">Analysis 3.13</a>). Most adverse events were minor, including mild temperature increases and chills, headaches and mild hypotension, nausea, vomiting, dizziness and lightheadedness, and rash. One severe adverse event of bronchospasm led to the participant being removed from <a href="./references#CD002827-bbs2-0003" title="DalakasMC , RakocevicG , SalajeghehM , DambrosiaJM , HahnAF , RajuR , et al. Placebo‐controlled trial of rituximab in IgM anti–myelin‐associated glycoprotein antibody demyelinating neuropathy. Annals of Neurology2009;65(3):286–93. [PUBMED: 19334068] ">Dalakas 2009</a>, despite receiving the drug; his data were not included in the published results. In <a href="./references#CD002827-bbs2-0004" title="LégerJM , VialaK , NicolasG , CréangeA , VallatJM , PougetJ , et al. Placebo controlled trial of rituximab in IgM anti‐myelin‐associated glycoprotein neuropathy. Neurology2013;80(24):2217‐25. [PUBMED: 23667063] ">Léger 2013</a>, one participant with rituximab was withdrawn from the study after developing a bradycardia. The RR for severe adverse events was 3.11 (95% CI 0.34 to 28.54; I<sup>2</sup> = 0%, 80 participants; <a href="./references#CD002827-fig-0022" title="">Analysis 3.14</a>), but this figure should be interpreted with caution, given the small number of participants and single‐integer events. </p> </section> </section> <section id="CD002827-sec-0061"> <h4 class="title">Cyclophosphamide and prednisolone combination versus placebo</h4> <p>The only trial to use this combination as an intervention was <a href="./references#CD002827-bbs2-0007" title="NiermeijerJMF ,  EurelingsM ,  Van der LindenMW ,   Lokhorst HM ,   Franssen H ,   Fischer K , et al. Intermittent cyclophosphamide with prednisone versus placebo for polyneuropathy with IgM monoclonal gammopathy. Neurology2007;69(1):50‐9. [PUBMED: 17606880] ">Niermeijer 2007</a>. See 'Summary of findings' Additional <a href="#CD002827-tbl-0003">Table 2</a>. Values for outcomes in this study were presented as means and 95% CIs. We calculated SDs from the 95% CIs. </p> <div class="table" id="CD002827-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">'Summary of findings' table: Cyclophosphamide and prednisone versus placebo</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Cyclophosphamide and corticosteroids compared to placebo for IgM anti‐myelin‐associated glycoprotein paraprotein‐associated peripheral neuropathies</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with IgM anti‐myelin‐associated glycoprotein paraprotein‐associated peripheral neuropathies<br/> <b>Settings:</b> hospital and outpatient treatment centres<br/> <b>Intervention:</b> cyclophosphamide and corticosteroids<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Relative effect <br/> (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Number of participants <br/> (studies)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Quality of the evidence <br/> (GRADE)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Comments</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Risk with placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Risk with cyclophosphamide and corticosteroids</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants improved in disability score at 6 months</b> <br/> Modifed Rankin Scale </p> <p>Scale from: 0 to 6 (normal to death)<br/> Follow‐up: mean 6 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 3.56</b> <br/> (0.41 to 30.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>35<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>53 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>189 per 1000</b> <br/> (22 to 1000) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean improvement in disability score at 6 months</b> </p> <p>Modifed Rankin Scale</p> <p>Scale from: 0 to 6 (normal to death)</p> <p>Follow‐up: 6 months<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean improvement in disability score at 6 months in the control groups was<br/> <b>0.11 units</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean improvement in disability score at 6 months in the intervention groups was<br/> <b>0.31 lower</b> <br/> (0.61 lower to 0.01 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Improvement in 10‐metre walk time at 6 months</b> ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant subjective impression of change at 6 months ‐ number of participants reporting improvement</b> ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in serum IgM paraprotein concentration after treatment</b> ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Any adverse event</b> <br/> ‐ not measured </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events not specifically collected but text notes in the paper (see text of review) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>IgM:</b> immunoglobulin M; <b>RR:</b> risk ratio </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup>Dowgraded once for imprecision (single small study).<br/> <sup>2</sup>Phase 1 of cross‐over trial only. </p> </div> </div> <p>The trial authors made original trial data available and we considered whether to carry out further statistical analysis to use the data after six months from phase two (see <a href="#CD002827-sec-0042">Effects of interventions</a> above). However, after discussion we did not consider the data to be valid, as the re‐allocation of participants was not truly random and the results would therefore be significantly biased. </p> <section id="CD002827-sec-0062"> <h5 class="title">Primary outcome measures</h5> <p>The mRS at six months was included as one of the outcomes of phase one of this trial, the only disability data that could be included in this review. At six months a (barely) significant improvement in the mean mRS was present, with a MD of ‐0.31 points (95% CI ‐0.61 to ‐0.01; 34 participants; <a href="./references#CD002827-fig-0023" title="">Analysis 4.1</a>), with no significant difference in the number of participants improved at six months when we extracted the dichotomous data from the dataset provided by the authors (3/16 improved with cyclophosphamide and prednisolone combination versus 1/19 with placebo, RR 3.56, 95% CI 0.41 to 30.99; 35 participants; <a href="./references#CD002827-fig-0024" title="">Analysis 4.2</a>. </p> </section> <section id="CD002827-sec-0063"> <h5 class="title">Secondary outcome measures</h5> <p>The authors of this trial used the Rivermead Mobility Index (RMI) as their primary outcome measure. We included the RMI as a secondary outcome under subjective clinical scores. No significant improvement in the RMI was present after six months of cyclophosphamide and prednisolone (MD 0.42, 95% CI ‐0.41 to 1.25; 34 participants; <a href="./references#CD002827-fig-0025" title="">Analysis 4.3</a>). </p> </section> <section id="CD002827-sec-0064"> <h5 class="title">Adverse events</h5> <p>Adverse events were not specifically sought in this trial. One participant receiving cyclophosphamide withdrew because of angina and was lost to follow‐up, and one participant withdrew because of rapid progression of neuropathy. A further participant, who was also cyclophosphamide‐treated, withdrew during the seven‐month to 12‐month phase. The trialists reported that nausea was significantly more common in the cyclophosphamide‐treated group (P = 0.001), but provided no further details. </p> <p>Three of 35 participants (8.6%) who had received cyclophosphamide developed an immunocytoma not requiring further treatment at five years of follow‐up. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD002827-sec-0065" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD002827-sec-0065"></div> <section id="CD002827-sec-0066"> <h3 class="title" id="CD002827-sec-0066">Randomised controlled trials (RCTs)</h3> <p>We identified eight RCTs for this update. Four fulfilled all our strict predefined inclusion criteria (<a href="./references#CD002827-bbs2-0001" title="ComiG , RoveriL , SwanA , WillisonH , BojarM , IllaI , et al. Inflammatory Neuropathy Cause And Treatment (INCAT) Group. A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy. Journal of Neurology2002;249(10):1370‐7. [PUBMED: 12382151] ">Comi 2002</a>; <a href="./references#CD002827-bbs2-0003" title="DalakasMC , RakocevicG , SalajeghehM , DambrosiaJM , HahnAF , RajuR , et al. Placebo‐controlled trial of rituximab in IgM anti–myelin‐associated glycoprotein antibody demyelinating neuropathy. Annals of Neurology2009;65(3):286–93. [PUBMED: 19334068] ">Dalakas 2009</a>; <a href="./references#CD002827-bbs2-0004" title="LégerJM , VialaK , NicolasG , CréangeA , VallatJM , PougetJ , et al. Placebo controlled trial of rituximab in IgM anti‐myelin‐associated glycoprotein neuropathy. Neurology2013;80(24):2217‐25. [PUBMED: 23667063] ">Léger 2013</a>; <a href="./references#CD002827-bbs2-0007" title="NiermeijerJMF ,  EurelingsM ,  Van der LindenMW ,   Lokhorst HM ,   Franssen H ,   Fischer K , et al. Intermittent cyclophosphamide with prednisone versus placebo for polyneuropathy with IgM monoclonal gammopathy. Neurology2007;69(1):50‐9. [PUBMED: 17606880] ">Niermeijer 2007</a>). The trials of Comi, Leger and Niermeijer had a low risk of bias, whereas <a href="./references#CD002827-bbs2-0003" title="DalakasMC , RakocevicG , SalajeghehM , DambrosiaJM , HahnAF , RajuR , et al. Placebo‐controlled trial of rituximab in IgM anti–myelin‐associated glycoprotein antibody demyelinating neuropathy. Annals of Neurology2009;65(3):286–93. [PUBMED: 19334068] ">Dalakas 2009</a> had a high risk of bias in multiple domains (<a href="#CD002827-fig-0002">Figure 2</a>). We included the four other RCTs that did not fulfil all the inclusion criteria, because their inclusion criteria closely approximated to those intended. </p> <p>According to evidence from two trials, IVIg may produce some short‐term benefit in the treatment of anti‐MAG IgM paraproteinaemic neuropathy. One double‐blind, placebo‐controlled study with minimal bias showed benefit of IVIg at four weeks in one of the primary outcome measures (mRS) and the 10‐metre walk time secondary outcome measure but no other significant outcomes (<a href="./references#CD002827-bbs2-0001" title="ComiG , RoveriL , SwanA , WillisonH , BojarM , IllaI , et al. Inflammatory Neuropathy Cause And Treatment (INCAT) Group. A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy. Journal of Neurology2002;249(10):1370‐7. [PUBMED: 12382151] ">Comi 2002</a>). The outcomes were available only at four weeks and were not available for the predefined endpoints of six and 12 months; it is not clear whether any short‐term benefit would be sustained or whether IVIg is clinically useful. Furthermore, this trial was of IgM paraproteinaemic neuropathy and not all the included participants had associated anti‐MAG activity. Evidence for any benefit from IVIg should be regarded with caution. </p> <p>Two trials with interferon alfa‐2a gave contradictory results. Interferon alfa‐2a appeared to be of benefit in treating anti‐MAG neuropathy when tested in an open trial with IVIg (<a href="./references#CD002827-bbs2-0005" title="MarietteX , ChastangC , ClavelouP , LouboutinJ‐P , LegerJM , BrouetJC . A randomised clinical trial comparing interferon‐alpha and intravenous immunoglobulin in polyneuropathy associated with monoclonal IgM. The IgM‐associated Polyneuropathy Study Group. Journal of Neurology, Neurosurgery and Psychiatry1997;63(1):28‐34. [PUBMED: 9221964] ">Mariette 1997</a>). Because this trial was not blinded it was at high risk of bias. The later, less biased, double‐blind, placebo‐controlled study of interferon alfa‐2a did not demonstrate any significant benefit from interferon alfa‐2a (<a href="./references#CD002827-bbs2-0006" title="MarietteX , BrouetJC , ChevretS , LegerJM , ClavelouP , PougetJ , et al. A randomized double blind trial versus placebo does not confirm the benefit of alpha‐interferon in polyneuropathy associated with monoclonal IgM. Journal of Neurology, Neurosurgery and Psychiatry2000;69(2):279‐80. [PUBMED: 10960293] ">Mariette 2000</a>). </p> <p>A single trial assessed the use of plasma exchange as additional treatment to chlorambucil (<a href="./references#CD002827-bbs2-0008" title="OksenhendlerE , ChevretS , LegerJM , LouboutinJP , BusselA , BrouetJC . Plasma exchange and chlorambucil in polyneuropathy associated with monoclonal IgM gammopathy. IgM‐associated Polyneuropathy Study Group. Journal of Neurology, Neurosurgery and Psychiatry1995;59(3):243‐7. [PUBMED: 7673949] ">Oksenhendler 1995</a>). No additional benefit was gained from the addition of plasma exchange in the predefined outcome measures at four or 12 months. This relatively large study lacked blinding and allocation concealment, and the results should therefore be interpreted with caution. Since the trial showed no additional benefit from plasma exchange, any possible bias did not lead to a significant result. </p> <p>A number of case reports and small case series have described use of rituximab for the treatment of paraproteinaemic neuropathy (<a href="./references#CD002827-bbs2-0009" title="BarohnRJ , RashidI , McVeyAL , HerbelinL , SkikneB , SapersteinDS . Rituximab for the treatment of IgM associated polyneuropathies. Journal of the Peripheral Nervous System2005;10 Suppl 1:4. ">Barohn 2005</a>; <a href="./references#CD002827-bbs2-0010" title="BenedettiL , GobbiM , GhiglioneE , VigoT , CarpoM , CocitoD , et al. Rituximab in anti‐MAG polyneuropathy. Journal of the Peripheral Nervous System2005;10(Suppl 1):5. ">Benedetti 2005</a>; <a href="./references#CD002827-bbs2-0011" title="BenedettiB , BrianiC , GrnadisM , VigoT , GobbiM , GhiglioneE , et al. Predictors of response to rituximab in patients with neuropathy and anti‐myelin associated glycoprotein immunoglobulin M. Journal of the Peripheral Nervous System2007;12(2):102‐7. ">Benedetti 2007</a>; <a href="./references#CD002827-bbs2-0012" title="BenedettiL , BrianiC , FranciottaD , CarpoM , PaduaL , ZaraG , et al. Long‐term effect of rituximab in anti‐MAG polyneuropathy. Neurology2008;71(21):1742‐4. ">Benedetti 2008</a>; <a href="./references#CD002827-bbs2-0013" title="CanavanJB , MoroneyJT , KeoganMT , HardimanO . Rituximab and IgM autoantibody‐associated peripheral neuropathy: The Irish experience. Neurology2002;Suppl 3:A233. ">Canavan 2002</a>; <a href="./references#CD002827-bbs2-0037" title="DelmontE , JeandelPY , HubertAM , MarcqL , BoucrautJ , DesnuelleC . Successful treatment with rituximab of one patient with CANOMAD neuropathy. Journal of Neurology2010;257(4):655‐7. ">Delmont 2010</a>; <a href="./references#CD002827-bbs2-0015" title="GoldfarbAR , WeimerLH , BranniganTH3rd . Rituximab treatment of an IgM monoclonal autonomic and sensory neuropathy. Muscle &amp; Nerve2005;31(4):510‐5. ">Goldfarb 2005</a>; <a href="./references#CD002827-bbs2-0049" title="GonoT , MatsudaM , ShimojimaY , IshiiW , YamamotoK , MoritaH , et al. Rituximab therapy in chronic inflammatory demyelinating polyradiculoneuropathy with anti‐SGPG IgM antibody. Journal of Clinical Neuroscience2006;13(6):683‐7. ">Gono 2006</a>; <a href="./references#CD002827-bbs2-0017" title="GorsonKC ,   Natarajan N ,   Ropper AH ,   Weinstein R . Rituximab treatment in patients with IVIg‐dependent immune polyneuropathy: a prospective pilot trial. Muscle &amp; Nerve2007;35(1):66‐9. ">Gorson 2007</a>; <a href="./references#CD002827-bbs2-0063" title="KellyJJ . Chronic peripheral neuropathy responsive to rituximab. Reviews in Neurological Diseases2006;3(2):78‐81. ">Kelly 2006</a>; <a href="./references#CD002827-bbs2-0019" title="KilidireasC ,  AnagnostopoulosA ,  KarandreasN ,  MouselimiL ,  DimopoulosMA . Rituximab therapy in monoclonal IgM‐related neuropathies. Leukemia &amp; Lymphoma2006;47(5):859‐64. ">Kilidireas 2006</a>; <a href="./references#CD002827-bbs2-0020" title="LatovN , ShermanWH . Therapy of neuropathy associated with anti‐MAG IgM monoclonal gammopathy with Rituxan (abstract). Neurology1999;52 Suppl 2:A551. ">Latov 1999</a>; <a href="./references#CD002827-bbs2-0066" title="LevineTD , PestronkA . IgM antibody‐related polyneuropathies: B‐cell depletion chemotherapy using rituximab. Neurology1999;52(8):1701‐4. ">Levine 1999</a>; <a href="./references#CD002827-bbs2-0023" title="PestronkA , FlorenceJ , MillerT , ChoksiR , Al‐LoziMT , LevineTD . Treatment of IgM antibody associated polyneuropathies using rituximab. Journal of Neurology, Neurosurgery and Psychiatry2003;74(4):485‐9. ">Pestronk 2003</a>; <a href="./references#CD002827-bbs2-0024" title="RenaudS , GregorM , FuhrP , LorenzD , DeuschlG , GratwohlA , et al. Rituximab in the treatment of polyneuropathy associated with anti‐MAG antibodies. Muscle &amp; Nerve2003;27(5):611‐5. ">Renaud 2003</a>; <a href="./references#CD002827-bbs2-0025" title="RenaudS , FuhrP , GregorM , SchweikertK , LorenzD , DanielsC , et al. High‐dose rituximab and anti‐MAG‐associated polyneuropathy. Neurology2006;66(5):742‐4. ">Renaud 2006</a>; <a href="./references#CD002827-bbs2-0095" title="WeideR , HeymannsJ , KopplerH . The polyneuropathy associated with Waldenström's macroglobulinaemia can be treated effectively with chemotherapy and the anti‐CD20 monoclonal antibody rituximab. British Journal of Haematology2000;109(4):838‐41. ">Weide 2000</a>; <a href="./references#CD002827-bbs2-0022" title="NiermeijerJM , EurelingsM , LokhorstHL , Van derPolWL , FranssenH , WokkeJH , et al. Rituximab for polyneuropathy with IgM monoclonal gammopathy. Journal of Neurology, Neurosurgery and Psychiatry2009;80(9):1036‐9. ">Niermeijer 2009</a>). The results were varied, with most reporting positive outcomes in the majority of participants but some very usefully reporting no response in all their reported cases (<a href="./references#CD002827-bbs2-0009" title="BarohnRJ , RashidI , McVeyAL , HerbelinL , SkikneB , SapersteinDS . Rituximab for the treatment of IgM associated polyneuropathies. Journal of the Peripheral Nervous System2005;10 Suppl 1:4. ">Barohn 2005</a>; <a href="./references#CD002827-bbs2-0082" title="Rojas‐GarcíaR , GallardoE , DeAndrésI , DeLunaN , JuarezC , SánchezP , et al. Chronic neuropathy with IgM antiganglioside antibodies: lack of long term response to rituximab. Neurology2003;61(12):1814–6. ">Rojas‐García 2003</a>), and some reporting deteriorations (<a href="./references#CD002827-bbs2-0033" title="BroglioL , LauriaG . Worsening after rituximab treatment in anti‐MAG neuropathy. Muscle &amp; Nerve2005;32(3):378‐9. ">Broglio 2005</a>; <a href="./references#CD002827-bbs2-0048" title="GironiM , SaresellaM , CeresaL , CalvoM , FerranteP , MerliF , et al. Clinical and immunological worsening in a patient affected with Waldenstrom macroglobulinemia and anti‐mag neuropathy after treatment with rituximab. Haematologica2006;91(6 Suppl):ECR 17. ">Gironi 2006</a>; <a href="./references#CD002827-bbs2-0077" title="NoronhaV , FynanTM , DuffyT . Flare in neuropathy following rituximab therapy for Waldenstrom’s macroglobulinemia. Journal of Clinical Oncology2006;24(1):e3. ">Noronha 2006</a>). We included the first rituximab RCT in the 2012 update (<a href="./references#CD002827-bbs2-0003" title="DalakasMC , RakocevicG , SalajeghehM , DambrosiaJM , HahnAF , RajuR , et al. Placebo‐controlled trial of rituximab in IgM anti–myelin‐associated glycoprotein antibody demyelinating neuropathy. Annals of Neurology2009;65(3):286–93. [PUBMED: 19334068] ">Dalakas 2009</a>), and we now include a further RCT (<a href="./references#CD002827-bbs2-0004" title="LégerJM , VialaK , NicolasG , CréangeA , VallatJM , PougetJ , et al. Placebo controlled trial of rituximab in IgM anti‐myelin‐associated glycoprotein neuropathy. Neurology2013;80(24):2217‐25. [PUBMED: 23667063] ">Léger 2013</a>). <a href="./references#CD002827-bbs2-0003" title="DalakasMC , RakocevicG , SalajeghehM , DambrosiaJM , HahnAF , RajuR , et al. Placebo‐controlled trial of rituximab in IgM anti–myelin‐associated glycoprotein antibody demyelinating neuropathy. Annals of Neurology2009;65(3):286–93. [PUBMED: 19334068] ">Dalakas 2009</a> had a high risk of bias in two assessed domains and unclear risks in three others of the six assessed. As such, we assessed the evidence from this trial as very low quality across the outcomes stipulated. The results should therefore be regarded with caution. With the removal of a participant from the analysis who should perhaps not have been randomised, the trial reported improvements in the INCAT leg score and the 10‐metre walk time, and in the whole group, the IgM levels and anti‐MAG titres. The study reported seven of 13 rituximab‐treated participants compared to none of the 13 participants in the placebo group experiencing improvement in "patient clinical assessments and questionnaires". In our analysis, although there was a trend in favour of the treatment group in all analyses, none of the clinical outcomes were statistically significantly different from placebo. However, rituximab did reduce IgM levels and anti‐MAG titres, as would be expected. The interpretation of the results in the original paper by the trial authors concludes that "The results warrant confirmation with a larger trial". We have now added the data from the larger and less biased <a href="./references#CD002827-bbs2-0004" title="LégerJM , VialaK , NicolasG , CréangeA , VallatJM , PougetJ , et al. Placebo controlled trial of rituximab in IgM anti‐myelin‐associated glycoprotein neuropathy. Neurology2013;80(24):2217‐25. [PUBMED: 23667063] ">Léger 2013</a> to the meta‐analysis. <a href="./references#CD002827-bbs2-0004" title="LégerJM , VialaK , NicolasG , CréangeA , VallatJM , PougetJ , et al. Placebo controlled trial of rituximab in IgM anti‐myelin‐associated glycoprotein neuropathy. Neurology2013;80(24):2217‐25. [PUBMED: 23667063] ">Léger 2013</a> was reported as demonstrating no change in its primary and secondary outcomes. However, the outcome changes, where they are comparable, are all in a similar direction and of similar magnitude to those of <a href="./references#CD002827-bbs2-0003" title="DalakasMC , RakocevicG , SalajeghehM , DambrosiaJM , HahnAF , RajuR , et al. Placebo‐controlled trial of rituximab in IgM anti–myelin‐associated glycoprotein antibody demyelinating neuropathy. Annals of Neurology2009;65(3):286–93. [PUBMED: 19334068] ">Dalakas 2009</a> (I<sup>2</sup> = 0% throughout). In meta‐analysis, comparing rituximab to placebo, significant improvements are seen in numbers of participants improved on the INCAT score (although the magnitude of this does not reach clinical significance), the biological parameters (IgM, anti‐MAG titres), the physical subscores of the SF36 (but not the mental), and perhaps importantly the patient clinical impression of change scores, both for improvement alone and stabilisation and improvement. The numbers of participants are small but the results demonstrate no heterogeneity. The results of <a href="./references#CD002827-bbs2-0004" title="LégerJM , VialaK , NicolasG , CréangeA , VallatJM , PougetJ , et al. Placebo controlled trial of rituximab in IgM anti‐myelin‐associated glycoprotein neuropathy. Neurology2013;80(24):2217‐25. [PUBMED: 23667063] ">Léger 2013</a> are more robust, at less risk of bias and more reliable, and support an effect of rituximab in stabilising or improving anti‐MAG neuropathy. </p> <p><a href="./references#CD002827-bbs2-0007" title="NiermeijerJMF ,  EurelingsM ,  Van der LindenMW ,   Lokhorst HM ,   Franssen H ,   Fischer K , et al. Intermittent cyclophosphamide with prednisone versus placebo for polyneuropathy with IgM monoclonal gammopathy. Neurology2007;69(1):50‐9. [PUBMED: 17606880] ">Niermeijer 2007</a> trialed cyclophosphamide and corticosteroids (CP) in combination, versus placebo. Ethical concerns led to modification of the protocol such that we could not use the data after the sixth month in the meta‐analysis. We found no significant improvements in the functional scales used (mRS and RMI), as displayed here, from moderate‐quality evidence. The trial reports significant improvements in validated impairment measures of strength and sensory dysfunction (not predefined outcomes in this meta‐analysis), which did not translate into functional benefits. </p> <p>This review has identified many problems with the trials of treatment for this indication, including variations in trial design, participant inclusion and exclusion criteria, analysis points, and outcome measures. Only six of the eight trials were blinded. Some trials employed a cross‐over design, which must be allowed for in analysis. In one study an alteration in the trial design for ethical reasons meant that data beyond the six‐month time point were not usable in this analysis (<a href="./references#CD002827-bbs2-0007" title="NiermeijerJMF ,  EurelingsM ,  Van der LindenMW ,   Lokhorst HM ,   Franssen H ,   Fischer K , et al. Intermittent cyclophosphamide with prednisone versus placebo for polyneuropathy with IgM monoclonal gammopathy. Neurology2007;69(1):50‐9. [PUBMED: 17606880] ">Niermeijer 2007</a>). Most studies did not use validated clinical and disability scales that are likely to detect changes (for example, the INCAT Sensory Sum Score (<a href="./references#CD002827-bbs2-0071" title="MerkiesIS , SchmitzPI , Van derMecheFG , VanDoornPA . Psychometric evaluation of a new sensory scale in immune‐mediated polyneuropathies. Inflammatory Neuropathy Cause and Treatment (INCAT) Group. Neurology2000;54(4):943‐9. ">Merkies 2000</a>)) and these should be considered in future studies. Further, more sensitive scales measuring both disability and specific domains of impairment that are affected in this predominantly sensory neuropathy are being developed. Although <a href="./references#CD002827-bbs2-0001" title="ComiG , RoveriL , SwanA , WillisonH , BojarM , IllaI , et al. Inflammatory Neuropathy Cause And Treatment (INCAT) Group. A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy. Journal of Neurology2002;249(10):1370‐7. [PUBMED: 12382151] ">Comi 2002</a> was possibly too short to detect meaningful changes, it did include validated, clinically useful, and reproducible endpoints such as the sensory sum score, 10‐metre walking time, nine‐hole peg test, the Rotterdam Scale (a handicap score), and the SF36 quality‐of‐life scale. <a href="./references#CD002827-bbs2-0003" title="DalakasMC , RakocevicG , SalajeghehM , DambrosiaJM , HahnAF , RajuR , et al. Placebo‐controlled trial of rituximab in IgM anti–myelin‐associated glycoprotein antibody demyelinating neuropathy. Annals of Neurology2009;65(3):286–93. [PUBMED: 19334068] ">Dalakas 2009</a> also used more up‐to‐date outcomes, although the trial was probably too small to detect significant change, and bias makes the results unreliable. Further work is ongoing to develop valid disability measures (see for example the <a href="http://www.comet-initiative.org/studies/details/252" target="_blank">PeriNomS project</a>). Objective endpoints such as presence of SNAPs were infrequently used, but in clinical practice these seldom change in the short to medium term. No study has included a measure of fatigue (<a href="./references#CD002827-bbs2-0070" title="MerkiesIS , SchmitzPI , SamijnJP , Van derMecheFG , VanDoornPA . Fatigue in immune‐mediated polyneuropathies. European Inflammatory Neuropathy Cause and Treatment (INCAT) Group. Neurology1999;53(8):1648‐54. ">Merkies 1999</a>), which is prevalent in chronic inflammatory demyelinating polyradiculoneuropathy but has not been investigated in anti‐MAG neuropathy. Furthermore, effective treatments, if identified, are likely to be expensive and possibly invasive, and investigators should therefore consider measures of quality of life and cost effectiveness in all trials. </p> <p>Only four trials confined recruitment to participants with anti‐MAG antibodies (<a href="./references#CD002827-bbs2-0003" title="DalakasMC , RakocevicG , SalajeghehM , DambrosiaJM , HahnAF , RajuR , et al. Placebo‐controlled trial of rituximab in IgM anti–myelin‐associated glycoprotein antibody demyelinating neuropathy. Annals of Neurology2009;65(3):286–93. [PUBMED: 19334068] ">Dalakas 2009</a>; <a href="./references#CD002827-bbs2-0004" title="LégerJM , VialaK , NicolasG , CréangeA , VallatJM , PougetJ , et al. Placebo controlled trial of rituximab in IgM anti‐myelin‐associated glycoprotein neuropathy. Neurology2013;80(24):2217‐25. [PUBMED: 23667063] ">Léger 2013</a>; <a href="./references#CD002827-bbs2-0005" title="MarietteX , ChastangC , ClavelouP , LouboutinJ‐P , LegerJM , BrouetJC . A randomised clinical trial comparing interferon‐alpha and intravenous immunoglobulin in polyneuropathy associated with monoclonal IgM. The IgM‐associated Polyneuropathy Study Group. Journal of Neurology, Neurosurgery and Psychiatry1997;63(1):28‐34. [PUBMED: 9221964] ">Mariette 1997</a>; <a href="./references#CD002827-bbs2-0006" title="MarietteX , BrouetJC , ChevretS , LegerJM , ClavelouP , PougetJ , et al. A randomized double blind trial versus placebo does not confirm the benefit of alpha‐interferon in polyneuropathy associated with monoclonal IgM. Journal of Neurology, Neurosurgery and Psychiatry2000;69(2):279‐80. [PUBMED: 10960293] ">Mariette 2000</a>). The anti‐MAG neuropathies constitute the majority of the IgM paraproteinaemic demyelinating neuropathies in terms of immunoreactivity. They are relatively homogeneous in their clinical features and are distinct from some other rare but identified subgroups (for example, those with IgM anti‐GM1/GD1b reactivity). Many IgM paraproteinaemic neuropathies have no identified antigen target and yet are not clinically very different from those with anti‐MAG antibodies. This is often used as an argument that anti‐MAG antibodies are not relevant in the pathogenesis. Although this may be the case, there is a considerable body of evidence in favour of anti‐MAG antibodies causing demyelination, as described in the <a href="#CD002827-sec-0016">Background</a>. Lack of anti‐MAG antibodies may simply reflect low detection through inadequate immunological identification, or alternative antigenic targets yet to be described. Subgroup analysis by anti‐MAG activity should be reported in future trials. </p> <p>Cochrane is increasingly concerned about the quality of data supplied for systematic reviews from original trials where a number of instances of fraudulent publishing have been uncovered. Any future trials in the area should eradicate the need for suspicion about the data published, by publishing, in full, the trial protocol on a clinical trials website, making minimal change (but being transparent with the change if required), publishing all the predefined outcomes for all trials, and making the data available for scrutiny. </p> </section> <section id="CD002827-sec-0067"> <h3 class="title" id="CD002827-sec-0067">Non‐randomised studies</h3> <p>As part of our systematic search of the literature for RCTs, we identified many case reports and small non‐randomised case series. These included all the therapies covered in the RCTs above, as well as other therapies not subjected to RCTs. These are documented in <a href="#CD002827-tbl-0004">Table 3</a> but this should not be regarded as a systematic presentation of the non‐randomised literature. </p> <div class="table" id="CD002827-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Details of non‐randomised studies</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study ID</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study design</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Particiant number (total)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant number (IgM)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant number (MAG)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number improved (IgM)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number improved (MAG)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0064" title="LatovN , ShermanWH , NemniR , GalassiG , ShyongJS , PennAS , et al. Plasma cell dyscrasia and peripheral neuropathy with a monoclonal antibody to peripheral nerve myelin. New England Journal of Medicine1980;303(11):618‐21. ">Latov 1980</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case report</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (anti‐myelin Abs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisolone + chlorambucil + plasma exchange</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0036" title="DalakasMC , EngelWK . Polyneuropathy with monoclonal gammopathy: studies of 11 patients. Annals of Neurology1981;10(1):45‐52. [MEDLINE: 81280471] ">Dalakas 1981</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Uncontrolled case series (response to Rx recorded in <a href="./references#CD002827-bbs2-0065" title="LatovN , HaysAP , ShermanWH . Peripheral neuropathy and anti‐MAG antibodies. Critical Reviews in Neurobiology1988;3(4):301‐32. ">Latov 1988</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. Prednisolone b. Prednisolone + chlorambucil</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. 0/1 b. 1/1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0069" title="MelmedC , FrailD , DuncanI , BraunP , DanoffD , FinlaysonM , et al. Peripheral neuropathy with IgM kappa monoclonal immunoglobulin directed against myelin‐associated glycoprotein. Neurology1983;33(11):1397‐405. [MEDLINE: 84040255] ">Melmed 1983</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Uncontrolled case series (response to Rx recorded in <a href="./references#CD002827-bbs2-0065" title="LatovN , HaysAP , ShermanWH . Peripheral neuropathy and anti‐MAG antibodies. Critical Reviews in Neurobiology1988;3(4):301‐32. ">Latov 1988</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. Corticosteroids b. Steroids + plasma exchange + chlorambucil</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. 3/3 b. 0/3</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0091" title="StefanssonK , MartonL , AntelJP , WollmannRL , RoosRP , ChejfecG , et al. Neuropathy accompanying IgM lambda monoclonal gammopathy. Acta Neuropathologica1983;59(4):255‐61. ">Stefansson 1983</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case report</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Plasmapheresis + immunosuppressant</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/1</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0068" title="MeierC , RobertsK , SteckA , HessC , MiloniE , TschoppL . Polyneuropathy in Waldenstrom's macroglobulinaemia: reduction of endoneurial IgM‐deposits after treatment with chlorambucil and plasmapheresis. Acta Neuropathologica1984;64(4):297‐307. ">Meier 1984</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case report</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Plasmapheresis + prednisolone + chlorambucil</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/1</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0085" title="ShermanWH , OlarteMR , McKiernanG , SweeneyK , LatovN , HaysAP . Plasma exchange treatment of peripheral neuropathy associated with plasma cell dyscrasia. Journal of Neurology, Neurosurgery and Psychiatry1984;47(8):813‐9. ">Sherman 1984</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retrospective case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Plasmapheresis + chlorambucil</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0031" title="BlandJH , GennariFJ , ErschlerWB , LatovN . IgMk monoclonal antibody directed against peripheral nerve myelin; clinical peripheral neuropathy and long‐term rheumatic disease. Journal of Rheumatology1985;12(6):1200. ">Bland 1985</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case report</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Plasmapheresis + chlorambucil</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/1</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0046" title="FrayneD , StarkeRJ . Peripheral neuropathy with gammopathy responding to plasmapheresis. Clinical and Experimental Neurology1985;21:195‐200. ">Frayne 1985</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 cases</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Plasma exchange</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0043" title="ErnerudhJ , BrodtkorbE , OlssonT , VedelerCA , NylandH , BerlinG . Peripheral neuropathy and monoclonal IgM with antibody activity against peripheral nerve myelin; effect of plasma exchange. Journal of Neuroimmunology1986;11(3):171‐8. ">Ernerudh 1986</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retrospective non‐randomised</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (anti‐myelin Abs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Plasma exchange</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/3 (temporary)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0054" title="HaflerDA , JohnsonD , KellyJJ , PanitchR , KyleR , WeinerHL . Monoclonal gammopathy and neuropathy; myelin associated glycoprotein reactivity and clinical characteristics. Neurology1986;36(1):75‐8. ">Hafler 1986</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Uncontrolled case series (response to Rx recorded in <a href="./references#CD002827-bbs2-0065" title="LatovN , HaysAP , ShermanWH . Peripheral neuropathy and anti‐MAG antibodies. Critical Reviews in Neurobiology1988;3(4):301‐32. ">Latov 1988</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a.Corticosteroids b. Plasma exchange c. Cyclophosphamide</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. 0/5 b. 1/5 c. 1/1</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0089" title="SmithT , ShermanW , OlarteMR , LovelaceRE . Peripheral neuropathy associated with plasma cell dyscrasia: a clinical and electrophysiological follow‐up study. Acta Neurologica Scandanavica1987;75(4):244‐8. ">Smith 1987</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prospective non‐randomised case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 (2 lymphoma)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (1 lymphoma)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. Chlorambucil + plasma exchange b. Plasma exchange</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. 3/4 b. 1/2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. 1/2 b. 1/1</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0053" title="HaasDC , TatumAH . Plasmapheresis alleviates neuropathy accompanying IgM anti‐myelin‐associated glycoprotein paraproteinemia. Annals of Neurology1988;23(4):394‐6. ">Haas 1988</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case report</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Plasma exchange</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/1</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0062" title="KellyJJ , AdelmanLS , BerkmanE , BhanI . Polyneuropathies associated with IgM monoclonal gammopathies. Archives of Neurology1988;45(12):1355‐9. ">Kelly 1988</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Uncontrolled case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisolone + cyclophosphamide (azathioprine or chlorambucil) + plasma exchange</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/4 (all 5 not treated)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/3 (All 5 not treated)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0065" title="LatovN , HaysAP , ShermanWH . Peripheral neuropathy and anti‐MAG antibodies. Critical Reviews in Neurobiology1988;3(4):301‐32. ">Latov 1988</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Uncontrolled case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. Plasmapheresis b. Prednisolone c. Chlorambucil d. Prednisolone + plasma exchange e. Plasma exchange + chlorambucil </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. 3/3 b. 0/1 c. 3/4 d. 0/1 e. 0/1</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0038" title="DonofrioPD , KellyJJJr . AAEE case report #17: Peripheral neuropathy in monoclonal gammopathy of undetermined significance. Muscle &amp; Nerve1989;12(1):1‐8. ">Donofrio 1989</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case report</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. Corticosteroids b. Plasma exchange + corticosteroids</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. 0/1 b. 1/1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0035" title="CookD , DalakasMC , GaldiA , BiondiD , PorterH . High‐dose intravenous immunoglobulin in the treatment of demyelinating neuropathy associated with monoclonal gammopathy [see comments]. Neurology1990;40:212‐4. [MEDLINE: 90137262] ">Cook 1990</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case reports</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. IVIg b. prednisolone</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. 2/2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. 1/1 b. 0/1</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0058" title="HodgkinsonSJ , PollardJD , McLeodJG . Cyclosporin A in the treatment of chronic demyelinating polyradiculoneuropathy. Journal of Neurology, Neurosurgery and Psychiatry1990;53(4):327‐30. ">Hodgkinson 1990</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Uncontrolled case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ciclosporin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0044" title="ErnerudhJH , VrethemM , AndersenO , LindbergC , BerlinG . Immunochemical and clinical effects of immunosuppressive treatment in monoclonal IgM neuropathy. Journal of Neurology, Neurosurgery and Psychiatry1992;55(10):930‐4. ">Ernerudh 1992</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prospective non‐randomised</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 (anti‐myelin Abs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. Plasma exchange b. Prednisolone c. Melphalan d. Chlorambucil e. Chlorambucil and plasma exchange f. Chlorambucil + prednisolone </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. 1/1 b. 1/2 c. 0/1 d. 0/1 e. 1/1 f. 1/2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0057" title="Hoang‐XuanK , LegerJM , Ben Younes‐ChennoufiA , SaidiH , BoucheP , BaumannN , et al. Treatment of immune deficient neuropathies with intravenous polyvalent immunoglobulins. An open study of 16 cases. Revue Neurologique1993;149(6‐7):385‐92. ">Hoang‐Xuan 1993</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open prospective</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (2 in <a href="./references#CD002827-bbs2-0067" title="LégerJM , Younes‐ChennoufiAB , ChassandeB , DavilaG , BoucheP , BaumannN , et al. Human immunoglobulin treatment of multifocal motor neuropathy and polyneuropathy associated with monoclonal gammopathy. Journal of Neurology, Neurosurgery and Psychiatry1994;57(Suppl):46‐9. ">Léger 1994</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IVIg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/1</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0067" title="LégerJM , Younes‐ChennoufiAB , ChassandeB , DavilaG , BoucheP , BaumannN , et al. Human immunoglobulin treatment of multifocal motor neuropathy and polyneuropathy associated with monoclonal gammopathy. Journal of Neurology, Neurosurgery and Psychiatry1994;57(Suppl):46‐9. ">Léger 1994</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open prospective</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IVIg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/5</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0086" title="ShermanWH , LatovN , LangeDE , HaysRD , YoungerDS . Fludarabine for IgM antibody‐mediated neuropathies. Annals of Neurology1994;36:326‐7. [ISSN 0364‐5134] ">Sherman 1994</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Abstract</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fludarabine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/8</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0087" title="SicilianoG , MoriconiL , GianniG , RichieriE , VignocchiMG , RossiB . Selective techniques of apheresis in polyneuropathy associated with monoclonal gammopathy of undetermined significance. Acta Neurologica Scandanavica1994;89(2):117‐22. ">Siciliano 1994</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case report</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Selective apheresis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0032" title="BlumeG , PestronkA , GoodnoughLT . Anti‐MAG antibody‐associated polyneuropathies: improvement following immunotherapy with monthly plasma exchange and IV cyclophosphamide. Neurology1995;45(8):1577‐80. ">Blume 1995</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Uncontrolled case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Plasma exchange + cyclophosphamide</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/4</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0042" title="EllieE , VitalA , SteckA , BoironJ‐M , VitalC , JulienJ . Neuropathy associated with 'benign' anti‐myelin‐associated glycoprotein IgM gammopathy: clinical, immunological, neurophysiological and pathological findings and response to treatment in 33 cases. Journal of Neurology1996;243(1):34‐43. ">Ellie 1996</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retrospective case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. Plasma exchange b. IVIg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. 2/6 b. 13/17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0078" title="NotermansNC , LokhorstHM , FranssenH , Van derGraafY , TeunissenLL , JennekensFG , et al. Intermittent cyclophosphamide and prednisone treatment of polyneuropathy associated with monoclonal gammopathy of undetermined significance. Neurology1996;47(5):1227‐33. ">Notermans 1996</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open prospective</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cyclophosphamide + prednisolone</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0050" title="GorsonKC , AllamG , RopperAH . Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy. Neurology1997;48(2):321‐8. ">Gorson 1997</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retrospective case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. Plasma exchange b. Prednisolone c. IVIg d. Cyclophosphamide + plasma exchange</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. 10/12? b. 1/2 c. 2/6 d. 2/2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0083" title="RudnickiSA , HarikSI , DhodapkarM , BarlogieB , EidelbergD . Nervous system dysfunction in Waldenstrom's macroglobulinemia: response to treatment. Neurology1998;51(4):1210‐3. ">Rudnicki 1998</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case report</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. Fludarabine + plasma exchange b. Bone marrow transplant</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. 0/1 b. 0/1</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0020" title="LatovN , ShermanWH . Therapy of neuropathy associated with anti‐MAG IgM monoclonal gammopathy with Rituxan (abstract). Neurology1999;52 Suppl 2:A551. "><b>Latov 1999</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case reports</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rituximab</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/2</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0066" title="LevineTD , PestronkA . IgM antibody‐related polyneuropathies: B‐cell depletion chemotherapy using rituximab. Neurology1999;52(8):1701‐4. ">Levine 1999</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Probably included in <a href="./references#CD002827-bbs2-0023" title="PestronkA , FlorenceJ , MillerT , ChoksiR , Al‐LoziMT , LevineTD . Treatment of IgM antibody associated polyneuropathies using rituximab. Journal of Neurology, Neurosurgery and Psychiatry2003;74(4):485‐9. ">Pestronk 2003</a> ‐ unclear </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rituximab</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0098" title="WilsonHC , LunnMPT , ScheyS , HughesRAC . Successful treatment of IgM paraproteinaemic neuropathy with fludarabine. Journal of Neurology, Neurosurgery and Psychiatry1999;66(5):575‐80. ">Wilson 1999</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open prospective</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fludarabine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/4</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0076" title="Nobile‐OrazioE , MeucciN , BaldiniL , DiTroiaA , ScarlatoG . Long‐term prognosis of neuropathy associated with anti‐MAG IgM M‐proteins and its relationship to immune therapies. Brain2000;123(Pt 4):710‐7. ">Nobile‐Orazio 2000</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retrospective case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. Plasma exchange b. Plasma exchange + chlorambucil c. Prednisolone d. IVIg e. Cyclophosphamide</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. 2/5 b. 2/2 c. 0/6 d. 0/2 e. 1/5</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0051" title="GorsonKC , RopperAH , WeinbergDH , WeinsteinR . Treatment experience in patients with anti‐myelin‐associated glycoprotein neuropathy. Muscle &amp; Nerve2001;24(6):778‐86. ">Gorson 2001</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retrospective case series (NB some cases in <a href="./references#CD002827-bbs2-0050" title="GorsonKC , AllamG , RopperAH . Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy. Neurology1997;48(2):321‐8. ">Gorson 1997</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. Plasma exchange b. IVIg c. Prednisolone d. Cyclophosphamide e. Plasma exchange + cyclophosphamide f. Interferon alfa‐2a g. Chlorambucil h. Azathioprine </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. 8/20 b. 3/19 c. 0/8 d. 3/6 e. 2/8 f. 1/8 g. 0/2 h. 0/2</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0092" title="TagawaY , YukiN , OhnishiA , HirataK , HosokawaS . Parameters for monitoring treatment effects in CIDP with anti‐MAG/SGPG IgM antibody. Muscle &amp; Nerve2001;24(5):701‐4. ">Tagawa 2001</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case report</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Plasmapheresis + cyclophosphamide</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/1</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0013" title="CanavanJB , MoroneyJT , KeoganMT , HardimanO . Rituximab and IgM autoantibody‐associated peripheral neuropathy: The Irish experience. Neurology2002;Suppl 3:A233. "><b>Canavan 2002</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retrospective case reports (abstract)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rituximab</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/2</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0047" title="GhoshA , LittlewoodT , DonaghyM . Cladribine in the treatment of IgM paraproteinaemic polyneuropathy. Neurology2002;59(8):1290‐1. ">Ghosh 2002</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case report</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cladribine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/1</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0023" title="PestronkA , FlorenceJ , MillerT , ChoksiR , Al‐LoziMT , LevineTD . Treatment of IgM antibody associated polyneuropathies using rituximab. Journal of Neurology, Neurosurgery and Psychiatry2003;74(4):485‐9. "><b>Pestronk 2003</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prospective open study</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rituximab</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear ‐ improvement</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0024" title="RenaudS , GregorM , FuhrP , LorenzD , DeuschlG , GratwohlA , et al. Rituximab in the treatment of polyneuropathy associated with anti‐MAG antibodies. Muscle &amp; Nerve2003;27(5):611‐5. "><b>Renaud 2003</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prospective open phase II study</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rituximab</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/9</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0009" title="BarohnRJ , RashidI , McVeyAL , HerbelinL , SkikneB , SapersteinDS . Rituximab for the treatment of IgM associated polyneuropathies. Journal of the Peripheral Nervous System2005;10 Suppl 1:4. "><b>Barohn 2005</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Uncontrolled case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rituximab</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002827-bbs2-0010" title="BenedettiL , GobbiM , GhiglioneE , VigoT , CarpoM , CocitoD , et al. Rituximab in anti‐MAG polyneuropathy. Journal of the Peripheral Nervous System2005;10(Suppl 1):5. "><b>Benedetti 2005</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled ?prospective (abstract)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rituximab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/13</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0033" title="BroglioL , LauriaG . Worsening after rituximab treatment in anti‐MAG neuropathy. Muscle &amp; Nerve2005;32(3):378‐9. ">Broglio 2005</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case report</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rituximab</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Worse</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0018" title="HamidouMA ,  BeliznaC ,  WiertlewskyS , AudrainM ,  BironC ,  GrolleauJ , et al. Intravenous cyclophosphamide in refractory polyneuropathy associated with IgM monoclonal gammopathy: an uncontrolled open trial. American Journal of Medicine2005;118(4):426‐30. "><b>Hamidou 2005</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Uncontrolled case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cyclophosphamide</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/9 improved, 2 stable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002827-bbs2-0019" title="KilidireasC ,  AnagnostopoulosA ,  KarandreasN ,  MouselimiL ,  DimopoulosMA . Rituximab therapy in monoclonal IgM‐related neuropathies. Leukemia &amp; Lymphoma2006;47(5):859‐64. "><b>Kilidireas 2006</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled case series</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rituximab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/4 improved</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0021" title="NiermeijerJMF ,  EurelingsM ,  LokhorstH ,  FranssenH ,  FijnheerR ,  WokkeJHJ , et al. Neurologic and hematologic response to fludarabine treatment in IgM MGUS polyneuropathy. Neurology2006;67(11):2076‐9. "><b>Niermeijer 2006</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open prospective</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fludarabine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/10 improved, all others stabilised</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/6 improved all others stabilised</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0025" title="RenaudS , FuhrP , GregorM , SchweikertK , LorenzD , DanielsC , et al. High‐dose rituximab and anti‐MAG‐associated polyneuropathy. Neurology2006;66(5):742‐4. "><b>Renaud 2006</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prospective follow‐up study to 2003</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐dose rituximab</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/7 improved (1 death)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0048" title="GironiM , SaresellaM , CeresaL , CalvoM , FerranteP , MerliF , et al. Clinical and immunological worsening in a patient affected with Waldenstrom macroglobulinemia and anti‐mag neuropathy after treatment with rituximab. Haematologica2006;91(6 Suppl):ECR 17. ">Gironi 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case report</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rituximab</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Worse</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0077" title="NoronhaV , FynanTM , DuffyT . Flare in neuropathy following rituximab therapy for Waldenstrom’s macroglobulinemia. Journal of Clinical Oncology2006;24(1):e3. ">Noronha 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case report</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rituximab</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Worse</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0022" title="NiermeijerJM , EurelingsM , LokhorstHL , Van derPolWL , FranssenH , WokkeJH , et al. Rituximab for polyneuropathy with IgM monoclonal gammopathy. Journal of Neurology, Neurosurgery and Psychiatry2009;80(9):1036‐9. "><b>Niermeijer 2009</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rituximab</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement in:</p> <p>ODSS 2/17,</p> <p>MRC sum score 11/17,</p> <p>Sensory sum score 10/17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/6</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0037" title="DelmontE , JeandelPY , HubertAM , MarcqL , BoucrautJ , DesnuelleC . Successful treatment with rituximab of one patient with CANOMAD neuropathy. Journal of Neurology2010;257(4):655‐7. ">Delmont 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case report</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rituximab (after IVIg, corticosteroids, chlorambucil)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0052" title="GrusonB , GhomariK , BeaumontM , GaridiR , JustA , MerleP , et al. Long‐term response to rituximab and fludarabine combination in IgM anti‐myelin‐associated glycoprotein neuropathy. Journal of the Peripheral Nervous System2011;16(3):180‐5. ">Gruson 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 (2 MGUS, 3 WM)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rituximab and fludarabine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/5 improved clinically, electrophysiologically, IgM level and anti‐MAG titre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All MAG</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0027" title="SmithBE , SuarezGA , WitzigTE , StevensJC , BoschEP , RossMA , et al. A phase II trial of rituximab for peripheral neuropathy associated with monoclonal gammopathy of undetermined significance (MGUS). Journal of the Peripheral Nervous System2011;16(Suppl s3):130. "><b>Smith 2011</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phase II non‐randomised case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/K</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rituximab</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NIS significant (&gt;10 pts) improvement at</p> <p>6 months 13/21, and 24 months 8/21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abs: antibodies; anti‐MAG; anti‐myelin‐associated glycoprotein; IgM: immunoglobulin M; IVIg; intravenous immunoglobulin; pts: participants; Rx: treatment; WM: Waldenstrom's macroglobulinemia </p> </div> </div> <section id="CD002827-sec-0068"> <h4 class="title">Plasma exchange and apheresis</h4> <p><a href="./references#CD002827-bbs2-0014" title="DyckPJ , LowPA , WindebankAJ , JaradehSS , GosselinS , BourqueP , et al. Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance. New England Journal of Medicine1991;325(21):1482‐6. [MEDLINE: 92049565] ">Dyck 1991</a> compared plasma exchange to sham exchange in a parallel‐group RCT with 39 participants, 21 of whom had an IgM paraprotein. We excluded this study, as there were no criteria specified for demyelination and the anti‐MAG status was not clear. <a href="./references#CD002827-bbs2-0014" title="DyckPJ , LowPA , WindebankAJ , JaradehSS , GosselinS , BourqueP , et al. Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance. New England Journal of Medicine1991;325(21):1482‐6. [MEDLINE: 92049565] ">Dyck 1991</a> found a significant improvement in the weakness component of the Neuropathy Disability Score (now known as the Neuropathy Impairment Score) in favour of plasma exchange in the IgG and IgA, but not the IgM subgroups. Functional changes were not reported. In eight case series of plasma exchange as monotherapy, improvement was reported in 24 of 48 cases of IgM paraprotein‐associated neuropathy (<a href="./references#CD002827-bbs2-0042" title="EllieE , VitalA , SteckA , BoironJ‐M , VitalC , JulienJ . Neuropathy associated with 'benign' anti‐myelin‐associated glycoprotein IgM gammopathy: clinical, immunological, neurophysiological and pathological findings and response to treatment in 33 cases. Journal of Neurology1996;243(1):34‐43. ">Ellie 1996</a>; <a href="./references#CD002827-bbs2-0043" title="ErnerudhJ , BrodtkorbE , OlssonT , VedelerCA , NylandH , BerlinG . Peripheral neuropathy and monoclonal IgM with antibody activity against peripheral nerve myelin; effect of plasma exchange. Journal of Neuroimmunology1986;11(3):171‐8. ">Ernerudh 1986</a>; <a href="./references#CD002827-bbs2-0044" title="ErnerudhJH , VrethemM , AndersenO , LindbergC , BerlinG . Immunochemical and clinical effects of immunosuppressive treatment in monoclonal IgM neuropathy. Journal of Neurology, Neurosurgery and Psychiatry1992;55(10):930‐4. ">Ernerudh 1992</a>; <a href="./references#CD002827-bbs2-0046" title="FrayneD , StarkeRJ . Peripheral neuropathy with gammopathy responding to plasmapheresis. Clinical and Experimental Neurology1985;21:195‐200. ">Frayne 1985</a>; <a href="./references#CD002827-bbs2-0050" title="GorsonKC , AllamG , RopperAH . Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy. Neurology1997;48(2):321‐8. ">Gorson 1997</a>; <a href="./references#CD002827-bbs2-0051" title="GorsonKC , RopperAH , WeinbergDH , WeinsteinR . Treatment experience in patients with anti‐myelin‐associated glycoprotein neuropathy. Muscle &amp; Nerve2001;24(6):778‐86. ">Gorson 2001</a>; <a href="./references#CD002827-bbs2-0053" title="HaasDC , TatumAH . Plasmapheresis alleviates neuropathy accompanying IgM anti‐myelin‐associated glycoprotein paraproteinemia. Annals of Neurology1988;23(4):394‐6. ">Haas 1988</a>; <a href="./references#CD002827-bbs2-0054" title="HaflerDA , JohnsonD , KellyJJ , PanitchR , KyleR , WeinerHL . Monoclonal gammopathy and neuropathy; myelin associated glycoprotein reactivity and clinical characteristics. Neurology1986;36(1):75‐8. ">Hafler 1986</a>; <a href="./references#CD002827-bbs2-0065" title="LatovN , HaysAP , ShermanWH . Peripheral neuropathy and anti‐MAG antibodies. Critical Reviews in Neurobiology1988;3(4):301‐32. ">Latov 1988</a>; <a href="./references#CD002827-bbs2-0076" title="Nobile‐OrazioE , MeucciN , BaldiniL , DiTroiaA , ScarlatoG . Long‐term prognosis of neuropathy associated with anti‐MAG IgM M‐proteins and its relationship to immune therapies. Brain2000;123(Pt 4):710‐7. ">Nobile‐Orazio 2000</a>; <a href="./references#CD002827-bbs2-0089" title="SmithT , ShermanW , OlarteMR , LovelaceRE . Peripheral neuropathy associated with plasma cell dyscrasia: a clinical and electrophysiological follow‐up study. Acta Neurologica Scandanavica1987;75(4):244‐8. ">Smith 1987</a>) (see <a href="#CD002827-tbl-0004">Table 3</a>). When described, the improvement was sustained at between eight and 36 months. <a href="./references#CD002827-bbs2-0087" title="SicilianoG , MoriconiL , GianniG , RichieriE , VignocchiMG , RossiB . Selective techniques of apheresis in polyneuropathy associated with monoclonal gammopathy of undetermined significance. Acta Neurologica Scandanavica1994;89(2):117‐22. ">Siciliano 1994</a> reported benefit in one person with an IgM paraprotein treated with selective apheresis, and <a href="./references#CD002827-bbs2-0074" title='NiemierkoE , WeinsteinR . Response of patients with IgM and IgA‐associated peripheral polyneuropathies to "off‐line" immunoadsorption treatment using the Prosorba Protein A column. Journal of Clinical Apheresis1999;14(4):159‐62. '>Niemierko 1999</a> reported another. Improvement with plasma exchange in combination with either pulsed intravenous cyclophosphamide, chlorambucil, protein A immunoadsorption, melphalan or adriamycin, with or without steroid, has been reported in 25% to 100% of participants, all in small studies (one to eight participants per treatment group) with follow‐up periods ranging from two to 34 months (<a href="./references#CD002827-bbs2-0031" title="BlandJH , GennariFJ , ErschlerWB , LatovN . IgMk monoclonal antibody directed against peripheral nerve myelin; clinical peripheral neuropathy and long‐term rheumatic disease. Journal of Rheumatology1985;12(6):1200. ">Bland 1985</a>; <a href="./references#CD002827-bbs2-0032" title="BlumeG , PestronkA , GoodnoughLT . Anti‐MAG antibody‐associated polyneuropathies: improvement following immunotherapy with monthly plasma exchange and IV cyclophosphamide. Neurology1995;45(8):1577‐80. ">Blume 1995</a>; <a href="./references#CD002827-bbs2-0039" title="DubasF ,  Pouplard‐BarthelaixA ,  DelestreF ,  EmileJ . Polyneuropathies with IgM monoclonal gammopathy. 12 cases. Revue Neurologique1987;143(10):670‐83. ">Dubas 1987</a>; <a href="./references#CD002827-bbs2-0051" title="GorsonKC , RopperAH , WeinbergDH , WeinsteinR . Treatment experience in patients with anti‐myelin‐associated glycoprotein neuropathy. Muscle &amp; Nerve2001;24(6):778‐86. ">Gorson 2001</a>; <a href="./references#CD002827-bbs2-0062" title="KellyJJ , AdelmanLS , BerkmanE , BhanI . Polyneuropathies associated with IgM monoclonal gammopathies. Archives of Neurology1988;45(12):1355‐9. ">Kelly 1988</a>; <a href="./references#CD002827-bbs2-0064" title="LatovN , ShermanWH , NemniR , GalassiG , ShyongJS , PennAS , et al. Plasma cell dyscrasia and peripheral neuropathy with a monoclonal antibody to peripheral nerve myelin. New England Journal of Medicine1980;303(11):618‐21. ">Latov 1980</a>; <a href="./references#CD002827-bbs2-0065" title="LatovN , HaysAP , ShermanWH . Peripheral neuropathy and anti‐MAG antibodies. Critical Reviews in Neurobiology1988;3(4):301‐32. ">Latov 1988</a>; <a href="./references#CD002827-bbs2-0068" title="MeierC , RobertsK , SteckA , HessC , MiloniE , TschoppL . Polyneuropathy in Waldenstrom's macroglobulinaemia: reduction of endoneurial IgM‐deposits after treatment with chlorambucil and plasmapheresis. Acta Neuropathologica1984;64(4):297‐307. ">Meier 1984</a>; <a href="./references#CD002827-bbs2-0076" title="Nobile‐OrazioE , MeucciN , BaldiniL , DiTroiaA , ScarlatoG . Long‐term prognosis of neuropathy associated with anti‐MAG IgM M‐proteins and its relationship to immune therapies. Brain2000;123(Pt 4):710‐7. ">Nobile‐Orazio 2000</a>; <a href="./references#CD002827-bbs2-0008" title="OksenhendlerE , ChevretS , LegerJM , LouboutinJP , BusselA , BrouetJC . Plasma exchange and chlorambucil in polyneuropathy associated with monoclonal IgM gammopathy. IgM‐associated Polyneuropathy Study Group. Journal of Neurology, Neurosurgery and Psychiatry1995;59(3):243‐7. [PUBMED: 7673949] ">Oksenhendler 1995</a>; <a href="./references#CD002827-bbs2-0083" title="RudnickiSA , HarikSI , DhodapkarM , BarlogieB , EidelbergD . Nervous system dysfunction in Waldenstrom's macroglobulinemia: response to treatment. Neurology1998;51(4):1210‐3. ">Rudnicki 1998</a>; <a href="./references#CD002827-bbs2-0085" title="ShermanWH , OlarteMR , McKiernanG , SweeneyK , LatovN , HaysAP . Plasma exchange treatment of peripheral neuropathy associated with plasma cell dyscrasia. Journal of Neurology, Neurosurgery and Psychiatry1984;47(8):813‐9. ">Sherman 1984</a>; <a href="./references#CD002827-bbs2-0089" title="SmithT , ShermanW , OlarteMR , LovelaceRE . Peripheral neuropathy associated with plasma cell dyscrasia: a clinical and electrophysiological follow‐up study. Acta Neurologica Scandanavica1987;75(4):244‐8. ">Smith 1987</a>; <a href="./references#CD002827-bbs2-0091" title="StefanssonK , MartonL , AntelJP , WollmannRL , RoosRP , ChejfecG , et al. Neuropathy accompanying IgM lambda monoclonal gammopathy. Acta Neuropathologica1983;59(4):255‐61. ">Stefansson 1983</a>; <a href="./references#CD002827-bbs2-0092" title="TagawaY , YukiN , OhnishiA , HirataK , HosokawaS . Parameters for monitoring treatment effects in CIDP with anti‐MAG/SGPG IgM antibody. Muscle &amp; Nerve2001;24(5):701‐4. ">Tagawa 2001</a>). </p> </section> <section id="CD002827-sec-0069"> <h4 class="title">Corticosteroids</h4> <p>Less information is available regarding response to steroid therapy. Four of five people treated with pulsed high‐dose intravenous dexamethasone improved, but the incidence of psychiatric side effects (three of six, one with IgG MGUS) was unacceptably high (<a href="./references#CD002827-bbs2-0079" title="NotermansNC , VermeulenM , LokhorstHM , VanDoornPA , Van denBergLH , TeunissenLL , et al. Pulsed high‐dose dexamethasone treatment of polyneuropathy associated with monoclonal gammopathy. Journal of Neurology1997;244(7):462‐3. ">Notermans 1997</a>). Oral prednisolone alone objectively improved only three of 30 people treated with monotherapy (<a href="./references#CD002827-bbs2-0035" title="CookD , DalakasMC , GaldiA , BiondiD , PorterH . High‐dose intravenous immunoglobulin in the treatment of demyelinating neuropathy associated with monoclonal gammopathy [see comments]. Neurology1990;40:212‐4. [MEDLINE: 90137262] ">Cook 1990</a>; <a href="./references#CD002827-bbs2-0036" title="DalakasMC , EngelWK . Polyneuropathy with monoclonal gammopathy: studies of 11 patients. Annals of Neurology1981;10(1):45‐52. [MEDLINE: 81280471] ">Dalakas 1981</a>; <a href="./references#CD002827-bbs2-0038" title="DonofrioPD , KellyJJJr . AAEE case report #17: Peripheral neuropathy in monoclonal gammopathy of undetermined significance. Muscle &amp; Nerve1989;12(1):1‐8. ">Donofrio 1989</a>; <a href="./references#CD002827-bbs2-0044" title="ErnerudhJH , VrethemM , AndersenO , LindbergC , BerlinG . Immunochemical and clinical effects of immunosuppressive treatment in monoclonal IgM neuropathy. Journal of Neurology, Neurosurgery and Psychiatry1992;55(10):930‐4. ">Ernerudh 1992</a>; <a href="./references#CD002827-bbs2-0050" title="GorsonKC , AllamG , RopperAH . Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy. Neurology1997;48(2):321‐8. ">Gorson 1997</a>; <a href="./references#CD002827-bbs2-0051" title="GorsonKC , RopperAH , WeinbergDH , WeinsteinR . Treatment experience in patients with anti‐myelin‐associated glycoprotein neuropathy. Muscle &amp; Nerve2001;24(6):778‐86. ">Gorson 2001</a>; <a href="./references#CD002827-bbs2-0054" title="HaflerDA , JohnsonD , KellyJJ , PanitchR , KyleR , WeinerHL . Monoclonal gammopathy and neuropathy; myelin associated glycoprotein reactivity and clinical characteristics. Neurology1986;36(1):75‐8. ">Hafler 1986</a>; <a href="./references#CD002827-bbs2-0065" title="LatovN , HaysAP , ShermanWH . Peripheral neuropathy and anti‐MAG antibodies. Critical Reviews in Neurobiology1988;3(4):301‐32. ">Latov 1988</a>; <a href="./references#CD002827-bbs2-0069" title="MelmedC , FrailD , DuncanI , BraunP , DanoffD , FinlaysonM , et al. Peripheral neuropathy with IgM kappa monoclonal immunoglobulin directed against myelin‐associated glycoprotein. Neurology1983;33(11):1397‐405. [MEDLINE: 84040255] ">Melmed 1983</a>; <a href="./references#CD002827-bbs2-0076" title="Nobile‐OrazioE , MeucciN , BaldiniL , DiTroiaA , ScarlatoG . Long‐term prognosis of neuropathy associated with anti‐MAG IgM M‐proteins and its relationship to immune therapies. Brain2000;123(Pt 4):710‐7. ">Nobile‐Orazio 2000</a>). Corticoteroids have been used in combination with azathioprine, cyclophosphamide, chlorambucil, and plasma exchange in several small studies, with improvement or stabilisation in 0% to 100% of participants at 14 to 54 months follow‐up (<a href="./references#CD002827-bbs2-0036" title="DalakasMC , EngelWK . Polyneuropathy with monoclonal gammopathy: studies of 11 patients. Annals of Neurology1981;10(1):45‐52. [MEDLINE: 81280471] ">Dalakas 1981</a>; <a href="./references#CD002827-bbs2-0038" title="DonofrioPD , KellyJJJr . AAEE case report #17: Peripheral neuropathy in monoclonal gammopathy of undetermined significance. Muscle &amp; Nerve1989;12(1):1‐8. ">Donofrio 1989</a>; <a href="./references#CD002827-bbs2-0042" title="EllieE , VitalA , SteckA , BoironJ‐M , VitalC , JulienJ . Neuropathy associated with 'benign' anti‐myelin‐associated glycoprotein IgM gammopathy: clinical, immunological, neurophysiological and pathological findings and response to treatment in 33 cases. Journal of Neurology1996;243(1):34‐43. ">Ellie 1996</a>; <a href="./references#CD002827-bbs2-0044" title="ErnerudhJH , VrethemM , AndersenO , LindbergC , BerlinG . Immunochemical and clinical effects of immunosuppressive treatment in monoclonal IgM neuropathy. Journal of Neurology, Neurosurgery and Psychiatry1992;55(10):930‐4. ">Ernerudh 1992</a>; <a href="./references#CD002827-bbs2-0062" title="KellyJJ , AdelmanLS , BerkmanE , BhanI . Polyneuropathies associated with IgM monoclonal gammopathies. Archives of Neurology1988;45(12):1355‐9. ">Kelly 1988</a>; <a href="./references#CD002827-bbs2-0065" title="LatovN , HaysAP , ShermanWH . Peripheral neuropathy and anti‐MAG antibodies. Critical Reviews in Neurobiology1988;3(4):301‐32. ">Latov 1988</a>; <a href="./references#CD002827-bbs2-0069" title="MelmedC , FrailD , DuncanI , BraunP , DanoffD , FinlaysonM , et al. Peripheral neuropathy with IgM kappa monoclonal immunoglobulin directed against myelin‐associated glycoprotein. Neurology1983;33(11):1397‐405. [MEDLINE: 84040255] ">Melmed 1983</a>; <a href="./references#CD002827-bbs2-0007" title="NiermeijerJMF ,  EurelingsM ,  Van der LindenMW ,   Lokhorst HM ,   Franssen H ,   Fischer K , et al. Intermittent cyclophosphamide with prednisone versus placebo for polyneuropathy with IgM monoclonal gammopathy. Neurology2007;69(1):50‐9. [PUBMED: 17606880] ">Niermeijer 2007</a>; <a href="./references#CD002827-bbs2-0075" title="Nobile‐OrazioE , BaldiniL , BarbieriS , MarmiroliP , SpagnolG , FrancomanoE , et al. Treatment of patients with neuropathy and anti‐MAG IgM M‐proteins. Annals of Neurology1988;24(1):93‐7. ">Nobile‐Orazio 1988</a>; <a href="./references#CD002827-bbs2-0076" title="Nobile‐OrazioE , MeucciN , BaldiniL , DiTroiaA , ScarlatoG . Long‐term prognosis of neuropathy associated with anti‐MAG IgM M‐proteins and its relationship to immune therapies. Brain2000;123(Pt 4):710‐7. ">Nobile‐Orazio 2000</a>; <a href="./references#CD002827-bbs2-0078" title="NotermansNC , LokhorstHM , FranssenH , Van derGraafY , TeunissenLL , JennekensFG , et al. Intermittent cyclophosphamide and prednisone treatment of polyneuropathy associated with monoclonal gammopathy of undetermined significance. Neurology1996;47(5):1227‐33. ">Notermans 1996</a>; <a href="./references#CD002827-bbs2-0091" title="StefanssonK , MartonL , AntelJP , WollmannRL , RoosRP , ChejfecG , et al. Neuropathy accompanying IgM lambda monoclonal gammopathy. Acta Neuropathologica1983;59(4):255‐61. ">Stefansson 1983</a>). </p> </section> <section id="CD002827-sec-0070"> <h4 class="title">Intravenous immunoglobulin</h4> <p>We have described the two RCTs of intravenous immunoglobulin (IVIg) versus placebo above (<a href="./references#CD002827-bbs2-0001" title="ComiG , RoveriL , SwanA , WillisonH , BojarM , IllaI , et al. Inflammatory Neuropathy Cause And Treatment (INCAT) Group. A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy. Journal of Neurology2002;249(10):1370‐7. [PUBMED: 12382151] ">Comi 2002</a>: <a href="./references#CD002827-bbs2-0002" title="DalakasMC , QuarlesRH , FarrerRG , DambrosiaJ , SoueidanS , SteinDP , et al. A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy. Annals of Neurology1996;40(5):792‐5. [PUBMED: 8957021] ">Dalakas 1996</a>), which provide low‐quality evidence for very short‐term improvement. Six other uncontrolled studies reported transient improvement, in 22 of 50 participants, with IVIg (<a href="./references#CD002827-bbs2-0035" title="CookD , DalakasMC , GaldiA , BiondiD , PorterH . High‐dose intravenous immunoglobulin in the treatment of demyelinating neuropathy associated with monoclonal gammopathy [see comments]. Neurology1990;40:212‐4. [MEDLINE: 90137262] ">Cook 1990</a>; <a href="./references#CD002827-bbs2-0042" title="EllieE , VitalA , SteckA , BoironJ‐M , VitalC , JulienJ . Neuropathy associated with 'benign' anti‐myelin‐associated glycoprotein IgM gammopathy: clinical, immunological, neurophysiological and pathological findings and response to treatment in 33 cases. Journal of Neurology1996;243(1):34‐43. ">Ellie 1996</a>; <a href="./references#CD002827-bbs2-0050" title="GorsonKC , AllamG , RopperAH . Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy. Neurology1997;48(2):321‐8. ">Gorson 1997</a>; <a href="./references#CD002827-bbs2-0051" title="GorsonKC , RopperAH , WeinbergDH , WeinsteinR . Treatment experience in patients with anti‐myelin‐associated glycoprotein neuropathy. Muscle &amp; Nerve2001;24(6):778‐86. ">Gorson 2001</a>; <a href="./references#CD002827-bbs2-0057" title="Hoang‐XuanK , LegerJM , Ben Younes‐ChennoufiA , SaidiH , BoucheP , BaumannN , et al. Treatment of immune deficient neuropathies with intravenous polyvalent immunoglobulins. An open study of 16 cases. Revue Neurologique1993;149(6‐7):385‐92. ">Hoang‐Xuan 1993</a>; <a href="./references#CD002827-bbs2-0067" title="LégerJM , Younes‐ChennoufiAB , ChassandeB , DavilaG , BoucheP , BaumannN , et al. Human immunoglobulin treatment of multifocal motor neuropathy and polyneuropathy associated with monoclonal gammopathy. Journal of Neurology, Neurosurgery and Psychiatry1994;57(Suppl):46‐9. ">Léger 1994</a>), whereas another did not report improvement (<a href="./references#CD002827-bbs2-0076" title="Nobile‐OrazioE , MeucciN , BaldiniL , DiTroiaA , ScarlatoG . Long‐term prognosis of neuropathy associated with anti‐MAG IgM M‐proteins and its relationship to immune therapies. Brain2000;123(Pt 4):710‐7. ">Nobile‐Orazio 2000</a>). </p> </section> <section id="CD002827-sec-0071"> <h4 class="title">Interferon alfa‐2a</h4> <p>A well‐performed randomised, double‐blind, placebo‐controlled study of 24 people (<a href="./references#CD002827-bbs2-0006" title="MarietteX , BrouetJC , ChevretS , LegerJM , ClavelouP , PougetJ , et al. A randomized double blind trial versus placebo does not confirm the benefit of alpha‐interferon in polyneuropathy associated with monoclonal IgM. Journal of Neurology, Neurosurgery and Psychiatry2000;69(2):279‐80. [PUBMED: 10960293] ">Mariette 2000</a>) confirmed the efficacy of interferon alfa‐2a as suggested by an earlier open study (see above). One of eight people treated with interferon alfa‐2a in a study by Gorson et al improved (<a href="./references#CD002827-bbs2-0051" title="GorsonKC , RopperAH , WeinbergDH , WeinsteinR . Treatment experience in patients with anti‐myelin‐associated glycoprotein neuropathy. Muscle &amp; Nerve2001;24(6):778‐86. ">Gorson 2001</a>). This participant remained stable (mild bilateral foot drop and pinprick and vibration loss in the feet, mRS 1) off all therapy for three years. Furthermore, the IgM paraprotein and anti‐MAG titre became unrecordable. A group of seven people treated with interferon alfa‐2a, and assessed with a novel measure of postural stability, improved (<a href="./references#CD002827-bbs2-0080" title="PougetJ , AzulayJPH , MesureS , AttarianS . Improvement of sensory ataxia in anti‐MAG antibody associated polyneuropathy with interferon alpha: A posturographic study. Neurology2000;54 Suppl 3:A47. ">Pouget 2000</a>). </p> </section> <section id="CD002827-sec-0072"> <h4 class="title">Cytotoxic therapies</h4> <p>Chemotherapeutic (or cytotoxic) therapies have been used singly or in combination with other drugs, but none (except <a href="./references#CD002827-bbs2-0007" title="NiermeijerJMF ,  EurelingsM ,  Van der LindenMW ,   Lokhorst HM ,   Franssen H ,   Fischer K , et al. Intermittent cyclophosphamide with prednisone versus placebo for polyneuropathy with IgM monoclonal gammopathy. Neurology2007;69(1):50‐9. [PUBMED: 17606880] ">Niermeijer 2007</a> using cyclophosphamide and corticosteroids, as above) in a controlled trial. These agents include cyclophosphamide (<a href="./references#CD002827-bbs2-0032" title="BlumeG , PestronkA , GoodnoughLT . Anti‐MAG antibody‐associated polyneuropathies: improvement following immunotherapy with monthly plasma exchange and IV cyclophosphamide. Neurology1995;45(8):1577‐80. ">Blume 1995</a>; <a href="./references#CD002827-bbs2-0050" title="GorsonKC , AllamG , RopperAH . Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy. Neurology1997;48(2):321‐8. ">Gorson 1997</a>; <a href="./references#CD002827-bbs2-0051" title="GorsonKC , RopperAH , WeinbergDH , WeinsteinR . Treatment experience in patients with anti‐myelin‐associated glycoprotein neuropathy. Muscle &amp; Nerve2001;24(6):778‐86. ">Gorson 2001</a>; <a href="./references#CD002827-bbs2-0054" title="HaflerDA , JohnsonD , KellyJJ , PanitchR , KyleR , WeinerHL . Monoclonal gammopathy and neuropathy; myelin associated glycoprotein reactivity and clinical characteristics. Neurology1986;36(1):75‐8. ">Hafler 1986</a>; <a href="./references#CD002827-bbs2-0018" title="HamidouMA ,  BeliznaC ,  WiertlewskyS , AudrainM ,  BironC ,  GrolleauJ , et al. Intravenous cyclophosphamide in refractory polyneuropathy associated with IgM monoclonal gammopathy: an uncontrolled open trial. American Journal of Medicine2005;118(4):426‐30. ">Hamidou 2005</a>; <a href="./references#CD002827-bbs2-0062" title="KellyJJ , AdelmanLS , BerkmanE , BhanI . Polyneuropathies associated with IgM monoclonal gammopathies. Archives of Neurology1988;45(12):1355‐9. ">Kelly 1988</a>; <a href="./references#CD002827-bbs2-0007" title="NiermeijerJMF ,  EurelingsM ,  Van der LindenMW ,   Lokhorst HM ,   Franssen H ,   Fischer K , et al. Intermittent cyclophosphamide with prednisone versus placebo for polyneuropathy with IgM monoclonal gammopathy. Neurology2007;69(1):50‐9. [PUBMED: 17606880] ">Niermeijer 2007</a>; <a href="./references#CD002827-bbs2-0076" title="Nobile‐OrazioE , MeucciN , BaldiniL , DiTroiaA , ScarlatoG . Long‐term prognosis of neuropathy associated with anti‐MAG IgM M‐proteins and its relationship to immune therapies. Brain2000;123(Pt 4):710‐7. ">Nobile‐Orazio 2000</a>; <a href="./references#CD002827-bbs2-0092" title="TagawaY , YukiN , OhnishiA , HirataK , HosokawaS . Parameters for monitoring treatment effects in CIDP with anti‐MAG/SGPG IgM antibody. Muscle &amp; Nerve2001;24(5):701‐4. ">Tagawa 2001</a>), fludarabine (29 participants, 11 anti‐MAG and nine of these with clinical improvement) (<a href="./references#CD002827-bbs2-0021" title="NiermeijerJMF ,  EurelingsM ,  LokhorstH ,  FranssenH ,  FijnheerR ,  WokkeJHJ , et al. Neurologic and hematologic response to fludarabine treatment in IgM MGUS polyneuropathy. Neurology2006;67(11):2076‐9. ">Niermeijer 2006</a>; <a href="./references#CD002827-bbs2-0083" title="RudnickiSA , HarikSI , DhodapkarM , BarlogieB , EidelbergD . Nervous system dysfunction in Waldenstrom's macroglobulinemia: response to treatment. Neurology1998;51(4):1210‐3. ">Rudnicki 1998</a>; <a href="./references#CD002827-bbs2-0086" title="ShermanWH , LatovN , LangeDE , HaysRD , YoungerDS . Fludarabine for IgM antibody‐mediated neuropathies. Annals of Neurology1994;36:326‐7. [ISSN 0364‐5134] ">Sherman 1994</a>; <a href="./references#CD002827-bbs2-0098" title="WilsonHC , LunnMPT , ScheyS , HughesRAC . Successful treatment of IgM paraproteinaemic neuropathy with fludarabine. Journal of Neurology, Neurosurgery and Psychiatry1999;66(5):575‐80. ">Wilson 1999</a>), fludarabine and rituximab (<a href="./references#CD002827-bbs2-0052" title="GrusonB , GhomariK , BeaumontM , GaridiR , JustA , MerleP , et al. Long‐term response to rituximab and fludarabine combination in IgM anti‐myelin‐associated glycoprotein neuropathy. Journal of the Peripheral Nervous System2011;16(3):180‐5. ">Gruson 2011</a>, see below), cladribine (one participant) (<a href="./references#CD002827-bbs2-0047" title="GhoshA , LittlewoodT , DonaghyM . Cladribine in the treatment of IgM paraproteinaemic polyneuropathy. Neurology2002;59(8):1290‐1. ">Ghosh 2002</a>), azathioprine (<a href="./references#CD002827-bbs2-0051" title="GorsonKC , RopperAH , WeinbergDH , WeinsteinR . Treatment experience in patients with anti‐myelin‐associated glycoprotein neuropathy. Muscle &amp; Nerve2001;24(6):778‐86. ">Gorson 2001</a>), mycophenolate (<a href="./references#CD002827-bbs2-0016" title="GorsonKC ,  AmatoAA ,  RopperAH . Efficacy of mycophenolate mofetil in patients with chronic immune demyelinating polyneuropathy. Neurology2004;63(4):715‐7. ">Gorson 2004</a>), chlorambucil alone (<a href="./references#CD002827-bbs2-0029" title="AndresE , VinzioS , MaloiselF , CarreS , PerrinAE , GoichotB , et al. Autoimmune peripheral neuropathies with anti‐MAG antibodies and hematological disorders. Five cases [Neuropathies péripheriques auto‐immunes a anticorps anti‐MAG et hémopathies. À propos de 5 observations]. Annales de Médecine Interne2001;152(3):147‐51. ">Andres 2001</a>; <a href="./references#CD002827-bbs2-0051" title="GorsonKC , RopperAH , WeinbergDH , WeinsteinR . Treatment experience in patients with anti‐myelin‐associated glycoprotein neuropathy. Muscle &amp; Nerve2001;24(6):778‐86. ">Gorson 2001</a>; <a href="./references#CD002827-bbs2-0065" title="LatovN , HaysAP , ShermanWH . Peripheral neuropathy and anti‐MAG antibodies. Critical Reviews in Neurobiology1988;3(4):301‐32. ">Latov 1988</a>; <a href="./references#CD002827-bbs2-0076" title="Nobile‐OrazioE , MeucciN , BaldiniL , DiTroiaA , ScarlatoG . Long‐term prognosis of neuropathy associated with anti‐MAG IgM M‐proteins and its relationship to immune therapies. Brain2000;123(Pt 4):710‐7. ">Nobile‐Orazio 2000</a>), and melphalan and chlorambucil (<a href="./references#CD002827-bbs2-0044" title="ErnerudhJH , VrethemM , AndersenO , LindbergC , BerlinG . Immunochemical and clinical effects of immunosuppressive treatment in monoclonal IgM neuropathy. Journal of Neurology, Neurosurgery and Psychiatry1992;55(10):930‐4. ">Ernerudh 1992</a>). Responses to treatment were variable. More extensive chemotherapy has been used in non‐MGUS associated anti‐MAG neuropathies, which are outside the scope of this review (<a href="./references#CD002827-bbs2-0029" title="AndresE , VinzioS , MaloiselF , CarreS , PerrinAE , GoichotB , et al. Autoimmune peripheral neuropathies with anti‐MAG antibodies and hematological disorders. Five cases [Neuropathies péripheriques auto‐immunes a anticorps anti‐MAG et hémopathies. À propos de 5 observations]. Annales de Médecine Interne2001;152(3):147‐51. ">Andres 2001</a>). </p> </section> <section id="CD002827-sec-0073"> <h4 class="title">Rituximab</h4> <p>Rituximab has been used in multiple cases in non‐randomised cohorts and cases series (<a href="./references#CD002827-bbs2-0009" title="BarohnRJ , RashidI , McVeyAL , HerbelinL , SkikneB , SapersteinDS . Rituximab for the treatment of IgM associated polyneuropathies. Journal of the Peripheral Nervous System2005;10 Suppl 1:4. ">Barohn 2005</a>; <a href="./references#CD002827-bbs2-0010" title="BenedettiL , GobbiM , GhiglioneE , VigoT , CarpoM , CocitoD , et al. Rituximab in anti‐MAG polyneuropathy. Journal of the Peripheral Nervous System2005;10(Suppl 1):5. ">Benedetti 2005</a>; <a href="./references#CD002827-bbs2-0011" title="BenedettiB , BrianiC , GrnadisM , VigoT , GobbiM , GhiglioneE , et al. Predictors of response to rituximab in patients with neuropathy and anti‐myelin associated glycoprotein immunoglobulin M. Journal of the Peripheral Nervous System2007;12(2):102‐7. ">Benedetti 2007</a>; <a href="./references#CD002827-bbs2-0012" title="BenedettiL , BrianiC , FranciottaD , CarpoM , PaduaL , ZaraG , et al. Long‐term effect of rituximab in anti‐MAG polyneuropathy. Neurology2008;71(21):1742‐4. ">Benedetti 2008</a>; <a href="./references#CD002827-bbs2-0013" title="CanavanJB , MoroneyJT , KeoganMT , HardimanO . Rituximab and IgM autoantibody‐associated peripheral neuropathy: The Irish experience. Neurology2002;Suppl 3:A233. ">Canavan 2002</a>; <a href="./references#CD002827-bbs2-0037" title="DelmontE , JeandelPY , HubertAM , MarcqL , BoucrautJ , DesnuelleC . Successful treatment with rituximab of one patient with CANOMAD neuropathy. Journal of Neurology2010;257(4):655‐7. ">Delmont 2010</a>; <a href="./references#CD002827-bbs2-0015" title="GoldfarbAR , WeimerLH , BranniganTH3rd . Rituximab treatment of an IgM monoclonal autonomic and sensory neuropathy. Muscle &amp; Nerve2005;31(4):510‐5. ">Goldfarb 2005</a>; <a href="./references#CD002827-bbs2-0049" title="GonoT , MatsudaM , ShimojimaY , IshiiW , YamamotoK , MoritaH , et al. Rituximab therapy in chronic inflammatory demyelinating polyradiculoneuropathy with anti‐SGPG IgM antibody. Journal of Clinical Neuroscience2006;13(6):683‐7. ">Gono 2006</a>; <a href="./references#CD002827-bbs2-0017" title="GorsonKC ,   Natarajan N ,   Ropper AH ,   Weinstein R . Rituximab treatment in patients with IVIg‐dependent immune polyneuropathy: a prospective pilot trial. Muscle &amp; Nerve2007;35(1):66‐9. ">Gorson 2007</a>; <a href="./references#CD002827-bbs2-0063" title="KellyJJ . Chronic peripheral neuropathy responsive to rituximab. Reviews in Neurological Diseases2006;3(2):78‐81. ">Kelly 2006</a>; <a href="./references#CD002827-bbs2-0019" title="KilidireasC ,  AnagnostopoulosA ,  KarandreasN ,  MouselimiL ,  DimopoulosMA . Rituximab therapy in monoclonal IgM‐related neuropathies. Leukemia &amp; Lymphoma2006;47(5):859‐64. ">Kilidireas 2006</a>; <a href="./references#CD002827-bbs2-0020" title="LatovN , ShermanWH . Therapy of neuropathy associated with anti‐MAG IgM monoclonal gammopathy with Rituxan (abstract). Neurology1999;52 Suppl 2:A551. ">Latov 1999</a>; <a href="./references#CD002827-bbs2-0066" title="LevineTD , PestronkA . IgM antibody‐related polyneuropathies: B‐cell depletion chemotherapy using rituximab. Neurology1999;52(8):1701‐4. ">Levine 1999</a>; <a href="./references#CD002827-bbs2-0022" title="NiermeijerJM , EurelingsM , LokhorstHL , Van derPolWL , FranssenH , WokkeJH , et al. Rituximab for polyneuropathy with IgM monoclonal gammopathy. Journal of Neurology, Neurosurgery and Psychiatry2009;80(9):1036‐9. ">Niermeijer 2009</a>; <a href="./references#CD002827-bbs2-0023" title="PestronkA , FlorenceJ , MillerT , ChoksiR , Al‐LoziMT , LevineTD . Treatment of IgM antibody associated polyneuropathies using rituximab. Journal of Neurology, Neurosurgery and Psychiatry2003;74(4):485‐9. ">Pestronk 2003</a>; <a href="./references#CD002827-bbs2-0024" title="RenaudS , GregorM , FuhrP , LorenzD , DeuschlG , GratwohlA , et al. Rituximab in the treatment of polyneuropathy associated with anti‐MAG antibodies. Muscle &amp; Nerve2003;27(5):611‐5. ">Renaud 2003</a>; <a href="./references#CD002827-bbs2-0025" title="RenaudS , FuhrP , GregorM , SchweikertK , LorenzD , DanielsC , et al. High‐dose rituximab and anti‐MAG‐associated polyneuropathy. Neurology2006;66(5):742‐4. ">Renaud 2006</a>; <a href="./references#CD002827-bbs2-0027" title="SmithBE , SuarezGA , WitzigTE , StevensJC , BoschEP , RossMA , et al. A phase II trial of rituximab for peripheral neuropathy associated with monoclonal gammopathy of undetermined significance (MGUS). Journal of the Peripheral Nervous System2011;16(Suppl s3):130. ">Smith 2011</a>; <a href="./references#CD002827-bbs2-0095" title="WeideR , HeymannsJ , KopplerH . The polyneuropathy associated with Waldenström's macroglobulinaemia can be treated effectively with chemotherapy and the anti‐CD20 monoclonal antibody rituximab. British Journal of Haematology2000;109(4):838‐41. ">Weide 2000</a>). About 50% to 60% of participants seem to respond in these uncontrolled studies, but two studies failed to show any benefit in five participants (<a href="./references#CD002827-bbs2-0009" title="BarohnRJ , RashidI , McVeyAL , HerbelinL , SkikneB , SapersteinDS . Rituximab for the treatment of IgM associated polyneuropathies. Journal of the Peripheral Nervous System2005;10 Suppl 1:4. ">Barohn 2005</a>; <a href="./references#CD002827-bbs2-0082" title="Rojas‐GarcíaR , GallardoE , DeAndrésI , DeLunaN , JuarezC , SánchezP , et al. Chronic neuropathy with IgM antiganglioside antibodies: lack of long term response to rituximab. Neurology2003;61(12):1814–6. ">Rojas‐García 2003</a>), and three studies reported worsening (<a href="./references#CD002827-bbs2-0033" title="BroglioL , LauriaG . Worsening after rituximab treatment in anti‐MAG neuropathy. Muscle &amp; Nerve2005;32(3):378‐9. ">Broglio 2005</a>; <a href="./references#CD002827-bbs2-0048" title="GironiM , SaresellaM , CeresaL , CalvoM , FerranteP , MerliF , et al. Clinical and immunological worsening in a patient affected with Waldenstrom macroglobulinemia and anti‐mag neuropathy after treatment with rituximab. Haematologica2006;91(6 Suppl):ECR 17. ">Gironi 2006</a>; <a href="./references#CD002827-bbs2-0077" title="NoronhaV , FynanTM , DuffyT . Flare in neuropathy following rituximab therapy for Waldenstrom’s macroglobulinemia. Journal of Clinical Oncology2006;24(1):e3. ">Noronha 2006</a>). Three fully‐published studies included 42 participants with anti‐MAG neuropathy treated with rituximab and documented improvements in strength, neurophysiological indices, and functional score up to two years (<a href="./references#CD002827-bbs2-0003" title="DalakasMC , RakocevicG , SalajeghehM , DambrosiaJM , HahnAF , RajuR , et al. Placebo‐controlled trial of rituximab in IgM anti–myelin‐associated glycoprotein antibody demyelinating neuropathy. Annals of Neurology2009;65(3):286–93. [PUBMED: 19334068] ">Dalakas 2009</a>; <a href="./references#CD002827-bbs2-0023" title="PestronkA , FlorenceJ , MillerT , ChoksiR , Al‐LoziMT , LevineTD . Treatment of IgM antibody associated polyneuropathies using rituximab. Journal of Neurology, Neurosurgery and Psychiatry2003;74(4):485‐9. ">Pestronk 2003</a>; <a href="./references#CD002827-bbs2-0024" title="RenaudS , GregorM , FuhrP , LorenzD , DeuschlG , GratwohlA , et al. Rituximab in the treatment of polyneuropathy associated with anti‐MAG antibodies. Muscle &amp; Nerve2003;27(5):611‐5. ">Renaud 2003</a>). However, neither <a href="./references#CD002827-bbs2-0023" title="PestronkA , FlorenceJ , MillerT , ChoksiR , Al‐LoziMT , LevineTD . Treatment of IgM antibody associated polyneuropathies using rituximab. Journal of Neurology, Neurosurgery and Psychiatry2003;74(4):485‐9. ">Pestronk 2003</a> nor <a href="./references#CD002827-bbs2-0024" title="RenaudS , GregorM , FuhrP , LorenzD , DeuschlG , GratwohlA , et al. Rituximab in the treatment of polyneuropathy associated with anti‐MAG antibodies. Muscle &amp; Nerve2003;27(5):611‐5. ">Renaud 2003</a> were adequately controlled. <a href="./references#CD002827-bbs2-0024" title="RenaudS , GregorM , FuhrP , LorenzD , DeuschlG , GratwohlA , et al. Rituximab in the treatment of polyneuropathy associated with anti‐MAG antibodies. Muscle &amp; Nerve2003;27(5):611‐5. ">Renaud 2003</a> had no controls and <a href="./references#CD002827-bbs2-0023" title="PestronkA , FlorenceJ , MillerT , ChoksiR , Al‐LoziMT , LevineTD . Treatment of IgM antibody associated polyneuropathies using rituximab. Journal of Neurology, Neurosurgery and Psychiatry2003;74(4):485‐9. ">Pestronk 2003</a> had a semi‐historical non‐randomised control group without blinding of the assessment of outcome measures. We describe the first two RCTs of rituximab above (<a href="./references#CD002827-bbs2-0003" title="DalakasMC , RakocevicG , SalajeghehM , DambrosiaJM , HahnAF , RajuR , et al. Placebo‐controlled trial of rituximab in IgM anti–myelin‐associated glycoprotein antibody demyelinating neuropathy. Annals of Neurology2009;65(3):286–93. [PUBMED: 19334068] ">Dalakas 2009</a>; <a href="./references#CD002827-bbs2-0004" title="LégerJM , VialaK , NicolasG , CréangeA , VallatJM , PougetJ , et al. Placebo controlled trial of rituximab in IgM anti‐myelin‐associated glycoprotein neuropathy. Neurology2013;80(24):2217‐25. [PUBMED: 23667063] ">Léger 2013</a>) </p> <p>A recent study describes the use of rituximab in combination with fludarabine in five participants, four of whom improved clinically and electrophysiologically, with serum IgM and anti‐MAG titre responses too. Improvement was sustained and, in this small series, treatment was without significant toxicity (<a href="./references#CD002827-bbs2-0052" title="GrusonB , GhomariK , BeaumontM , GaridiR , JustA , MerleP , et al. Long‐term response to rituximab and fludarabine combination in IgM anti‐myelin‐associated glycoprotein neuropathy. Journal of the Peripheral Nervous System2011;16(3):180‐5. ">Gruson 2011</a>). </p> </section> <section id="CD002827-sec-0074"> <h4 class="title">Others</h4> <p>Some more novel therapies have been tried, including ciclosporin in two participants (<a href="./references#CD002827-bbs2-0058" title="HodgkinsonSJ , PollardJD , McLeodJG . Cyclosporin A in the treatment of chronic demyelinating polyradiculoneuropathy. Journal of Neurology, Neurosurgery and Psychiatry1990;53(4):327‐30. ">Hodgkinson 1990</a>), and a single participant underwent autologous stem cell transplantation (ASCT) (<a href="./references#CD002827-bbs2-0083" title="RudnickiSA , HarikSI , DhodapkarM , BarlogieB , EidelbergD . Nervous system dysfunction in Waldenstrom's macroglobulinemia: response to treatment. Neurology1998;51(4):1210‐3. ">Rudnicki 1998</a>). In this one person, the ASCT was followed after two years by improvements in symptoms, signs, and neurophysiological indices, although he had been treated with other agents including fludarabine prior to the transplant. Neither ciclosporin nor ASCT have been subjected to a RCT. </p> </section> <section id="CD002827-sec-0075"> <h4 class="title">Economic considerations</h4> <p>The treatments discussed are all expensive. In 2005, the approximate cost of IVIg was about GBP 3600 for the standard 2.0 g/kg dose in a 70 kg adult, and in 2012 about GBP 4500. Fludarabine and rituximab cost approximately GBP 5000 per course, and an autologous stem cell transplant costs approximately GBP 25,000 to 35,000. We cannot overstate the importance of subjecting such agents to early and adequate clinical trials. </p> </section> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD002827-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/urn:x-wiley:14651858:media:CD002827:CD002827-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/image_t/tCD002827-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="PRISMA chart for searched to included studies of IgM paraproteinaemic neuropathy" data-id="CD002827-fig-0001" src="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/image_n/nCD002827-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>PRISMA chart for searched to included studies of IgM paraproteinaemic neuropathy</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/full#CD002827-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/image_n/nCD002827-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002827-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/urn:x-wiley:14651858:media:CD002827:CD002827-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/image_t/tCD002827-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD002827-fig-0002" src="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/image_n/nCD002827-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/full#CD002827-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/image_n/nCD002827-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002827-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/urn:x-wiley:14651858:media:CD002827:CD002827-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/image_t/tCD002827-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 3 Rituximab versus placebo, outcome: 3.1 Number of participants improved on INCAT score (see text) at 8‐12 months." data-id="CD002827-fig-0003" src="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/image_n/nCD002827-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Forest plot of comparison: 3 Rituximab versus placebo, outcome: 3.1 Number of participants improved on INCAT score (see text) at 8‐12 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/full#CD002827-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/image_n/nCD002827-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002827-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/urn:x-wiley:14651858:media:CD002827:CD002827-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/image_t/tCD002827-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 IVIg versus interferon alfa‐2a, Outcome 1 Change in Clinical Neuropathy Disability Score (CNDS) at six months." data-id="CD002827-fig-0004" src="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/image_n/nCD002827-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 IVIg versus interferon alfa‐2a, Outcome 1 Change in Clinical Neuropathy Disability Score (CNDS) at six months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/references#CD002827-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/image_n/nCD002827-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002827-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/urn:x-wiley:14651858:media:CD002827:CD002827-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/image_t/tCD002827-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 IVIg versus interferon alfa‐2a, Outcome 2 Subjective score at six months." data-id="CD002827-fig-0005" src="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/image_n/nCD002827-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 IVIg versus interferon alfa‐2a, Outcome 2 Subjective score at six months.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/references#CD002827-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/image_n/nCD002827-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002827-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/urn:x-wiley:14651858:media:CD002827:CD002827-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/image_t/tCD002827-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 IVIg versus interferon alfa‐2a, Outcome 3 Number of participants improved by at least 20% on NIS at 6 months." data-id="CD002827-fig-0006" src="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/image_n/nCD002827-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 IVIg versus interferon alfa‐2a, Outcome 3 Number of participants improved by at least 20% on NIS at 6 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/references#CD002827-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/image_n/nCD002827-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002827-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/urn:x-wiley:14651858:media:CD002827:CD002827-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/image_t/tCD002827-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Interferon alfa‐2a versus placebo, Outcome 1 Change in the CNDS at 6 months (maximum 93)." data-id="CD002827-fig-0007" src="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/image_n/nCD002827-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Interferon alfa‐2a versus placebo, Outcome 1 Change in the CNDS at 6 months (maximum 93). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/references#CD002827-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/image_n/nCD002827-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002827-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/urn:x-wiley:14651858:media:CD002827:CD002827-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/image_t/tCD002827-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Interferon alfa‐2a versus placebo, Outcome 2 Number improved in CNDS by 20% at 6 months." data-id="CD002827-fig-0008" src="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/image_n/nCD002827-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Interferon alfa‐2a versus placebo, Outcome 2 Number improved in CNDS by 20% at 6 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/references#CD002827-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/image_n/nCD002827-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002827-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/urn:x-wiley:14651858:media:CD002827:CD002827-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/image_t/tCD002827-CMP-003-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Rituximab versus placebo, Outcome 1 Number of participants improved on INCAT score (see text) at 8‐12 months." data-id="CD002827-fig-0009" src="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/image_n/nCD002827-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Rituximab versus placebo, Outcome 1 Number of participants improved on INCAT score (see text) at 8‐12 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/references#CD002827-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/image_n/nCD002827-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002827-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/urn:x-wiley:14651858:media:CD002827:CD002827-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/image_t/tCD002827-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Rituximab versus placebo, Outcome 2 Mean improvement in INCAT score (see text) at 8 ‐ 12 months." data-id="CD002827-fig-0010" src="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/image_n/nCD002827-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Rituximab versus placebo, Outcome 2 Mean improvement in INCAT score (see text) at 8 ‐ 12 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/references#CD002827-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/image_n/nCD002827-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002827-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/urn:x-wiley:14651858:media:CD002827:CD002827-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/image_t/tCD002827-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Rituximab versus placebo, Outcome 3 Rituximab vs placebo. Mean improvement in INCAT score at 8 ‐ 9 months (post hoc data)." data-id="CD002827-fig-0011" src="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/image_n/nCD002827-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Rituximab versus placebo, Outcome 3 Rituximab vs placebo. Mean improvement in INCAT score at 8 ‐ 9 months (post hoc data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/references#CD002827-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/image_n/nCD002827-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002827-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/urn:x-wiley:14651858:media:CD002827:CD002827-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/image_t/tCD002827-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Rituximab versus placebo, Outcome 4 Mean improvement in NIS at 12 months." data-id="CD002827-fig-0012" src="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/image_n/nCD002827-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Rituximab versus placebo, Outcome 4 Mean improvement in NIS at 12 months.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/references#CD002827-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/image_n/nCD002827-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002827-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/urn:x-wiley:14651858:media:CD002827:CD002827-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/image_t/tCD002827-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Rituximab versus placebo, Outcome 5 Improvement in 10‐metre walk time at 8 ‐ 12 months." data-id="CD002827-fig-0013" src="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/image_n/nCD002827-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Rituximab versus placebo, Outcome 5 Improvement in 10‐metre walk time at 8 ‐ 12 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/references#CD002827-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/image_n/nCD002827-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002827-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/urn:x-wiley:14651858:media:CD002827:CD002827-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/image_t/tCD002827-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Rituximab versus placebo, Outcome 6 Number improved in 10‐metre walk at 6 months." data-id="CD002827-fig-0014" src="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/image_n/nCD002827-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 Rituximab versus placebo, Outcome 6 Number improved in 10‐metre walk at 6 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/references#CD002827-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/image_n/nCD002827-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002827-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/urn:x-wiley:14651858:media:CD002827:CD002827-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/image_t/tCD002827-CMP-003-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Rituximab versus placebo, Outcome 7 Change in IgM level 8 months after treatment." data-id="CD002827-fig-0015" src="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/image_n/nCD002827-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 Rituximab versus placebo, Outcome 7 Change in IgM level 8 months after treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/references#CD002827-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/image_n/nCD002827-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002827-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/urn:x-wiley:14651858:media:CD002827:CD002827-CMP-003-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/image_t/tCD002827-CMP-003-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Rituximab versus placebo, Outcome 8 Change in IgM anti‐MAG titre at 8 ‐ 12 months." data-id="CD002827-fig-0016" src="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/image_n/nCD002827-CMP-003-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3 Rituximab versus placebo, Outcome 8 Change in IgM anti‐MAG titre at 8 ‐ 12 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/references#CD002827-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/image_n/nCD002827-CMP-003-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002827-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/urn:x-wiley:14651858:media:CD002827:CD002827-CMP-003-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/image_t/tCD002827-CMP-003-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Rituximab versus placebo, Outcome 9 Participant subjective impression of change stable or improved at 8 ‐ 12 months." data-id="CD002827-fig-0017" src="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/image_n/nCD002827-CMP-003-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3 Rituximab versus placebo, Outcome 9 Participant subjective impression of change stable or improved at 8 ‐ 12 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/references#CD002827-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/image_n/nCD002827-CMP-003-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002827-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/urn:x-wiley:14651858:media:CD002827:CD002827-CMP-003-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/image_t/tCD002827-CMP-003-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Rituximab versus placebo, Outcome 10 Participant subjective impression of change improved at 8 ‐ 12 months." data-id="CD002827-fig-0018" src="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/image_n/nCD002827-CMP-003-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.10</div> <div class="figure-caption"> <p>Comparison 3 Rituximab versus placebo, Outcome 10 Participant subjective impression of change improved at 8 ‐ 12 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/references#CD002827-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/image_n/nCD002827-CMP-003-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002827-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/urn:x-wiley:14651858:media:CD002827:CD002827-CMP-003-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/image_t/tCD002827-CMP-003-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Rituximab versus placebo, Outcome 11 Mean change in SF36 physical subscores at 12 months." data-id="CD002827-fig-0019" src="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/image_n/nCD002827-CMP-003-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.11</div> <div class="figure-caption"> <p>Comparison 3 Rituximab versus placebo, Outcome 11 Mean change in SF36 physical subscores at 12 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/references#CD002827-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/image_n/nCD002827-CMP-003-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002827-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/urn:x-wiley:14651858:media:CD002827:CD002827-CMP-003-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/image_t/tCD002827-CMP-003-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Rituximab versus placebo, Outcome 12 Mean change in SF36 mental health subscores at 12 months." data-id="CD002827-fig-0020" src="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/image_n/nCD002827-CMP-003-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.12</div> <div class="figure-caption"> <p>Comparison 3 Rituximab versus placebo, Outcome 12 Mean change in SF36 mental health subscores at 12 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/references#CD002827-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/image_n/nCD002827-CMP-003-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002827-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/urn:x-wiley:14651858:media:CD002827:CD002827-CMP-003-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/image_t/tCD002827-CMP-003-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Rituximab versus placebo, Outcome 13 Any adverse event." data-id="CD002827-fig-0021" src="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/image_n/nCD002827-CMP-003-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.13</div> <div class="figure-caption"> <p>Comparison 3 Rituximab versus placebo, Outcome 13 Any adverse event.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/references#CD002827-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/image_n/nCD002827-CMP-003-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002827-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/urn:x-wiley:14651858:media:CD002827:CD002827-CMP-003-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/image_t/tCD002827-CMP-003-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Rituximab versus placebo, Outcome 14 Severe adverse event." data-id="CD002827-fig-0022" src="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/image_n/nCD002827-CMP-003-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.14</div> <div class="figure-caption"> <p>Comparison 3 Rituximab versus placebo, Outcome 14 Severe adverse event.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/references#CD002827-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/image_n/nCD002827-CMP-003-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002827-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/urn:x-wiley:14651858:media:CD002827:CD002827-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/image_t/tCD002827-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Cyclophosphamide and steroids versus placebo, Outcome 1 Improvement in modified Rankin Scale at 6 months." data-id="CD002827-fig-0023" src="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/image_n/nCD002827-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Cyclophosphamide and steroids versus placebo, Outcome 1 Improvement in modified Rankin Scale at 6 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/references#CD002827-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/image_n/nCD002827-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002827-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/urn:x-wiley:14651858:media:CD002827:CD002827-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/image_t/tCD002827-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Cyclophosphamide and steroids versus placebo, Outcome 2 Number of participants improved on modified Rankin Scale at 6 months." data-id="CD002827-fig-0024" src="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/image_n/nCD002827-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Cyclophosphamide and steroids versus placebo, Outcome 2 Number of participants improved on modified Rankin Scale at 6 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/references#CD002827-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/image_n/nCD002827-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002827-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/urn:x-wiley:14651858:media:CD002827:CD002827-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/image_t/tCD002827-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Cyclophosphamide and steroids versus placebo, Outcome 3 Improvement in Rivermead Mobility Index (subjective participant score) at 6 months." data-id="CD002827-fig-0025" src="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/image_n/nCD002827-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Cyclophosphamide and steroids versus placebo, Outcome 3 Improvement in Rivermead Mobility Index (subjective participant score) at 6 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/references#CD002827-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/media/CDSR/CD002827/image_n/nCD002827-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD002827-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Rituximab versus placebo for treating IgM anti‐myelin‐associated glycoprotein paraprotein‐associated peripheral neuropathy</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Should rituximab versus placebo be used for IgM anti‐myelin‐associated glycoprotein paraprotein‐associated peripheral neuropathies?</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with IgM anti‐myelin‐associated glycoprotein paraprotein‐associated peripheral neuropathies<br/> <b>Setting:</b> hospital and outpatient treatment centres<br/> <b>Intervention:</b> rituximab<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with rituximab</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants improved in disability</b> <br/> Assessed with: INCAT score or INCAT Leg Disability Score<br/> Follow‐up: range 8 to 12 months<sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 3.51<br/> (1.30 to 9.45) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>73<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Statistically significant effect in meta‐analysis</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>74 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>260 per 1000<br/> (96 to 700) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean improvement in disability</b> </p> <p>Assessed with: INCAT score or INCAT leg disability score<br/> Scale from: 0 to 12 in INCAT and 0 to 7 in INCAT leg disability.<br/> Follow‐up: range 8 to 12 months<sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean improvement in INCAT score (see text) at 8 to 12 months was ‐0.18</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean improvement in INCAT score (see text) at 8 to 12 months in the intervention group was 0.45 lower (0.85 lower to 0.05 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Statistically significant improvement versus placebo but probably less than MCID</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Improvement in 10‐metre walk time</b> at 8 to 12 months<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean improvement in 10‐metre walk time at 8 to 12 months was 0.14 seconds</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean improvement in 10‐metre walk time at 8 to 12 months in the intervention group was 0.35 seconds more (1.89 more to 1.19 less) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68<br/> (2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MCID for 10‐metre walk approximately 0.4 seconds. Borders on clinically significant improvement, but wide CIs </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Participant subjective impression of change stable or improved at 8 to 12 months</b> <br/> Assessed with: VAS </p> <p>from: 0 to 10<br/> Follow‐up: mean 8 months<sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.86<br/> (1.27 to 2.71) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>70<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Patient global impression of change improved similarly in both studies in a time‐dependent manner (see data tables) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>447 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>832 per 1000<br/> (568 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in serum IgM paraprotein concentration 8 months after treatment</b><sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in IgM level 8 months after treatment was 32.3 mg/L</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in IgM level 8 months after treatment in the intervention group was 287.7 mg/L lower (328.98 lower to 244.42 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An unsurprising reduction in IgM in the rituximab‐treated group</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Any adverse event</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.18<br/> (0.84 to 1.66) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>80<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No statistically significant difference in adverse effects. Serious adverse effects too few to make comment. Consistency of adverse event collection always suspect </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>561 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>662 per 1000<br/> (471 to 931) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>IgM:</b> immunoglobulin M; <b>INCAT score:</b> Inflammatory Neuropathy Cause and Treatment score;<b>MCID:</b> minimum clinically important difference; <b>RR:</b> risk ratio; <b>VAS:</b> visual analogue scale </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>The outcomes in the rituximab study were recorded at between 8 and 12 months, which is rational for the treatment of a disease with rituximab. Thus we have reported this interval for this intervention (see text).<br/> <sup>2</sup>Downgraded twice for imprecision (small underpowered studies) and unresponsive outcome measures.<br/> <sup>3</sup>Downgraded twice for imprecision (small underpowered studies) and indirectness (patient impression of change).<br/> <sup>4</sup>Downgraded once for imprecision (small underpowered studies).<br/> <sup>5</sup>Downgraded three times for imprecision (small studies and small even numbers), trial design and inconsistent adverse event recording. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Rituximab versus placebo for treating IgM anti‐myelin‐associated glycoprotein paraprotein‐associated peripheral neuropathy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/full#CD002827-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD002827-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">'Summary of findings' table: Intravenous immunoglobulin (IVIg) versus placebo</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>IVIg versus placebo for IgM anti‐myelin‐associated glycoprotein paraprotein‐associated peripheral neuropathies</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with IgM anti‐myelin‐associated glycoprotein paraprotein‐associated peripheral neuropathies<br/> <b>Settings:</b> hospital and outpatient treatment centres<br/> <b>Intervention:</b> IVIg versus placebo </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Outcomes</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Relative effect <br/> (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Number of participants <br/> (studies)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Quality of the evidence <br/> (GRADE)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Comments</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Risk with placebo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Risk with IVIg </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants improved in disability score at 6 months</b> ‐ not reported </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term outcomes only, not reported at 6 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean improvement in disability score at 6 months</b> ‐ not reported </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term outcomes only, not reported at 6 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Improvement in 10‐metre walk time at 6 months</b> ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Short‐term outcomes only, not reported at 6 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant subjective impression of change at 6 months ‐ number of participants reporting improvement</b> ‐ not reported </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term outcomes only, not reported at 6 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in serum IgM paraprotein concentration 8 months after treatment</b> ‐ not reported </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term outcomes only, not reported at 6 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Any adverse event</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Data for the anti‐MAG subgroup were not available. In one study, one participant had an aseptic meningitis and a rash after IVIg treatment, with 2 moderate adverse events in the placebo group. In the other trial, there were no serious adverse events with IVIg, but mild and transient effects were "more common in the IVIg than the placebo group". </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No further analysis was possible.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Incomplete reporting of adverse events in one study. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">'Summary of findings' table: Intravenous immunoglobulin (IVIg) versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/full#CD002827-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD002827-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">'Summary of findings' table: Cyclophosphamide and prednisone versus placebo</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Cyclophosphamide and corticosteroids compared to placebo for IgM anti‐myelin‐associated glycoprotein paraprotein‐associated peripheral neuropathies</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with IgM anti‐myelin‐associated glycoprotein paraprotein‐associated peripheral neuropathies<br/> <b>Settings:</b> hospital and outpatient treatment centres<br/> <b>Intervention:</b> cyclophosphamide and corticosteroids<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Relative effect <br/> (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Number of participants <br/> (studies)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Quality of the evidence <br/> (GRADE)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Comments</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Risk with placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Risk with cyclophosphamide and corticosteroids</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants improved in disability score at 6 months</b> <br/> Modifed Rankin Scale </p> <p>Scale from: 0 to 6 (normal to death)<br/> Follow‐up: mean 6 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 3.56</b> <br/> (0.41 to 30.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>35<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>53 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>189 per 1000</b> <br/> (22 to 1000) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean improvement in disability score at 6 months</b> </p> <p>Modifed Rankin Scale</p> <p>Scale from: 0 to 6 (normal to death)</p> <p>Follow‐up: 6 months<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean improvement in disability score at 6 months in the control groups was<br/> <b>0.11 units</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean improvement in disability score at 6 months in the intervention groups was<br/> <b>0.31 lower</b> <br/> (0.61 lower to 0.01 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Improvement in 10‐metre walk time at 6 months</b> ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant subjective impression of change at 6 months ‐ number of participants reporting improvement</b> ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in serum IgM paraprotein concentration after treatment</b> ‐ not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Any adverse event</b> <br/> ‐ not measured </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events not specifically collected but text notes in the paper (see text of review) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>IgM:</b> immunoglobulin M; <b>RR:</b> risk ratio </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Dowgraded once for imprecision (single small study).<br/> <sup>2</sup>Phase 1 of cross‐over trial only. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">'Summary of findings' table: Cyclophosphamide and prednisone versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/full#CD002827-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD002827-tbl-0004"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Details of non‐randomised studies</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study ID</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study design</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Particiant number (total)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant number (IgM)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant number (MAG)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number improved (IgM)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number improved (MAG)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0064" title="LatovN , ShermanWH , NemniR , GalassiG , ShyongJS , PennAS , et al. Plasma cell dyscrasia and peripheral neuropathy with a monoclonal antibody to peripheral nerve myelin. New England Journal of Medicine1980;303(11):618‐21. ">Latov 1980</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case report</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (anti‐myelin Abs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisolone + chlorambucil + plasma exchange</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0036" title="DalakasMC , EngelWK . Polyneuropathy with monoclonal gammopathy: studies of 11 patients. Annals of Neurology1981;10(1):45‐52. [MEDLINE: 81280471] ">Dalakas 1981</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Uncontrolled case series (response to Rx recorded in <a href="./references#CD002827-bbs2-0065" title="LatovN , HaysAP , ShermanWH . Peripheral neuropathy and anti‐MAG antibodies. Critical Reviews in Neurobiology1988;3(4):301‐32. ">Latov 1988</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. Prednisolone b. Prednisolone + chlorambucil</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. 0/1 b. 1/1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0069" title="MelmedC , FrailD , DuncanI , BraunP , DanoffD , FinlaysonM , et al. Peripheral neuropathy with IgM kappa monoclonal immunoglobulin directed against myelin‐associated glycoprotein. Neurology1983;33(11):1397‐405. [MEDLINE: 84040255] ">Melmed 1983</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Uncontrolled case series (response to Rx recorded in <a href="./references#CD002827-bbs2-0065" title="LatovN , HaysAP , ShermanWH . Peripheral neuropathy and anti‐MAG antibodies. Critical Reviews in Neurobiology1988;3(4):301‐32. ">Latov 1988</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. Corticosteroids b. Steroids + plasma exchange + chlorambucil</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. 3/3 b. 0/3</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0091" title="StefanssonK , MartonL , AntelJP , WollmannRL , RoosRP , ChejfecG , et al. Neuropathy accompanying IgM lambda monoclonal gammopathy. Acta Neuropathologica1983;59(4):255‐61. ">Stefansson 1983</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case report</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Plasmapheresis + immunosuppressant</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/1</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0068" title="MeierC , RobertsK , SteckA , HessC , MiloniE , TschoppL . Polyneuropathy in Waldenstrom's macroglobulinaemia: reduction of endoneurial IgM‐deposits after treatment with chlorambucil and plasmapheresis. Acta Neuropathologica1984;64(4):297‐307. ">Meier 1984</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case report</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Plasmapheresis + prednisolone + chlorambucil</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/1</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0085" title="ShermanWH , OlarteMR , McKiernanG , SweeneyK , LatovN , HaysAP . Plasma exchange treatment of peripheral neuropathy associated with plasma cell dyscrasia. Journal of Neurology, Neurosurgery and Psychiatry1984;47(8):813‐9. ">Sherman 1984</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retrospective case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Plasmapheresis + chlorambucil</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0031" title="BlandJH , GennariFJ , ErschlerWB , LatovN . IgMk monoclonal antibody directed against peripheral nerve myelin; clinical peripheral neuropathy and long‐term rheumatic disease. Journal of Rheumatology1985;12(6):1200. ">Bland 1985</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case report</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Plasmapheresis + chlorambucil</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/1</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0046" title="FrayneD , StarkeRJ . Peripheral neuropathy with gammopathy responding to plasmapheresis. Clinical and Experimental Neurology1985;21:195‐200. ">Frayne 1985</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 cases</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Plasma exchange</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0043" title="ErnerudhJ , BrodtkorbE , OlssonT , VedelerCA , NylandH , BerlinG . Peripheral neuropathy and monoclonal IgM with antibody activity against peripheral nerve myelin; effect of plasma exchange. Journal of Neuroimmunology1986;11(3):171‐8. ">Ernerudh 1986</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retrospective non‐randomised</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (anti‐myelin Abs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Plasma exchange</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/3 (temporary)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0054" title="HaflerDA , JohnsonD , KellyJJ , PanitchR , KyleR , WeinerHL . Monoclonal gammopathy and neuropathy; myelin associated glycoprotein reactivity and clinical characteristics. Neurology1986;36(1):75‐8. ">Hafler 1986</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Uncontrolled case series (response to Rx recorded in <a href="./references#CD002827-bbs2-0065" title="LatovN , HaysAP , ShermanWH . Peripheral neuropathy and anti‐MAG antibodies. Critical Reviews in Neurobiology1988;3(4):301‐32. ">Latov 1988</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a.Corticosteroids b. Plasma exchange c. Cyclophosphamide</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. 0/5 b. 1/5 c. 1/1</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0089" title="SmithT , ShermanW , OlarteMR , LovelaceRE . Peripheral neuropathy associated with plasma cell dyscrasia: a clinical and electrophysiological follow‐up study. Acta Neurologica Scandanavica1987;75(4):244‐8. ">Smith 1987</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prospective non‐randomised case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 (2 lymphoma)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (1 lymphoma)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. Chlorambucil + plasma exchange b. Plasma exchange</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. 3/4 b. 1/2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. 1/2 b. 1/1</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0053" title="HaasDC , TatumAH . Plasmapheresis alleviates neuropathy accompanying IgM anti‐myelin‐associated glycoprotein paraproteinemia. Annals of Neurology1988;23(4):394‐6. ">Haas 1988</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case report</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Plasma exchange</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/1</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0062" title="KellyJJ , AdelmanLS , BerkmanE , BhanI . Polyneuropathies associated with IgM monoclonal gammopathies. Archives of Neurology1988;45(12):1355‐9. ">Kelly 1988</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Uncontrolled case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisolone + cyclophosphamide (azathioprine or chlorambucil) + plasma exchange</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/4 (all 5 not treated)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/3 (All 5 not treated)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0065" title="LatovN , HaysAP , ShermanWH . Peripheral neuropathy and anti‐MAG antibodies. Critical Reviews in Neurobiology1988;3(4):301‐32. ">Latov 1988</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Uncontrolled case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. Plasmapheresis b. Prednisolone c. Chlorambucil d. Prednisolone + plasma exchange e. Plasma exchange + chlorambucil </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. 3/3 b. 0/1 c. 3/4 d. 0/1 e. 0/1</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0038" title="DonofrioPD , KellyJJJr . AAEE case report #17: Peripheral neuropathy in monoclonal gammopathy of undetermined significance. Muscle &amp; Nerve1989;12(1):1‐8. ">Donofrio 1989</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case report</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. Corticosteroids b. Plasma exchange + corticosteroids</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. 0/1 b. 1/1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0035" title="CookD , DalakasMC , GaldiA , BiondiD , PorterH . High‐dose intravenous immunoglobulin in the treatment of demyelinating neuropathy associated with monoclonal gammopathy [see comments]. Neurology1990;40:212‐4. [MEDLINE: 90137262] ">Cook 1990</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case reports</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. IVIg b. prednisolone</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. 2/2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. 1/1 b. 0/1</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0058" title="HodgkinsonSJ , PollardJD , McLeodJG . Cyclosporin A in the treatment of chronic demyelinating polyradiculoneuropathy. Journal of Neurology, Neurosurgery and Psychiatry1990;53(4):327‐30. ">Hodgkinson 1990</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Uncontrolled case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ciclosporin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0044" title="ErnerudhJH , VrethemM , AndersenO , LindbergC , BerlinG . Immunochemical and clinical effects of immunosuppressive treatment in monoclonal IgM neuropathy. Journal of Neurology, Neurosurgery and Psychiatry1992;55(10):930‐4. ">Ernerudh 1992</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prospective non‐randomised</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 (anti‐myelin Abs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. Plasma exchange b. Prednisolone c. Melphalan d. Chlorambucil e. Chlorambucil and plasma exchange f. Chlorambucil + prednisolone </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. 1/1 b. 1/2 c. 0/1 d. 0/1 e. 1/1 f. 1/2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0057" title="Hoang‐XuanK , LegerJM , Ben Younes‐ChennoufiA , SaidiH , BoucheP , BaumannN , et al. Treatment of immune deficient neuropathies with intravenous polyvalent immunoglobulins. An open study of 16 cases. Revue Neurologique1993;149(6‐7):385‐92. ">Hoang‐Xuan 1993</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open prospective</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (2 in <a href="./references#CD002827-bbs2-0067" title="LégerJM , Younes‐ChennoufiAB , ChassandeB , DavilaG , BoucheP , BaumannN , et al. Human immunoglobulin treatment of multifocal motor neuropathy and polyneuropathy associated with monoclonal gammopathy. Journal of Neurology, Neurosurgery and Psychiatry1994;57(Suppl):46‐9. ">Léger 1994</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IVIg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/1</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0067" title="LégerJM , Younes‐ChennoufiAB , ChassandeB , DavilaG , BoucheP , BaumannN , et al. Human immunoglobulin treatment of multifocal motor neuropathy and polyneuropathy associated with monoclonal gammopathy. Journal of Neurology, Neurosurgery and Psychiatry1994;57(Suppl):46‐9. ">Léger 1994</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open prospective</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IVIg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/5</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0086" title="ShermanWH , LatovN , LangeDE , HaysRD , YoungerDS . Fludarabine for IgM antibody‐mediated neuropathies. Annals of Neurology1994;36:326‐7. [ISSN 0364‐5134] ">Sherman 1994</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Abstract</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fludarabine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/8</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0087" title="SicilianoG , MoriconiL , GianniG , RichieriE , VignocchiMG , RossiB . Selective techniques of apheresis in polyneuropathy associated with monoclonal gammopathy of undetermined significance. Acta Neurologica Scandanavica1994;89(2):117‐22. ">Siciliano 1994</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case report</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Selective apheresis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0032" title="BlumeG , PestronkA , GoodnoughLT . Anti‐MAG antibody‐associated polyneuropathies: improvement following immunotherapy with monthly plasma exchange and IV cyclophosphamide. Neurology1995;45(8):1577‐80. ">Blume 1995</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Uncontrolled case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Plasma exchange + cyclophosphamide</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/4</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0042" title="EllieE , VitalA , SteckA , BoironJ‐M , VitalC , JulienJ . Neuropathy associated with 'benign' anti‐myelin‐associated glycoprotein IgM gammopathy: clinical, immunological, neurophysiological and pathological findings and response to treatment in 33 cases. Journal of Neurology1996;243(1):34‐43. ">Ellie 1996</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retrospective case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. Plasma exchange b. IVIg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. 2/6 b. 13/17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0078" title="NotermansNC , LokhorstHM , FranssenH , Van derGraafY , TeunissenLL , JennekensFG , et al. Intermittent cyclophosphamide and prednisone treatment of polyneuropathy associated with monoclonal gammopathy of undetermined significance. Neurology1996;47(5):1227‐33. ">Notermans 1996</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open prospective</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cyclophosphamide + prednisolone</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0050" title="GorsonKC , AllamG , RopperAH . Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy. Neurology1997;48(2):321‐8. ">Gorson 1997</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retrospective case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. Plasma exchange b. Prednisolone c. IVIg d. Cyclophosphamide + plasma exchange</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. 10/12? b. 1/2 c. 2/6 d. 2/2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0083" title="RudnickiSA , HarikSI , DhodapkarM , BarlogieB , EidelbergD . Nervous system dysfunction in Waldenstrom's macroglobulinemia: response to treatment. Neurology1998;51(4):1210‐3. ">Rudnicki 1998</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case report</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. Fludarabine + plasma exchange b. Bone marrow transplant</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. 0/1 b. 0/1</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0020" title="LatovN , ShermanWH . Therapy of neuropathy associated with anti‐MAG IgM monoclonal gammopathy with Rituxan (abstract). Neurology1999;52 Suppl 2:A551. "><b>Latov 1999</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case reports</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rituximab</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/2</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0066" title="LevineTD , PestronkA . IgM antibody‐related polyneuropathies: B‐cell depletion chemotherapy using rituximab. Neurology1999;52(8):1701‐4. ">Levine 1999</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Probably included in <a href="./references#CD002827-bbs2-0023" title="PestronkA , FlorenceJ , MillerT , ChoksiR , Al‐LoziMT , LevineTD . Treatment of IgM antibody associated polyneuropathies using rituximab. Journal of Neurology, Neurosurgery and Psychiatry2003;74(4):485‐9. ">Pestronk 2003</a> ‐ unclear </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rituximab</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0098" title="WilsonHC , LunnMPT , ScheyS , HughesRAC . Successful treatment of IgM paraproteinaemic neuropathy with fludarabine. Journal of Neurology, Neurosurgery and Psychiatry1999;66(5):575‐80. ">Wilson 1999</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open prospective</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fludarabine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/4</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0076" title="Nobile‐OrazioE , MeucciN , BaldiniL , DiTroiaA , ScarlatoG . Long‐term prognosis of neuropathy associated with anti‐MAG IgM M‐proteins and its relationship to immune therapies. Brain2000;123(Pt 4):710‐7. ">Nobile‐Orazio 2000</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retrospective case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. Plasma exchange b. Plasma exchange + chlorambucil c. Prednisolone d. IVIg e. Cyclophosphamide</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. 2/5 b. 2/2 c. 0/6 d. 0/2 e. 1/5</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0051" title="GorsonKC , RopperAH , WeinbergDH , WeinsteinR . Treatment experience in patients with anti‐myelin‐associated glycoprotein neuropathy. Muscle &amp; Nerve2001;24(6):778‐86. ">Gorson 2001</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retrospective case series (NB some cases in <a href="./references#CD002827-bbs2-0050" title="GorsonKC , AllamG , RopperAH . Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy. Neurology1997;48(2):321‐8. ">Gorson 1997</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. Plasma exchange b. IVIg c. Prednisolone d. Cyclophosphamide e. Plasma exchange + cyclophosphamide f. Interferon alfa‐2a g. Chlorambucil h. Azathioprine </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. 8/20 b. 3/19 c. 0/8 d. 3/6 e. 2/8 f. 1/8 g. 0/2 h. 0/2</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0092" title="TagawaY , YukiN , OhnishiA , HirataK , HosokawaS . Parameters for monitoring treatment effects in CIDP with anti‐MAG/SGPG IgM antibody. Muscle &amp; Nerve2001;24(5):701‐4. ">Tagawa 2001</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case report</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Plasmapheresis + cyclophosphamide</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/1</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0013" title="CanavanJB , MoroneyJT , KeoganMT , HardimanO . Rituximab and IgM autoantibody‐associated peripheral neuropathy: The Irish experience. Neurology2002;Suppl 3:A233. "><b>Canavan 2002</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retrospective case reports (abstract)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rituximab</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/2</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0047" title="GhoshA , LittlewoodT , DonaghyM . Cladribine in the treatment of IgM paraproteinaemic polyneuropathy. Neurology2002;59(8):1290‐1. ">Ghosh 2002</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case report</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cladribine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/1</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0023" title="PestronkA , FlorenceJ , MillerT , ChoksiR , Al‐LoziMT , LevineTD . Treatment of IgM antibody associated polyneuropathies using rituximab. Journal of Neurology, Neurosurgery and Psychiatry2003;74(4):485‐9. "><b>Pestronk 2003</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prospective open study</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rituximab</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear ‐ improvement</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0024" title="RenaudS , GregorM , FuhrP , LorenzD , DeuschlG , GratwohlA , et al. Rituximab in the treatment of polyneuropathy associated with anti‐MAG antibodies. Muscle &amp; Nerve2003;27(5):611‐5. "><b>Renaud 2003</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prospective open phase II study</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rituximab</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/9</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0009" title="BarohnRJ , RashidI , McVeyAL , HerbelinL , SkikneB , SapersteinDS . Rituximab for the treatment of IgM associated polyneuropathies. Journal of the Peripheral Nervous System2005;10 Suppl 1:4. "><b>Barohn 2005</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Uncontrolled case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rituximab</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002827-bbs2-0010" title="BenedettiL , GobbiM , GhiglioneE , VigoT , CarpoM , CocitoD , et al. Rituximab in anti‐MAG polyneuropathy. Journal of the Peripheral Nervous System2005;10(Suppl 1):5. "><b>Benedetti 2005</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled ?prospective (abstract)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rituximab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/13</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0033" title="BroglioL , LauriaG . Worsening after rituximab treatment in anti‐MAG neuropathy. Muscle &amp; Nerve2005;32(3):378‐9. ">Broglio 2005</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case report</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rituximab</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Worse</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0018" title="HamidouMA ,  BeliznaC ,  WiertlewskyS , AudrainM ,  BironC ,  GrolleauJ , et al. Intravenous cyclophosphamide in refractory polyneuropathy associated with IgM monoclonal gammopathy: an uncontrolled open trial. American Journal of Medicine2005;118(4):426‐30. "><b>Hamidou 2005</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Uncontrolled case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cyclophosphamide</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/9 improved, 2 stable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002827-bbs2-0019" title="KilidireasC ,  AnagnostopoulosA ,  KarandreasN ,  MouselimiL ,  DimopoulosMA . Rituximab therapy in monoclonal IgM‐related neuropathies. Leukemia &amp; Lymphoma2006;47(5):859‐64. "><b>Kilidireas 2006</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled case series</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rituximab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/4 improved</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0021" title="NiermeijerJMF ,  EurelingsM ,  LokhorstH ,  FranssenH ,  FijnheerR ,  WokkeJHJ , et al. Neurologic and hematologic response to fludarabine treatment in IgM MGUS polyneuropathy. Neurology2006;67(11):2076‐9. "><b>Niermeijer 2006</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open prospective</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fludarabine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/10 improved, all others stabilised</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/6 improved all others stabilised</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0025" title="RenaudS , FuhrP , GregorM , SchweikertK , LorenzD , DanielsC , et al. High‐dose rituximab and anti‐MAG‐associated polyneuropathy. Neurology2006;66(5):742‐4. "><b>Renaud 2006</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prospective follow‐up study to 2003</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐dose rituximab</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/7 improved (1 death)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0048" title="GironiM , SaresellaM , CeresaL , CalvoM , FerranteP , MerliF , et al. Clinical and immunological worsening in a patient affected with Waldenstrom macroglobulinemia and anti‐mag neuropathy after treatment with rituximab. Haematologica2006;91(6 Suppl):ECR 17. ">Gironi 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case report</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rituximab</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Worse</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0077" title="NoronhaV , FynanTM , DuffyT . Flare in neuropathy following rituximab therapy for Waldenstrom’s macroglobulinemia. Journal of Clinical Oncology2006;24(1):e3. ">Noronha 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case report</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rituximab</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Worse</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0022" title="NiermeijerJM , EurelingsM , LokhorstHL , Van derPolWL , FranssenH , WokkeJH , et al. Rituximab for polyneuropathy with IgM monoclonal gammopathy. Journal of Neurology, Neurosurgery and Psychiatry2009;80(9):1036‐9. "><b>Niermeijer 2009</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rituximab</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement in:</p> <p>ODSS 2/17,</p> <p>MRC sum score 11/17,</p> <p>Sensory sum score 10/17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/6</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0037" title="DelmontE , JeandelPY , HubertAM , MarcqL , BoucrautJ , DesnuelleC . Successful treatment with rituximab of one patient with CANOMAD neuropathy. Journal of Neurology2010;257(4):655‐7. ">Delmont 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case report</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rituximab (after IVIg, corticosteroids, chlorambucil)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0052" title="GrusonB , GhomariK , BeaumontM , GaridiR , JustA , MerleP , et al. Long‐term response to rituximab and fludarabine combination in IgM anti‐myelin‐associated glycoprotein neuropathy. Journal of the Peripheral Nervous System2011;16(3):180‐5. ">Gruson 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 (2 MGUS, 3 WM)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rituximab and fludarabine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/5 improved clinically, electrophysiologically, IgM level and anti‐MAG titre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All MAG</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002827-bbs2-0027" title="SmithBE , SuarezGA , WitzigTE , StevensJC , BoschEP , RossMA , et al. A phase II trial of rituximab for peripheral neuropathy associated with monoclonal gammopathy of undetermined significance (MGUS). Journal of the Peripheral Nervous System2011;16(Suppl s3):130. "><b>Smith 2011</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phase II non‐randomised case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/K</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rituximab</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NIS significant (&gt;10 pts) improvement at</p> <p>6 months 13/21, and 24 months 8/21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>Abs: antibodies; anti‐MAG; anti‐myelin‐associated glycoprotein; IgM: immunoglobulin M; IVIg; intravenous immunoglobulin; pts: participants; Rx: treatment; WM: Waldenstrom's macroglobulinemia </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Details of non‐randomised studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/full#CD002827-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002827-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">IVIg versus interferon alfa‐2a</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Change in Clinical Neuropathy Disability Score (CNDS) at six months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Subjective score at six months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Number of participants improved by at least 20% on NIS at 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">IVIg versus interferon alfa‐2a</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/references#CD002827-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002827-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Interferon alfa‐2a versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Change in the CNDS at 6 months (maximum 93) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Number improved in CNDS by 20% at 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Interferon alfa‐2a versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/references#CD002827-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002827-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Rituximab versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Number of participants improved on INCAT score (see text) at 8‐12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.51 [1.30, 9.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Mean improvement in INCAT score (see text) at 8 ‐ 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.45 [‐0.85, ‐0.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Rituximab vs placebo. Mean improvement in INCAT score at 8 ‐ 9 months (post hoc data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.33 [‐0.73, 0.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Mean improvement in NIS at 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Improvement in 10‐metre walk time at 8 ‐ 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.35 [‐1.89, 1.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Number improved in 10‐metre walk at 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Change in IgM level 8 months after treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Change in IgM anti‐MAG titre at 8 ‐ 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐17.79 [‐33.33, ‐2.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Participant subjective impression of change stable or improved at 8 ‐ 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.86 [1.27, 2.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Participant subjective impression of change improved at 8 ‐ 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.67 [1.84, 50.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Mean change in SF36 physical subscores at 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Mean change in SF36 mental health subscores at 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Any adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.84, 1.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Severe adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.11 [0.34, 28.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Rituximab versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/references#CD002827-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002827-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Cyclophosphamide and steroids versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Improvement in modified Rankin Scale at 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Number of participants improved on modified Rankin Scale at 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Improvement in Rivermead Mobility Index (subjective participant score) at 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Cyclophosphamide and steroids versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002827.pub4/references#CD002827-tbl-0008">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD002827.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD002827-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD002827-note-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD002827-note-0003">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD002827-note-0002">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD002827-note-0001">Русский</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002827\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002827\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002827\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002827\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002827\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002827\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002827\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002827\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002827\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002827\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002827\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002827\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002827\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002827\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002827\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002827\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002827\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002827\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=tIsQXAzh&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002827.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD002827.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD002827.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD002827.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002827.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740724506872"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD002827.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740724506876"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD002827.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e647d580cf44a',t:'MTc0MDcyNDUwNy4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 